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Epithelial ovarian carcinoma (EOC) is the most lethal gynaecologic 
malignancy, with a low 5-year relative survival of only 44%. The possible 
reasons for these low survival rates are the high incidence of chemoresistance 
found with EOC and a lack of consideration of the high degree of 
heterogeneity of EOC in the current standard of care. Thus, the thesis is 
divided into two parts in an attempt to address these two concerns. 
A classification scheme was previously developed to assess this high 
degree of heterogeneity in EOC, based on gene expression patterns of 1,538 
tumours. Five, biologically distinct subgroups (Epi-A, Epi-B, Mes, Stem-A 
and Stem-B) were identified, each with significantly distinct 
clinicopathological characteristics, deregulated pathways, and patient 
prognoses. Rather than the current scheme of grouping patients together, the 
proposed classification scheme could be used to stratify patients and align 
them to subtype-specific therapies with the highest likelihood of benefit. Thus, 
in the first part of the thesis, the objective was to identify potential molecular 
targets that can be utilised for subtype-specific therapies. For this purpose, a 
pooled lentivirus library of short-hairpin RNAs (shRNAs) targeting 16,000 
genes was screened for shRNAs that modulate cell growth (proliferation 
and/or viability) in a subtype-specific manner. The screen indeed revealed 
growth determinants that can be distinguished amongst the proposed subtypes. 
Focusing on the poor-prognosis Stem-A subtype, two genes involved in 
tubulin processing— TUBGCP4 and NAT10—were found to be functionally 
relevant for cell growth. In support of these findings, the pathway analyses of 
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ovarian clinical tumours and ovarian cancer cell lines predicted the Stem-A 
subtype to have a significantly higher activity of microtubule/tubulin-related 
pathways than the non-Stem-A subtype. Furthermore, Stem-A representative 
cell lines were found to be specifically more susceptible to the tubulin 
polymerisation inhibitor drugs, vincristine and vinorelbine, but not to the 
microtubule stabilising drug, paclitaxel. These findings highlight the 
significance of TUBGCP4, NAT10 and tubulin polymerisation to Stem-A 
cells, and may serve as a potential platform to develop subtype-specific 
therapies. 
The second focus of this thesis was to address the high incidence of 
chemoresistance. Since their introduction in the late 1970s, platinum-based 
drugs, such as cisplatin, have been the standard of care for EOC patients. 
Unfortunately, despite initial results, a large fraction of EOC acquires 
platinum resistance, leading to relapse and treatment failure. Thus, the 
objective for the second part of the thesis was to identify potential molecular 
targets that might be exploited for reverting platinum resistance in EOC. 
Here, the pooled shRNA lentivirus library was screened for shRNAs 
that would decrease the cell viability of a cisplatin-resistant cell line in the 
presence of cisplatin. shRNAs targeting ABCC3, KCNH3, KCNN1, MLH1, 
MRPL3 and RPS6KA1 were found to enhance cisplatin sensitivity of the 
resistant cell line. In particular, the combinatorial treatment of cisplatin with a 
RPS6KA1-specific inhibitor, SL0101, specifically rendered Epi-A 
representative cell lines, but not Stem-A representative cell lines, more 
sensitive to cisplatin. Further investigation of these findings may lead to an 
 ix 
 
increased understanding of cisplatin resistance mechanisms and facilitate the 
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CHAPTER 1  
INTRODUCTION 
 
1.1 Overview of ovarian cancer 
1.1.1 Definition of ovarian cancer 
According to the description by the National Cancer Institute, United 
States of America, ovarian cancer is defined as any malignant tumours that 
develop in the ovarian tissues. Based on the presumed cells of origin, ovarian 
cancer is commonly classified as epithelial ovarian carcinoma (EOC), ovarian 
germ cell tumour or sex cord-stromal tumour. EOC is believed to derive from 
epithelial cells that cover the outer surface of the ovary (Auersperg et al, 
1998), and alone accounts for 95% of all cancers in the ovaries (Quirk & 
Natarajan, 2005). In addition, EOC is the most lethal group among ovarian 
cancers and the prime cause of death for patients with gynaecological 
malignancies (Auersperg et al, 2001). Hence, being the most common and 
most dangerous type of ovarian cancer, EOC has been the focus of most 
ovarian cancer research and is also the focal point in this thesis. 
On the other hand, ovarian germ cell tumours and sex cord-stromal 
tumours are rare events, accounting for only 2% to 3% and 1.2% of all ovarian 
cancers, respectively (Matei et al, 2013; Quirk & Natarajan, 2005). Ovarian 
germ cell tumours arise from primitive germ cells in the embryonic gonad 
(Downs & Boente, 2003), which tend to occur in teenagers and women in their 
twenties. The age of diagnosis ranges from 6 to 40 years (Gershenson et al, 
1984; Matei et al, 2013). Sex cord-stromal tumours are a morphologically 
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diverse group of neoplasms composed of cells derived from gonadal sex cords, 
specialised gonadal stroma and fibroblasts (Deavers et al, 2003), and account 
for most hormone producing tumours (Judson & Boente, 2003). Unlike germ 
cell tumours, sex cord-stromal tumours are more common in adult women and 
can be found in peri- and post-menopausal women (Judson & Boente, 2003). 
The majority of germ cell tumours as well as sex cord-stromal tumours are 
presented as early-stage disease and usually considered as low-grade 
malignancies (Colombo et al, 2012; Koulouris & Penson, 2009). Owing to the 
advancements in surgical management and chemotherapy regimens, the 
overall prognosis of these rare tumours are very favourable today, and most 
patients survive the disease devoid of treatment-related toxicities, such as the 
loss of fertility (Matei et al, 2013). Even in the setting of advanced disease, the 
patients can be cured (Downs & Boente, 2003; Judson & Boente, 2003). 
 
1.1.2 Epidemiology of ovarian cancer 
Globally, ovarian cancer represents the eighth most common type of 
cancer among females, with 225,500 women estimated to be diagnosed with 
ovarian cancer in 2008 (Jemal et al, 2011). Despite its relatively low 
incidence, ovarian cancer is the seventh most frequent cause of cancer-related 
deaths in females, causing more than 140,000 deaths worldwide every year 
(Jemal et al, 2011). It accounts for 4.2% of all cancer deaths in women and has 
the highest mortality rates of any gynaecologic malignancy (Jemal et al, 
2011). In the United States, it was reported that more women died from 
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ovarian cancer than from all other gynaecologic cancers combined (Howlader 
et al, 2013).  
Like most types of cancer, notable geographic variation in ovarian 
cancer incidence and mortality patterns have been observed. For example, the 
lifetime risk of developing ovarian cancer for the average woman in 
economically developed regions is 1.0%, compared to only 0.5% in less 
economically developed regions (Jemal et al, 2011). Similarly, the mortality 
rate in developed regions (5.1 per 100,000 women) is almost twice as high as 
developing regions (3.1 per 100,000 women) (Jemal et al, 2011). Even within 
the same region, ethnic factors can also influence the incidence rates of 
ovarian cancer. In the United States, incidence rates are the highest among 
white women, but the lowest among Native American women (Runnebaum & 
Stickeler, 2001). Such demographic disparities may be attributed to the 
availability of advanced detection services, and/or the regional differences in 
prevalence and distribution of major risk factors. 
Ovarian cancer most commonly occurs in peri- or post-menopausal 
women. The median age of diagnosis is at 58 years, with about 90% of 
patients older than 40 years (Runnebaum & Stickeler, 2001). Overall 
incidence of ovarian cancer rose with increasing age up to mid-70s, before 
declining slightly among women beyond 80 years (Goodman et al, 2003). It is 
thought that with each passing decade of aging, more time is afforded to 
accumulate random genetic alterations favourable for ovarian carcinogenesis. 
Furthermore, ovarian cancer patients beyond 65 years have higher case-fatality 
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ratios than patients less than 65 years (Lowe et al, 2013). These make age as 
one of the greatest risk factor of ovarian cancer. 
Today the overall 5-year relative survival for women diagnosed with 
ovarian cancer is 44% (Howlader et al, 2013; Roland et al, 2013), having only 
minimal, but statistically significant improvements in the last several decades 
(Lowe et al, 2013). Compared to the substantial decreases in mortality rates 
observed in cancers of the breast and cervix, the modest improvements for 
ovarian cancer may or may not have meaningful clinical significance (Lowe et 
al, 2013; Siegel et al, 2013).  
The poor prognosis of ovarian cancer is largely due to the lack of 
reliable screening strategies, late stage of disease presentation, high recurrence 
rate of the disease, and poor response of recurrent disease to current 
chemotherapeutic regimens. Because of its insidious onset, the majority of 
ovarian cancers are detected at an advanced stage with metastases present 
beyond the ovaries, at which point the disease is rarely curable using existing 
treatment schemes. Accordingly, more than half of the patients (61%) in the 
United States are diagnosed with disseminated disease, for whom the 5-year 
relative survival is only 27.3% (Howlader et al, 2013). In contrast, only 15% 
of the patients present with localised disease and have a high 5-year relative 
survival of 91.9% (Howlader et al, 2013). Additionally, patients with 
advanced ovarian cancer have increased risk of recurrence, with almost 90% 
of patients diagnosed with distant disease experiencing recurrence of the 
disease compared to less than 10% among patients diagnosed with localised 
disease (Lowe et al, 2013). Given the low 5-year survival rate of advanced 
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ovarian cancer, there is still significant unmet need to develop reliable 
screening strategies and more effective therapeutic regimens. 
1.1.3 Risk factors of ovarian cancer 
Women with a family history of ovarian or breast cancer are of 
particular risk for having an inherited predisposition. The increased risk for the 
disease is largely due to the inheritance of a germline mutation in high-
penetrance cancer susceptibility genes, such as BRCA1, BRCA2, MLH1, 
MSH2 (Schorge et al, 2010). Hereditary ovarian cancer occurs in two different 
forms. The more common is the hereditary breast and ovarian cancer (HBOC) 
syndrome, accounting for more than 90% of all inherited ovarian cancers 
(Schorge et al, 2010). HBOC syndrome is due to the germline mutations in 
BRCA1 or BRCA2 genes, with at least two-thirds of the cases associated with 
BRCA1 mutations, and up to one-third linked to BRCA2 mutations 
(Holschneider & Berek, 2000). Both BRCA1 and BRCA2 are tumour 
suppressor genes that are involved in the maintenance of genome integrity. 
Thus, inheritance of a mutation in these genes dramatically elevates lifetime 
risk of ovarian cancer from a baseline of 1.0% to 39% for BRCA1 carriers and 
22% for BRCA2 carriers (Chen et al, 2006). Of particular note, women who 
are of Ashkenazi ancestry are especially susceptible to hereditary ovarian 
cancer, owing to the high prevalence of BRCA1 or BRCA2 mutation (1 in 40 
carrier rate). However, in the general population, such germline mutations are 
rare, and are carried by less than 1 in 500 individuals (Szabo & King, 1997).  
The other form of hereditary ovarian cancer is the association with 
hereditary nonpolyposis colon cancer (HNPCC) syndrome, also called Lynch 
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II syndrome. HNPCC syndrome is caused by the germline mutations of genes 
involved in the DNA mismatch-repair pathway, and almost 10% of women 
with this syndrome develop ovarian cancer (Aarnio et al, 1999).  
As it would be expected for familial diseases, the average age of 
diagnosis for hereditary ovarian cancer is 48 years, significantly lower than 
that of sporadic ovarian cancers in the general population (Boyd & Rubin, 
1997). However, only an estimated 10% of ovarian cancers are based on 
inherited predisposition (Runnebaum & Stickeler, 2001), and thus, its overall 
impact on mortality is relatively small. 
The other ovarian cancers are believed to develop sporadically without 
an obvious autosomal-dominant inheritance (Runnebaum & Stickeler, 2001), 
and numerous risk factors, besides age, have been identified. Among them, 
reproductive factors received the widest attention. As first proposed by 
Fathalla in 1971, it was surmised that incessant ovulation results in the 
repeated rupture of the ovarian epithelium and subsequent repair by clonal 
expansion may increase the rate of mutations, which may confer increased 
malignancy (Fathalla, 1971). In addition, the increase in sex steroid hormones 
production during ovulation may enhance cell proliferation and transformation 
in the ovarian epithelium (Berchuck et al, 2008). These has been supported by 
a case-control study showing that increase in 1 year worth of ovulation was 
associated with a 6% increase in ovarian cancer risk (Purdie et al, 2003).  
On the other hand, reduction in ovulatory events by pregnancy or oral 
contraceptive use was found to dramatically reduce ovarian cancer risk 
(Riman et al, 2002; Risch et al, 1994), as reflected in observations that 
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regardless of the age at first pregnancy, each child delivery confers a 16% risk 
reduction (Hankinson et al, 1995), while prolonged consumption of oral 
contraceptives reduce risk by up to 53% (Schlesselman, 1995). Additionally, 
the progestogenic hormonal milieu associated with pregnancy and oral 
contraceptive use may also exert a protective effect against ovarian cancer by 
stimulating apoptosis of genetically damaged epithelial cells that otherwise 
might evolve to a malignant phenotype (Rodriguez et al, 2002). 
Interestingly, surgical interventions, such as tubal ligation and 
hysterectomy can also reduce ovarian cancer risk by 18-35% (Miracle-
McMahill et al, 1997; Rice et al, 2013). The inverse associations observed 
may be explained by the possible impediment of retrograde transport of 
inflammatory agents or other potential carcinogens through the fallopian tubes 
to the ovaries after tubal ligation or hysterectomy, and thereby prevent tumour 
formation (Green et al, 1997; Hankinson et al, 1993). Alternatively, surgical 
interventions may possibly lower ovarian cancer risk through the disruption of 
blood supply towards the ovaries, resulting in the loss of ovarian function 
(Hankinson et al, 1993). 
A variety of dietary and environmental factors have also been found by 
numerous studies to be associated with ovarian carcinogenesis, but with weak 
or inconsistent correlation. Examples of such factors include alcohol 
consumption (Runnebaum & Stickeler, 2001), amount and composition of 
dietary fats (La Vecchia et al, 1987), use of talc in genital hygiene (Cramer et 
al, 1999), radiation exposure (Pettersson et al, 1985), and high-level physical 
activity (Mink et al, 1996). Several of these risk factors are highly related to 
 8 
 
the diverse cultural habits and lifestyle practices of the world (Runnebaum & 
Stickeler, 2001), and as mentioned earlier, may possibly explain for the 
notable geographic disparities in ovarian cancer incidence and mortality 
patterns. 
It is important to note that very few or none of the numerous 
epidemiological risk factors identified to date, are presently used in the clinic 
to guide clinical surveillance or interventions, with the exception of those rare 
cases with family history of ovarian or breast cancer. Thus, a deeper 
understanding of the molecular genetic features of ovarian cancer would be an 
essential and complementary approach to epidemiologic and clinical studies. 
 
1.1.4 Cell of origin of epithelial ovarian carcinoma 
 Epithelial ovarian carcinoma which makes up more than 85% of 
human ovarian cancers, is the focus of most ovarian cancer research. Even so, 
early events in ovarian carcinogenesis remain remarkably unknown, and are 
complicated by the recent controversy with regards to the cell of origin of this 
disease. The long-held view was that EOC arises by malignant transformation 
of epithelium lining the ovarian surface (Auersperg et al, 1998), also referred 
as ovarian surface epithelium (OSE). Normal OSE is a phenotypically 
uncommitted mesothelium, composing of a monolayer of flat to cuboidal 
epithelial cells, having both epithelial and mesenchymal characteristics. The 
invaginations of OSE into the ovarian stroma (Feeley & Wells, 2001) and/or 
aggregation of OSE within the stroma during postovulatory repair (Ahmed et 
al, 2007) may result in the formation of inclusion cysts, which are believed to 
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be the most likely site of early neoplastic transformation. Sequentially, 
accumulation of stromal-derived growth factors, OSE-derived cytokines 
and/or other bioactive molecules within the confined sites of inclusion cysts 
may promote the neoplastic progression of OSE-lined cysts (Auersperg et al, 
2001).  
However, recent publications suggested that EOC develops from cells 
of extra-ovarian origins, such as the fallopian tube epithelium (O'Shannessy et 
al, 2013), other derivatives of the secondary Mullerian system (Dubeau, 2008) 
or the transitional area between the OSE, mesothelium and tubal epithelium 
(hilum region) (Cheng et al, 2005). The dilemma as to where EOC actually 
originates, rises from the fact that ovarian epithelial neoplasms are 
morphologically, as well as genetically similar to normal non-ovarian 
epithelial cells of the female reproductive tract, even though they are not 
developmentally related to the ovary (Cheng et al, 2005; Dubeau, 2008; 
O'Shannessy et al, 2013). In comparison, none of the normal cellular 
constituents of the ovary show morphologic features that resemble EOCs 
(Dubeau, 2008). Proponents of OSE as the cell of origin account for these 
observations by stipulating that OSE-lined cells become more differentiated as 
it transform and acquire complex epithelial characteristics of the Mullerian 
duct-derived epithelia, i.e., the oviduct, endometrium, and uterine cervix 
(Auersperg et al, 2001). On the other hand, others argue that this notion is at 
odds with our current understanding of cancer development, whereby 
malignant cells become less differentiated than the epithelium from which 
they arise. Instead, it would seem much more likely that EOCs originate from 
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cells in which epithelial features of Mullerian epithelium are already present 
(Dubeau, 2008).  
Presently, the contribution of ovary and various segments of the 
Mullerian system to the genesis of EOC is unclear, complicated by the fact 
that majority of the patients are presented with advanced disease, where wide-
spread growth of tumour tissue extend throughout the peritoneal cavity and 
obscures the primary site (Bowtell, 2010).  
 
1.1.5 Heterogeneity in epithelial ovarian carcinoma 
 Epithelial ovarian carcinoma is a series of molecularly and 
etiologically distinct diseases. Even when all patients with EOC are given the 
same treatment regimen, they display a broad range of clinical outcomes 
(Sabatier et al, 2009). To date, multiple genetic and epigenetic abnormalities 
have been detected in different patients with EOC (Bast et al, 2009). Such 
abnormalities are linked to signalling pathways that are involved in 
proliferation, apoptosis, motility, adhesion and invasion, but how these 
changes are selected during carcinogenesis and drive the heterogeneous 
clinical behaviour of EOC is not yet clear. Consequently, EOC is highly 
heterogeneous and also, among the least understood of all major human 
malignancies.  
It is currently accepted that the tumour progression of EOC can be 
broadly divided into two categories termed Type I and Type II, which 
correspond to two distinct pathways of tumorigenesis (Shih Ie & Kurman, 
2004; Singer et al, 2003). Type I includes low-grade tumours and borderline 
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tumours of low malignant potential whereas Type II, accounting for three 
fourths of all EOCs, is composed of high-grade tumours with very aggressive 
clinical behaviour (Gadducci et al, 2012). In general, Type I tumours have an 
indolent clinical behaviour, are poorly responsive to conventional 
chemotherapy, lack TP53 gene mutations, and are genetically stable (Bowtell, 
2010). These neoplasms arise by progressive transformation from clearly 
recognised precursor lesions, such as cystadenoma, atypical proliferative 
tumour and noninvasive carcinoma, reminiscent of the adenoma-carcinoma 
sequence in colorectal cancer (Shih Ie & Kurman, 2004). Nevertheless, Type I 
ovarian carcinomas form a heterogeneous group of tumours, with each of the 
various histological types categorised as Type I having distinct mutations of 
genes involved in different signalling pathways (Singer et al, 2003). For 
example, high frequency of BRAF or KRAS mutations were found in low-
grade serous tumours (Singer et al, 2003), while mucinous and endometrioid 
tumours are associated with KRAS and β–catenin mutations respectively 
(Auner et al, 2009; Catasus et al, 2004; Lengyel, 2010).  
Conversely, Type II tumours have a more direct and aggressive 
development from either OSE-lined cysts or other epithelial source, and also 
disseminate early to the peritoneal cavity (Lengyel, 2010). These neoplasms 
have a high incidence of TP53 mutations, rarely harbour mutations of BRAF, 
KRAS and β–catenin, and are often found with widespread DNA copy number 
aberrations (Kuo et al, 2009; Singer et al, 2005). Such high levels of DNA 
amplifications and deletions are believed to be the determinant of further Type 
II tumours evolution, through the enhancement of the expression of genes in 
favour of tumour growth, as well as the suppression of tumour suppressor 
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genes (Bowtell, 2010). However, little is known about the potential 
contributions of thousands of genes whose expressions could be altered by the 
highly aberrant genome.  
Heterogeneity in EOC is also apparent in tumour histopathology, 
where based on morphological criteria, EOC can be classified into four 
distinct main histotypes; serous, mucinous, endometrioid and clear cell. 
Among them, high-grade serous carcinoma is the most common, accounting 
for approximately 70% of all ovarian carcinoma and almost two-thirds of 
ovarian cancer deaths (Bowtell, 2010).  
Recent genomic findings indicate that these distinct histotypes 
resemble well-differentiated normal cells that line the fallopian tube (serous), 
endometrium (endometrioid), endocervix (mucinous), or cells that form nests 
within the vagina (clear cell) (Bast et al, 2009; Kurman & Shih, 2010). 
Moreover, some of these histotypes bear more resemblance with certain types 
of breast cancer or renal cancer than with other histotypes similarly classified 
as ovarian cancer. For example, high-grade serous ovarian carcinoma and 
clear cell ovarian carcinoma share similar transcriptional features with basal-
like breast carcinoma and renal clear cell carcinoma respectively (Bowtell, 
2010; The Cancer Genome Atlas Research Network, 2012; Zorn et al, 2005).  
These discrete histological types also differ with respect to variable 
clinical features, including epidemiological risk, spread patterns, somatic 
mutations, chemotherapeutic response and patient prognosis (Gilks & Prat, 
2009). For instance, only 15% of patients with clear cell carcinoma respond to 
conventional chemotherapy, in sharp contrast with the high response rate 
 13 
 
(80%) observed for high-grade serous carcinoma (du Bois et al, 2003; Takano 
et al, 2006).  
Even with similar histological features, heterogeneity can still be 
observed in each of the histotypes. This is illustrated by the diverse clinical 
outcomes displayed in patients with high-grade serous carcinoma, in spite of 
the same or very similar treatment regimens (Gilks & Prat, 2009). In addition, 
heterogeneous pattern of genomic aberrations, which are of clinical 
significance, has also been observed in clear cell carcinoma (Tan et al, 2011). 
Essentially, EOC should not be viewed and treated as a single disease entity. 
 
1.1.6 Metastasis in epithelial ovarian carcinoma 
The spread of ovarian carcinoma differs markedly from the classic 
pattern of hematogenous metastasis found in most other cancers. For instance, 
metastasis in breast cancer involves the following steps: partial loss or 
complete loss of the epithelial phenotype, increased motility and invasiveness, 
intravasation into the blood circulation, survival in the circulation, 
extravasation to secondary sites, and finally the establishment of metastases in 
distant organs (Chambers et al, 2002; Gupta & Massague, 2006). In the case of 
ovarian carcinoma, primary tumour cells do also experience profound 
phenotypic changes, including the disruption of E-cadherin-mediated 
intercellular adhesion and the acquisition of migratory and invasive properties, 
through the epithelial to mesenchymal transition (EMT) process (Ahmed et al, 
2007; Thiery et al, 2009). These changes allow the detachment of malignant 
cells from the primary tumour into the peritoneal cavity. Once in the 
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peritoneum, the cells often aggregate and form spheroid-like structures, which 
can be transported throughout the cavity by the physiological movement of 
peritoneal fluid, resulting in the extensive seeding of malignant cells onto the 
mesothelial lining of the peritoneum (Lengyel, 2010). Upon adhesion to the 
mesothelial cells, the metastatic colonies undergo mesenchymal to epithelial 
transition (MET) to an epithelial phenotype for enhanced proliferation and 
forms the bulk of the secondary tumour mass (Ahmed et al, 2007; Thiery et al, 
2009). Hence, it is thought that ovarian carcinomas metastasize through a 
passive and relatively easy mechanism, without any anatomical barrier to 
prevent widespread metastasis throughout the peritoneal cavity. This was 
supported by clinical observations and retrospective clinical studies which 
suggest that EOCs grow efficiently within the peritoneal cavity, but rarely 
metastasize through the hematogenous circulation to distant organs (Lengyel, 
2010). 
The unique metastatic behaviour of ovarian carcinoma may account for 
the high percentage of ovarian cancer patients diagnosed with disseminated 
disease. In fact, making use of ovarian carcinomas from women with BRCA1 
mutations as a model for sporadic ovarian carcinomas, it was estimated that 
more than half of ovarian carcinomas had already spread into the space around 
the gut, stomach and liver (Stage III), or to the distant organs (Stage IV) when 
they are only 3cm in size (Brown & Palmer, 2009). Hence, together with 
heterogeneity, the metastatic behaviour of EOC augments the challenge of 




1.1.7 Screening strategies for epithelial ovarian carcinoma 
The high mortality rate of EOC is believed to be attributed to the late 
stage of disease presentation, while survival is longer when cancer remains 
localised at the time of diagnosis. However, non-specific symptoms and the 
lack of reliable early screening strategy hinder the diagnosis of EOC at the 
more curable early stage. Consequently, only 15% of the patients present with 
localised disease (Howlader et al, 2013). Moreover, it was suggested that on 
average, EOCs have already progressed to a late stage for approximately 1 
year prior to their discovery (Brown & Palmer, 2009). Thus, given the inverse 
relationship between survival and disease stage at diagnosis, the ability to 
detect early disease and prevent their progression to invasive disease will offer 
the most effective way to save lives.  
In order for early detection tests to be clinically useful, they should be 
able to identify the precursors of advanced stage disease with both high 
sensitivity and specificity (Clarke-Pearson, 2009). Unfortunately, we currently 
know little of the early natural history of EOCs. The low percentages of EOCs 
that present clinically at early stages are typically not precursors to those that 
present at late stages (Vaughan et al, 2011), and thus, cannot be used as 
models for rational design of effective screening strategy. The challenge is 
further complicated by recent evidences suggesting that to achieve even 50% 
sensitivity in detecting early stage EOC in normal-risk women, any screening 
test has to be able to detect tumours less than 1.3cm in diameter (Brown & 
Palmer, 2009). Accordingly, it is a great challenge to identify specific 
molecular markers and develop assays that can provide the necessary 
sensitivity and specificity to detect this low prevalence disease. 
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Presently, CA125 tumour antigen measurement, transvaginal 
ultrasonography (TVU) and pelvic examination are used as diagnostic tests to 
detect presence of EOC. Among these tests, only CA125 is recommended for 
monitoring ovarian cancer patients’ response to therapy, as well as post-
treatment monitoring for recurrent disease (Sturgeon et al, 2008). However, 
for the purpose of early detection, these tests have limited clinical utility, as 
they are often associated with false-positive and false negative results 
(Johnson et al, 2008; Schorge et al, 2010). Since further diagnostic evaluation 
usually involves invasive surgical procedure, such false-positive results will 
lead to unnecessary surgical intervention and could even cause serious 
complications. Indeed, the recently completed Prostate, Lung, Colorectal and 
Ovarian (PLCO) trial concluded that annual screening performed with CA125 
and TVU does not reduce ovarian cancer mortality in normal-risk women, but 
instead increases unnecessary surgical interventions (Buys et al, 2011; 
Partridge et al, 2009). Even when ovarian cancers were detected, 72% of the 
cases were late stage (Partridge et al, 2009). On the basis of current data, 
widespread screening for ovarian cancer is not recommended (Sawyers et al, 
2013).  
 
1.1.8 Therapeutic regimens for epithelial ovarian carcinoma 
Surgery followed by chemotherapy has been the mainstays of first-line 
treatment regimen for ovarian cancer patients. Patients are first subjected to 
surgical cytoreduction to remove all grossly visible tumours, and at the same 
time provide opportunities for clinicians to accurately establish the diagnosis 
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and extent of the disease (Coleman et al, 2013; du Bois et al, 2009). Although 
such surgical procedure is rarely practiced in other malignancies, the removal 
of tumours in ovarian cancer patients to less than 1 cm residual disease has 
consistently been associated with better overall survival (Eisenkop et al, 1998; 
Hoskins et al, 1994). 
Given the high chemosensitivity of EOC, chemotherapy was often 
administered to patients following surgery, so as to eradicate residual disease. 
In the past, commonly used drugs included cyclophosphamide, melphalan and 
chlorambucil (Vella et al, 2011). When cisplatin was introduced to clinical 
practice in 1978, platinum-based therapy was shown to generate a higher 
number of responsive patients, increase response duration and progression-
free interval (Vella et al, 2011). Since then, platinum derivatives, such as 
cisplatin and carboplatin, become the standard of care for ovarian cancer 
patients.  
In the late 1990s, two randomised phase III trials led to the 
combination of cisplatin with paclitaxel as adjuvant treatment of advanced 
stage ovarian cancer (McGuire et al, 1996; Piccart et al, 2000). Compared with 
cisplatin and cyclophosphamide combination, patients treated with cisplatin 
and paclitaxel were shown in both studies to have significantly higher overall 
clinical response rate and complete clinical remission rate, and also 
experienced significantly longer progression-free survival and overall survival 
(McGuire et al, 1996; Piccart et al, 2000). Therefore, the combination of 
platinum and paclitaxel is presently the treatment of choice as first-line 
therapy for all ovarian cancer patients. 
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Briefly, paclitaxel is a taxane that binds to the taxoid-binding site of β-
tubulin, resulting in the enhancement of microtubule polymerization (Schiff et 
al, 1979). Such microtubule stabilising activity suppresses microtubule 
dynamics, and thus, arrest cell proliferation. Apart from taxanes, other 
microtubule-targeted agents, such as vinca alkaloids are also currently 
administered in a broad range of solid tumours and haematological 
malignancies, while extensive research are dedicated to examine the clinical 
relevance of other agents (Dimitroulis & Stathopoulos, 2005; Dumontet & 
Jordan, 2010).  
Although the administration of platinum-taxane based therapy has been 
standardised (intravenously once every 3 weeks for 6 to 9 cycles), there are 
still doubts over its optimal dose and schedule. A recent study in Japan 
suggested that dose-intensification schedule of weekly paclitaxel 
administration at lower doses together with standard doses and schedules of 
carboplatin prolonged progression-free survival and overall survival compared 
to the conventional regimen (Katsumata et al, 2009). In addition, peritoneal 
delivery of chemotherapy has been shown to increase overall survival 
compared to intravenous therapy (Armstrong et al, 2006). Since most of the 
tumours are confined within the peritoneal cavity, this route of administration 
will be able to achieve high local concentration of the drugs, but is also highly 
toxic to the patients (Gore et al, 2006). Both of these approaches are still under 
evaluation and may well have a role in future management of ovarian cancer 
patients (Coleman et al, 2013). 
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At the present time, 60 to 80% of patients with advanced EOC will 
respond to the combination of platinum- and taxane-based chemotherapy and 
achieve complete clinical remission (Kigawa, 2013), while approximately 
20% to 30% of the advanced-stage patients present with platinum-refractory 
disease (intrinsic platinum resistance) and continue to have progressive 
disease even during treatment (Cannistra, 2004). Despite the high 
chemosensitivity of the disease to first-line therapy, maintenance of disease-
free status has proven to be elusive, with over two-thirds of the patients 
experiencing recurrent disease (Herzog & Pothuri, 2006). Depending on the 
time interval from completion of first-line platinum-based chemotherapy until 
recurrence, patients usually receive non-platinum single agent regimen 
(relapsed disease within 6 months after treatment) or platinum-based 
chemotherapy (relapsed disease more than 6 months after treatment) (Coleman 
et al, 2013). However, due to the development of drug resistance, the response 
rates and time to progression typically fall with each relapse (Vaughan et al, 
2011).  
Collectively, intrinsic and acquired platinum resistance are among the 
major reasons of treatment failures, resulting in the low 5-year relative 
survival of 27.3% for advanced stage disease (Howlader et al, 2013). 
Additionally, current therapeutic regimens fail to take into account the high 
degree of heterogeneity in EOC (Vaughan et al, 2011). Hence, identification 
of new therapeutic approaches is necessary to improve the survival outcome of 





1.1.9 Strategies to improve therapeutic for epithelial ovarian carcinoma  
 Ovarian cancer research lags behind more advanced stages of 
investigations in other cancer types, leading to delayed introduction of new 
targeted therapeutics into clinical practice. In fact, the drugs used in the clinic 
today for EOC are similar to those used in the late-70s, albeit with reduced 
side effects (Vaughan et al, 2011). With the possible exception of 
angiogenesis inhibitors, such as bevacizumab, attempts to improve patient 
survival by including other drugs have not been encouraging (Bookman et al, 
2009). The recently concluded phase 3 randomised trial conducted by 
International Collaboration on Ovarian Neoplasms (ICON7) indeed showed 
that bevacizumab treatment improved progression-free survival, particularly in 
patients at high risk of disease progression (Perren et al, 2011), but at the same 
time, it is also associated with a small but clinically significant decrement in 
quality-of-life (Canevari et al, 2013; Stark et al, 2013). Hence, much effort is 
still needed to develop therapeutic regimens with better therapeutic index and 
smaller negative impact on patients’ quality-of-life. 
Rather than the current scheme of grouping patients together, one 
potential approach could be the stratification of patients to molecularly 
targeted therapies with the highest likelihood of benefit. Such therapies have 
been successfully incorporated into standard treatment for other malignancies, 
such as chronic myelogenous leukaemia, ER- or Her2-positive breast cancer, 
and EGFR-mutated lung cancer (Quintas-Cardama et al, 2009; Rosell et al, 
2010; Yaziji et al, 2004). A key point of these successes is the development of 
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precision medicine – the use of the right treatment for the right patient at the 
right time. Despite the high degree of heterogeneity in EOC, all women 
diagnosed with EOC are given the same regimen, with no prognostic 
classifications currently powerful enough to identify patients who are most 
likely to benefit from any particular regimen (Vaughan et al, 2011). As a 
result, therapeutic regimens are less than perfectly adapted to each patient 
(Sabatier et al, 2009). Therefore, there is an urgent need to define molecularly 
homogeneous subsets that respond similarly to treatment, followed by the 
development / identification of compounds that can inhibit the biological 
drivers of each individual subset. 
Another approach to improve patient survival would be to circumvent 
resistance of recurrent EOC disease to standard chemotherapy. Many women 
respond well to the initial platinum-based treatment, but often relapse with 
platinum-resistant disease (Vaughan et al, 2011). Despite extensive research 
dedicated to this area, the precise mechanisms of platinum resistance remain 
elusive and are likely to be multi-factorial (Coleman et al, 2013). Thus, in 
order to achieve more durable response to therapy, genome-wide knockdown 
and expression approaches could be used as a strategy to identify promising 
candidates for which inhibition would revert the resistance to platinum-based 
therapy. In fact, application of such approaches has led to the successful 
identification of CDK12 as a synthetic lethal partner of the PARP1/2 inhibitor, 
olaparib (Bajrami et al, 2013).  
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Therefore, this thesis is divided into two parts; addressing the two 
aforementioned approaches that will hopefully lead to better therapeutic 
regimens for EOC.  
 
1.2 Dissecting heterogeneity in epithelial ovarian carcinoma 
1.2.1 Basis for dissecting cancer heterogeneity 
In the multistep process of tumorigenesis, normal cells acquire a series 
of random abnormalities that ultimately lead to the development of most of the 
hallmarks of cancer – enhanced proliferation, reduced apoptosis, resistance to 
anoikis, angiogenesis, increased invasion and metastasis, etc (Hanahan & 
Weinberg, 2011). As a result, the spectrum of somatic genomic and 
epigenomic aberrations can vary substantially among individual tumours that 
appear clinically similar (Garay & Gray, 2012). However, certain driver 
aberrations can occur frequently enough, such that they can define molecularly 
homogeneous subsets that respond similarly to treatment (Alizadeh et al, 
2000; Collisson et al, 2011; Sorlie et al, 2001). Hence, the utility of such 
classification scheme to identify patients’ subgroups and direct them to 
appropriate targeted therapies can have substantial therapeutic benefit (Druker 
et al, 2001; Slamon et al, 2001). 
With the help of high throughput technologies, homogeneous 
subgroups can be defined based on transcriptional profiles, genomic 
aberrations, promoter methylation patterns and protein expression. mRNA 
expression profiling is particularly well established and has been instrumental 
in characterising the complex biological diversity of human cancers (Alizadeh 
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et al, 2000; Perou et al, 2000; Verhaak et al, 2010). Subtypes identified 
through expression microarray analyses are coupled with multiple clinical 
parameters, such as patient prognosis, age of onset and molecular marker 
expression (Perou et al, 2000; Verhaak et al, 2010). Already, predictors of 
prognosis, as well as the ability to identify patient subgroups that are most 
likely to benefit from particular therapies have been developed for other 
cancers and are being tested in prospective randomised clinical trials. For 
example, the basal expression subtype of breast cancer, which has an 
unfavourable prognosis, and does not benefit from anti-oestrogenics or 
Herceptin is currently being investigated in relation to response to simvastatin 
(http://www.clinicaltrials.gov/ct/ show/NCT00807950). Here, I describe some 
major studies that have attempted to define molecularly homogenous 
subgroups in EOC. 
 
1.2.2 Published studies on molecular classification of epithelial ovarian 
carcinoma 
Efforts to dissect EOC heterogeneity have correlated expression 
patterns with clinical features, such as histological types, aggressiveness and 
patient outcomes (Denkert et al, 2009; Helland et al, 2011; Mok et al, 2009; 
The Cancer Genome Atlas Research Network, 2011; Tothill et al, 2008). Of 
particular note, The Cancer Genome Atlas (TCGA) and the Australian 
Ovarian Cancer Study (AOCS) have in recent years demonstrated the 
existence of molecular subtypes in EOC defined by transcriptional patterns 
(The Cancer Genome Atlas Research Network, 2011; Tothill et al, 2008). 
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Making use of expression microarray data from 285 serous and 
endometrioid invasive tumours of the ovary, peritoneum, and fallopian tube, 
AOCS identified six molecular subtypes - C1, C2, C3, C4, C5 and C6, which 
are associated with molecular and histopathological characteristics, and patient 
survival (Tothill et al, 2008). Both C1 and C5 subtypes were found to confer 
poorer clinical outcomes as compared with other subtypes (Tothill et al, 2008). 
On further investigation, they found Let-7 pathway to be specifically altered in 
the poor prognosis C5 subtype, and suggested it as one of the drivers 
responsible for the biological and clinical behaviour of C5 subtype (Helland et 
al, 2011). 
On the other hand, TCGA analysed promoter methylation, DNA copy 
number aberration, as well as expression patterns of messenger RNA and 
microRNA in 489 high-grade serous ovarian adenocarcinomas (The Cancer 
Genome Atlas Research Network, 2011). Focusing on their mRNA expression 
analysis, the existence of at least four expression subtypes - differentiated, 
immunoreactive, mesenchymal, proliferative, was reported (The Cancer 
Genome Atlas Research Network, 2011). The subtypes were named based on 
their distinct gene clusters. For instance, the immunoreactive subtype is 
characterised by T-cell chemokine ligands CXCL11, CXCL10, and the 
receptor CXCR3, while high expression of proliferative markers such as 
MCM2 and PCNA defined the proliferative subtype. These subtypes were 
originally found to be not significantly correlated with survival duration (The 
Cancer Genome Atlas Research Network, 2011), but subsequent study 
observed association with survival duration when the TCGA classification 
scheme was applied onto expression profiles obtained from other published 
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studies (Verhaak et al, 2013). 
Due to varied histotype presentation, samples sizes and analytical 
criteria, the reported molecular subtypes of EOC by TCGA and AOCS are 
similar but not completely the same (The Cancer Genome Atlas Research 
Network, 2011; Tothill et al, 2008). Thus, a refined classification scheme with 
intense phenotypic characterisation remains to be established. Also, the 
molecular targets relevant to cancer cell growth in these transcriptional 
subtypes have not been identified.  
 
1.2.3 Proposed molecular classification of epithelial ovarian carcinoma 
Previously, our group also proposed a classification scheme to address 
the high degree of heterogeneity in EOC. This scheme was published together 
with the results in Chapter 3 and 4 in EMBO Molecular Medicine (Tan et al, 
2013). 
For our proposed molecular classification, we used a large collection 
of ovarian tumour gene expression data (n = 1,538; serous: 1,335, mucinous: 
27, clear cell: 25, endometrioid: 96, and others: 55 samples) derived from 16 
independent studies (Anglesio et al, 2008; Bild et al, 2006; Bowen et al, 2009; 
Denkert et al, 2009; Hendrix et al, 2006; Hogdall et al, 2003; Hsu et al, 2007; 
Iorio et al, 2010; Jochumsen et al, 2009; Jochumsen et al, 2007; Mok et al, 
2009; Pejovic et al, 2009; The Cancer Genome Atlas Research Network, 2011; 
Tone et al, 2008; Tothill et al, 2008; Tung et al, 2009). The strong batch-effect 
among the independent datasets was removed by ComBat, through the 
elimination of technical differences across data collection sites, while 
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conserving meaningful variations (Fig. 1.1) (Chen et al, 2011; Johnson et al, 
2007). A preliminary statistical power analysis showed that 1,500 or more 
samples were required to achieve sufficient statistical power (≥ 0.8) in 
capturing the complexity and dynamicity of EOC (Fig. 1.2) (Fox & Mathers, 
1997). Importantly, known prognostic factors were correlated with patient 
overall survival by univariate and multivariate Cox proportional hazards 







Figure 1.1 Removal of batch effect from combined expression microarray 
data for epithelial ovarian carcinoma.  
Effect of ComBat standardisation in the principle component analysis (PCA) 
of 16 independent cohorts. Left panel. Prior to ComBat standardisation, the 
combined ovarian cancer gene expression data showed technical variations. 
Right panel. After ComBat standardisation of the same data, the technical 












Figure 1.2 Statistical power plots for each molecular subtype.  
Statistical power plots to distinguish one subtype from the others. Arrows 
indicate the number of samples required to attain a statistical power of 0.8 for 
distinguishing amongst molecular subtypes. x-axis is the number of samples; 







Table 1.1. Univariate and multivariate Cox proportional hazards 





(Total n = 
539) 
Univariate 
(HR, 95% CI) 
p-value 
Multivariate 
(HR, 95% CI) 
p-value 
Age (yr)           
< 55 175 (32.47%) 1   1   
≥ 55 364 (67.53%) 1.403 (1.071 - 1.839)  0.0141 1.285 (0.9781-1.687) * 0. 07173 * 
            
Stage           
I or II 47 (8.72%) 1   1   
III or IV 492 (91.28%) 3.907 (1.843-8.285) 0.00038 3.429 (1.591-7.389) * 0.00165 * 
            
Grade           
1 17 (3.15%) 1   1   
≥ 2 522 (96.85%) 2.58 (0.9578-6.949) 0.0608 1.365 (0.494-3.763) * 0.54799 * 
            
Metastasis           
Primary 500 (92.76%) 1   1   
Metastasis 39 (7.24%) 1.349 (0.8323-2.185) 0.224 1.391 (0.854-2.27) * 0.1853 * 
            
Subtype           
Non-Epi-A 483 (89.61%) 1   1   
Epi-A 56 (10.39%) 0.7103 (0.4498-1.122) 0.142 0.9449 (0.583-1.53) ** 0.8176 ** 
            
Non-Epi-B 384 (71.24%) 1   1   
Epi-B 155 (28.76%) 0.69 (0.5206-0.9144) 0.0098 0.7347 (0.553-0.976) ** 0.033 ** 
            
Non-Mes 361 (66.98%) 1   1   
Mes 178 (33.02%) 1.171 (0.907-1.513) 0.225 1.01 (0.777-1.324) ** 0.9164 ** 
            
Non-Stem-A 411 (76.25%) 1   1   
Stem-A 128 (23.75%) 1.417 (1.075-1.868) 0.0135 1.382 (1.045-1.83) * 0.0234 * 
            
Non-Stem-B 517 (95.92%) 1   1   
Stem-B 22 (4.08%) 1.204 (0.6383-2.271) 0.567 1.14 (0.603-2.149) ** 0.6886 ** 
 
* Multivariate Cox regression analysis of clinical variables with Stem-A 
subtype.  
** For multivariate Cox regression, each subtype was independently analysed 
with the other clinical variables (age, stage, grade, and metastasis) from the 
remaining subtypes. 
p-values below 0.05 are shown in red. 




To identify EOC molecular subtypes, consensus clustering was applied 
to the collection and five clusters – Epithelial-A (Epi-A), Epithelial-B (Epi-B), 
Mesenchymal (Mes), Stem-like-A (Stem-A) and Stem-like-B (Stem-B), that 
were characterised by markers of differentiation or cell-type status and stromal 
components were detected (Fig. 1.3A) (Tan et al, 2013). For instance, Epi-A 
and Epi-B tumour clusters are characterised by epithelial cell markers, such as 
CDH1, EPCAM, CD24 and various keratin genes. The Mes tumour subtype 
predominantly expressed fibroblastic/mesenchymal genes, such as PDGFRA, 
VCAM1, ZEB1, TWIST1, and extracellular matrix genes, including collagen 
and FN1. The Stem-A and Stem-B tumour clusters did not share many gene 
markers, but expressed typical markers for epithelial stem cells: LGR5 and 
PROM1 respectively (Fodde, 2009). Stem-A tumours also expressed more 
MYCN, NCAM, CDH2 and proliferation-related genes, suggesting neural 
characteristics. Epi-B and Mes tumours expressed inflammatory genes, such 
as multiple interferon down-stream genes, MHC class II genes and 
immunoglobulin genes. The silhouette plot (Rousseeuw, 1987) and SigClust 
(Liu et al, 2008) analysis confirmed tumour similarity within each subtype, 
indicating the robustness of the proposed classification (Fig. 1.3B). 
On comparison of our proposed subgrouping scheme with that of 
AOCS (Tothill et al, 2008), an overall concordance of 82.9% for all of the 
subtypes was found (Fig. 1.4A), implying that the proposed large-scale 
analysis confirmed the previous study. The proposed molecular subtypes were 
also noted to be akin to that of TCGA (Fig. 1.4A) (The Cancer Genome Atlas 
Research Network, 2011). However, the subtyping schemes from these 
published studies did not show a one-to-one match with our proposed 
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classification (Fig. 1.4A; see the mutual relationships among Epi-A or Epi-B; 
C2, C3 or C4; Immunoreactive or Differentiated). In addition, the Stem-B/C6 
subtype, which comprised most of the non-serous tumours, was identified 
from the analyses of multi-histotype ovarian cancers by both AOCS (Tothill et 
al, 2008) and us but not by TCGA in their analysis of only high-grade serous 
ovarian adenocarcinomas (Fig. 1.4A) (The Cancer Genome Atlas Research 
Network, 2011). The overwhelming number of serous tumours in the 
collection (n = 1,274) might have caused the classification of most of the 
biologically distinct non-serous histotypes into the same molecular subtype 
(Stem-B) (Fig. 1.4B). Intriguingly, some of the serous tumours were also 
classified into the Stem-B subtype (Fig. 1.4B), implying the presence of a 
unique less serous subgroup within serous carcinoma. This notion was 
supported by the fact that serous samples of Stem-B subtype have significantly 
lower expression level of WT1 gene, a marker for serous adenocarcinoma of 
the ovary (Lawrenson & Gayther, 2009; Tan et al, 2013). Overall, our 
proposed EOC classification is predominantly a combination of discrimination 
by histotype and the molecular subtypes defined by AOCS (Tothill et al, 2008) 
and TCGA (The Cancer Genome Atlas Research Network, 2011), but also 
reveal novel biological features. For consistency, the proposed molecular 






1.2.4 Clinical relevance of proposed epithelial ovarian carcinoma 
subtypes 
The proposed subtypes have also been correlated with various 
clinicopathological parameters so as to ascertain their clinical relevance. 
Indeed, significant correlation was found between the proposed subtype and 
patient outcome, with Epi-A, Epi-B and Stem-B subtypes showing better 
prognosis in the Kaplan-Meier analysis, while Mes and Stem-A tumours were 
linked with poorer outcomes (Fig. 1.5A). Even when only high-grade serous 
carcinomas are analysed, the proposed subtypes also showed similar 
significant distinctions in survival in Kaplan-Meier curves (Fig. 1.5B). On 
closer examination, the poor prognosis Stem-A tumours can also be found at 
stages 1 and 2 having poorer outcomes than those of other subtypes (Fig. 
1.6A), and were also found to be enriched in older patients (Fig. 1.6B). On the 
other hand, the other poor prognosis subtype – Mes, included more advanced 
staged and metastasised tumours (Fig. 1.6C). In the univariate and multivariate 
Cox regression analyses, both Stem-A and Epi-B subtypes are identified as 
prognostic factors that are independent of multiple clinical parameters and 
status (Table 1.1).  
Pathway analysis also revealed clear distinctions in the enrichment of the gene 
expression signatures for various pathways (Fig. 1.7). Through the application 
of single sample gene set enrichment analysis (ss-GSEA) on 1,538 samples 
using 6,898 gene sets, 207 gene sets were found to be subtype-specific 
(Subramanian et al, 2005). For instance, Mes tumours correlated with 
Metastases and TGFβ-related pathways, consistent with their link with 
epithelial-mesenchymal transition (EMT) and metastasis (Fig. 1.7) (Maruyama 
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et al, 2000; Yin et al, 1999). In comparison, chromatin remodelling gene sets 
were highly enriched in the Stem-A subtype (Fig. 1.7). Overall, the proposed 
expression-based subtyping scheme is able to dissect EOC heterogeneity into 
subgroups with similar biological properties and clinical relevance.  
 
1.2.5 Predictive model for proposed molecular subtype classification 
A predictive framework based on a Binary Regression (BinReg) model was 
also developed as a potential diagnostic tool for quantitative gene expression-
based subgroup assignment (Tan et al, 2013). The predictive capability of the 
model was demonstrated to be comparable with those reported in previous 
studies for multiple breast cancer cohorts (Calza et al, 2006; Haibe-Kains et al, 
2012). In addition, extensive validation exercises were carried out, affirming 
the accuracy and robustness of the model (Tan et al, 2013). However, details 
of the model and the validations performed are beyond the scope of this thesis, 








Figure 1.3 Proposed molecular classification of epithelial ovarian carcinoma.  
A. Gene expression heatmap for the five tumour clusters (red = high; green = low expression). Consensus clustering of 1,538 
samples identified five subtypes, designated by the associated gene components. Note the similarities between Epi-A/Stem-B 
subtype tumours, between Epi-A/Epi-B subtypes for epithelial genes, and the expression pattern of Epi-A/Stem genes. B. 
Silhouette plot. Note the large proportion of clinical samples with positive silhouette width (SW) values, suggestive of tumour 
similarity within each subtype. SigClust (Liu et al, 2008) p-values indicative of significance of clustering are shown to the right of 









Figure 1.4 Comparison of proposed classification with published schemes and the distribution of proposed subtypes in 
each histotype.  
A. Comparison of the proposed molecular subtype with previously published subtyping schemes for EOC by AOCS (Tothill et al, 
2008) and TCGA (The Cancer Genome Atlas Research Network, 2011). Note that Epi-B subtype carries an immunoreactive and a 
differentiated component, and also that TCGA molecular subtyping lacks Stem-B/C6 population. B. Subtype distribution by 
histologies. Note the large proportion of clinical samples classified as Stem-B in non-serous histotypes (Endometrioid, Mucinous 








Figure 1.5 Correlation of proposed subtypes with overall survival.  
A. Kaplan-Meier survival analysis for each subtype. Among data for 1,538 patient samples, survival information for 978 samples 
was available (Epi-A: 80, Epi-B: 264, Mes: 284, Stem-A: 220, Stem-B: 61 and others: 69 samples) and used for the Kaplan-Meier 
analysis. B. Prognostic feature of subtypes in high-grade serous ovarian EOC only. A total of 863 samples in this category were 
analysed (Epi-A; 63, Epi-B; 258, Mes; 280, Stem-A; 217, and Stem-B; 45 samples). Note that the proposed molecular 








Figure 1.6 Clinicopathological characterisation of proposed molecular 
subtypes. 
A. Kaplan-Meier survival analyses stratified by clinical stage. Note that 
patients with stage I or II Stem-A ovarian carcinomas have worse outcome, 
with statistical significance. Epi-A and Epi-B subtypes show better prognoses 
overall, but Stem-B cancers are no longer benign at advanced stages. B and C. 
Histograms showing the relationship between expression subtypes with age 
distribution (B, where the mean age in years is shown underneath) and 
primary or metastasised tumours (C). Definition of metastasised tumour 
follows the original description in the literature (Anglesio et al, 2008; Bowen 











Figure 1.7 Subtype-specific pathway enrichment. 
Heatmap shows subtype-specific single sample gene set enrichment analysis 
(ss-GSEA) scores (false discovery rate (FDR) in significance analysis of 
microarrays (SAM) q = 0%, receiver operation curve (ROC) >0.85) for 1,538 
ovarian cancer samples. Red = high; green = low enrichment scores. Gene sets 
are aligned in descending value of ROC. Samples are aligned by subtype 
classification and silhouette width (SW) (Fig. 1.3B). Deep colour = positive 
SW (core samples); pale colour = samples classified, but negative SW. 
“Others” indicates the unclassified samples not grouped in any of the five 
subtypes in the initial CC analysis in Fig. 1.3A. Arrows indicate positions of 




1.2.6 Representative cell lines as model for the proposed molecular 
subtypes 
The availability of the proposed classification scheme to dissect the 
complexity of EOC pave the way for further work into the identification of 
relevant molecular targets, that will lead to the development of precision 
medicine for EOC. However, a major challenge is to identify cell lines that 
reflect the relevant underlying tumour biology (Chin et al, 2011). Expression 
studies of cultured breast cancer cell lines have shown that in vitro cells retain 
subtype characteristics corresponding to those of their in vivo counterparts, 
indicating that matching breast cancer cell lines by expression data could 
represent in vivo tumours (Gatza et al, 2010; Neve et al, 2006; Perou et al, 
2000). Hence, cell lines corresponding to each proposed EOC subtype could 
be used for in vitro modelling. 
By performing two rounds of consensus clustering on the expression 
microarray data of 142 cultured EOC cell lines, we identified representative 
cell lines for each proposed subtypes (Fig. 1.8A) (Tan et al, 2013). The 
robustness of the classification was unambiguously supported by similarity 
matrices, as well as the positive silhouette width values (Rousseeuw, 1987) 
with significant p-value by SigClust (Fig. 1.8A) (Liu et al, 2008). 
Furthermore, a high correlation between clinical tumour subtype and cell line 
subtype was demonstrated in the Spearman correlation map analysis (Fig. 
1.8B; average spearman rho = 0.80), demonstrating a high level of similarity 
between EOC cell lines and tumour transcriptomic expression patterns.  
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Similar to clinical samples, pathway analysis on the cell lines data also 
revealed clear distinctions in the enrichment of the gene expression signatures 
for various pathways (Fig. 1.9). As expected, Epi-A cell lines were 
characterised by cell adhesion-related gene sets, reflecting enrichment of 
epithelial cell markers. Notably, 33 cell line subtype-specific gene sets were 
shared with tumours, indicating similarity between cell lines and tumours in 
the pattern of pathway enrichment. Overlapped gene sets include the 
enrichment of fibrinolysis pathway and chromatin modification in the Mes and 
Stem-A subtypes, respectively (Fig. 1.9). Additionally, the proposed 
molecular subtypes were shown to have significant correlation with in vitro 
phenotypes, such as population doubling time and anchorage-independent cell 
growth potential (Fig. 1.10). Representative cell lines of the better prognosis 
Epi-A and Epi-B subtypes have longer population doubling times and 
decreased colony-forming ability, which may reflect the less-aggressive 
behaviour of clinical tumours (Fig. 1.10).  
Intriguingly, we also identified representative cell lines for the C1/Mes 
subtype, which is known to be driven by stromal elements (Tan et al, 2013; 
Tothill et al, 2008). Though stromal elements are not part of any cell line 
model, stromal-related gene sets were found to be specifically enriched in our 
Mes tumours (Fig. 1.7), as well as in Mes representative cell lines (Fig. 1.9) 
(Tan et al, 2013). In addition, Mes tumours are not only characterised by 
stromal gene expression signature, but also predominantly expressed 
fibroblastic/mesenchymal genes, such as VCAM1, ZEB1, TWIST1, and 
extracellular matrix genes, including collagen and FN1 (Fig. 1.3A) (Tan et al, 
2013). Expression of these genes are also enhanced in Mes representative cell 
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lines (Fig. 1.8A) (Tan et al, 2013). Therefore, even though subtype-
representative cell lines are admittedly not the perfect in vitro models for 
clinical tumour subtypes, these cell lines are thus far, the most representative 
models readily available for molecular subtype study. 
At the same time, it should be noted that a recent study identified 
several commonly used ovarian cancer cell lines as poor models of high-grade 
serous ovarian cancer, and consequently, forced a significant re-evaluation of 
many of the cell lines used in ovarian cancer research (Domcke et al, 2013). 
Unfortunately, these important findings were only published in 2013, and 
thus, were impossible to be factored into this thesis.  
With the availability of a classification scheme to dissect the 
heterogeneity in EOC, as well as representative cell line models, the first part 
of this thesis strives to identify functionally relevant targets for the proposed 
subtypes, which hopefully will lay the foundation for developing therapeutics 







Figure 1.8 Identification of representative cell lines for proposed molecular subtype. 
A. EOC cell line classification. Left panel. Consensus clustering matrix of 142 EOC cell lines. Red = high; white = low similarity. 
Middle panel. Gene expression heatmap of EOC cell lines. Red = high; green = low expression. Right panel. Silhouette analysis 
for each proposed subtype. Column to the right of silhouette plot is the SigClust (Liu et al, 2008) p-value indicative of cluster 
significance for each subtype. B. Heatmap of Spearman correlation Rho of gene expression between clinical tumour subtype (n = 
1,538) and EOC cell line subtype (n = 142). Yellow indicates a perfect correlation (Rho = 1) whereas black indicates no 











Figure 1.9 Cell line subtype-specific pathway enrichment. 
Heatmap shows subtype-specific single sample gene set enrichment analysis 
(ss-GSEA) scores (false discovery rate (FDR) in significance analysis of 
microarrays (SAM) q = 0%, receiver operation curve (ROC) >0.85) for 142 
cultured EOC cell lines. Red = high; green = low enrichment scores. Gene sets 
are aligned in descending value of ROC. Samples are aligned by subtype 
classification and silhouette width (SW) (Fig. 1.8A). Deep colour = positive 
SW (core samples); pale colour = samples classified, but negative SW. Arrows 








Figure 1.10 Characterisation of in vitro phenotypes of representative cell lines. 
Dot plots show the population doubling time of representative cell lines as measured by the MTS assay (Left panel) (Matsumura 
et al, 2011) and the anchorage-independent cell growth ability for each representative cell line as measured by the methylcellulose 
assay (Right panel) (Mori et al, 2009). Log10-transformed colony number is shown. p-values were computed by Mann-Whitney 




1.3 Platinum resistance in epithelial ovarian carcinoma 
1.3.1 Overview of the platinum-based chemotherapy 
The first member of a class of platinum-containing anti-cancer drugs, 
cis-diamminedichloroplatinum(II), best known as cisplatin or CDDP, was first 
described by Michele Peyrone in 1845. For a long time, it was known as 
Peyrone’s salt until its cytotoxic and antiproliferative property was discovered 
serendipitously in 1965, by Barnett Rosenberg. At that time, Barnett 
Rosenberg was investigating the involvement of electric field in cell division 
when he noticed that bacterial cell growth was inhibited by a soluble platinum 
complex (cisplatin) discharged during electrolysis from the platinum 
electrodes. Subsequently, it was found to be effective at regressing tumours in 
rats (Rosenberg et al, 1969), leading to the approval by the FDA in 1978 for 
the treatment of testicular and bladder cancer. In testicular cancer, cisplatin is 
particularly effective, with an overall cure rate of more than 95% (Kartalou & 
Essigmann, 2001). Presently, cisplatin is employed against a wide range of 
solid malignancies, including ovarian, colorectal, lung, and head and neck 
cancers.  
However, the treatment is limited by its high toxicity and effects on 
kidneys (nephrotoxicity), peripheral nerves (neurotoxicity) and the inner ear 
(ototoxicity) (Kelland, 2007). Much effort has been made in designing new 
platinum drugs that could lessen or remove the severe side effects of cisplatin, 
while retaining its anticancer properties. A major breakthrough in this regard 
was achieved in the mid-1980s, with the introduction of carboplatin (Harrap, 
1985). In contrast to cisplatin, carboplatin does not displays nephrotoxicity 
and neurotoxicity, but instead frequently leads to reversible thrombocytopenia 
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(Kelland, 2007). The active form of carboplatin is identical to that of cisplatin, 
except that carboplatin requires higher concentration to exert similar effects 
and has slower rate of adduct formation (Knox et al, 1986). Though the 
potency of carboplatin is reduced, numerous randomised clinical trials 
reported comparable survival rates between cisplatin and carboplatin regimens 
(Aabo et al, 1998). As a result, carboplatin was granted FDA approval in 
1989, and is now widely accepted as one of the standards in treating ovarian 
cancer. 
Apart from high toxicity, the clinical usefulness of cisplatin in ovarian 
cancer is also limited by the high incidence of acquired and intrinsic resistance 
of cells to the drug. As mentioned in the earlier section, the majority of the 
ovarian cancer patients experience initial therapeutic success with platinum-
based chemotherapy, while only approximately 20% of patients have 
platinum-refractory disease (Cannistra, 2004). Unfortunately, a large fraction 
of the originally sensitive tumours eventually develops resistance against 
platinum-based therapies (Vaughan et al, 2011). Of note, most cisplatin 
resistant tumours also fail to respond to carboplatin (Galluzzi et al, 2012). 
Numerous attempts were thus made to develop new, improved platinum drugs 
to overcome chemoresistance, and so far, only oxaliplatin has been approved 
by the FDA for the treatment of colorectal cancer (Kelland, 2007). However, 
cisplatin and oxaliplatin induces disparate recognition and processing events, 
and exerts anticancer activity on contrasting range of tumours (Chaney et al, 
2005; Rixe et al, 1996). For instance, colorectal cancer which was initially 
acknowledged to be insensitive to platinum drugs, was found to be responsive 
to oxaliplatin-based regimen (Goldberg et al, 2004; Rothenberg et al, 2003).  
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In recent years, the development of platinum(IV) carboxylate prodrugs 
have been encouraging. A prominent example is satraplatin, which is the first 
orally administered platinum drug under active clinical investigation (Kelland, 
2007). Platinum(IV) carboxylates contain cisplatin or carboplatin conjugated 
with symmetric bioactive axial groups, which could potentially be any 
chemical moiety of choice (Wang & Lippard, 2005). In fact, platinum(IV) 
carboxylates with enzyme inhibitors and moieties that can potentiate cisplatin 
activities have been reported (Ang et al, 2005; Barnes et al, 2004). Notably, 
the potential of platinum(IV) carboxylates is further expanded by the recent 
development of a new class of asymmetric platinum(IV) carboxylates, which 
can contain two different functional axial groups (Chin et al, 2012). In their 
study, Chin et al (2012) combined both hydrophilic and lipophilic ligands onto 
the same cisplatin template, leading to novel platinum(IV) carboxylates with 
better aqueous solubility and are also equally efficacious against in vitro 
cancer cells as cisplatin. Though platinum(IV) carboxylates offer unlimited 
number of exciting possibilities, none have yet been shown to provide 
significant advantage over cisplatin and carboplatin (Galluzzi et al, 2012). 
Overall, the main limitation to the effectiveness of cisplatin in the 
battle against solid neoplasms is the high incidence of chemoresistance. 
Accordingly, circumventing platinum resistance remains one of the main 






1.3.2 Mode of action of cisplatin 
It has been suggested prominently in the past that cisplatin exerts its 
anticancer effects via the formation of platinum-DNA adducts, which in turn, 
leads to the inhibition of DNA replication, cell cycle arrest and/or apoptosis 
(Kartalou & Essigmann, 2001; Michalke, 2010). In concordance with this 
hypothesis, platinum adduct levels in blood cells of cancer patients was found 
to be directly correlated with clinical response (Reed et al, 1986).  
For cisplatin to avidly bind to DNA, it has to be intracellularly 
activated by a series of aquation reactions to form a positively charged aquated 
species. Besides DNA, these highly reactive molecules also react with a 
variety of cytoplasmic substrates, particularly with endogenous nucleophiles, 
including reduced glutathione, methionine, metallothioneins and sulphur-
containing proteins (Galluzzi et al, 2012; Michalke, 2010). Such bindings will 
deplete the reduced species and offset the redox balance of the cell, making 
the cell more susceptible to oxidative stress, but at the same time, these 
reduced species can also serve as a sequester and prevent the interaction of 
aquated cisplatin with DNA (Koberle et al, 2010).  
In the nucleus, aquated cisplatin leads to the formation of inter- and 
intra-strand platinum-DNA adducts cause distortion in the DNA and impedes 
cellular processes, such as replication and transcription (Mello et al, 1995; 
Uchida et al, 1986). If the extent of the damage is limited, the cell may induce 
cell cycle arrest and attempt to re-establish DNA integrity through DNA repair 
pathways, such as nucleotide excision repair (NER) and mismatch repair 
(MMR) system (Furuta et al, 2002; Kunkel & Erie, 2005). Generally, the DNA 
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damage will be beyond repair and this activates signalling cascades that 
ultimately leads to apoptosis. However, multiple signalling pathways that 
control cell growth, differentiation and stress responses, have been implicated 
as the linking pathway(s) between platinum-DNA binding and apoptosis 
(Kelland, 2007). Moreover, attempts to decipher the relative contribution of 
these pathways are further complicated by contrasting reports in the literature 
(Galluzzi et al, 2012). 
Taken together, the effectiveness of platinum drugs to form platinum-
DNA adducts seems to be dependent on the availability of platinum to interact 
with DNA, as well as the downstream signalling cascade to elicit cell cycle 
arrest and/or cell death (Kelland, 2007). Though adduct formation is well-
characterised to be the major mode of action of cisplatin, it should also be 
noted that cisplatin-induced apoptosis can also occur independently of DNA 
damage (Berndtsson et al, 2007; Mandic et al, 2003). All these imply that the 
antineoplastic effect of cisplatin can be mediated by multiple mechanisms and 
the alterations in any of these mechanisms can lead to cancer cells presenting a 
platinum resistance phenotype. A simple graphical illustration of the mode of 
action of cisplatin is shown in Figure 1.11. 
 
1.3.3 Mechanisms of cisplatin resistance 
To date, several mechanisms of cisplatin resistance have been 
described, and can be broadly classified into two main categories: (1) 
mechanisms that prevent formation of platinum-DNA adducts and (2) 
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mechanisms that prevent the activation of cisplatin-induced apoptosis 
following adducts formation (Galluzzi et al, 2012; Kelland, 2007).  
The first category can be mediated through the modulation of 
intracellular accumulation of cisplatin, as well as the increased removal of 
platinum-induced DNA lesions by repair pathways. For instance, aquated 
cisplatin can be subjected to increased efflux from the cells, due to the 
upregulation of membrane transporters, such as the ATP-binding cassette 
(ABC) family of plasma membrane transporters (Liedert et al, 2003; 
Yamasaki et al, 2011) and the copper-extruding P-type ATPases (Nakayama et 
al, 2002). Intracellular accumulation of cisplatin can also be reduced through 
the downregulation of cisplatin uptake (Ishida et al, 2002), as well as increased 
expression of cisplatin sequester proteins, such as glutathione and 
metallothioneins (Chen & Kuo, 2010; Kasahara et al, 1991). Alternatively, 
resistance can be acquired through the increased ability of DNA repair 
pathways to remove adducts (Kelland, 2007) and the increased tolerance of 
DNA polymerases to bypass adducts (Hoffmann et al, 1995). In fact, 
expression of ERCC1, a critical gene within the NER repair pathway is found 
to be negatively correlated with cellular sensitivity to cisplatin (Li et al, 2000). 
The importance of DNA repair pathways is further exemplified by testicular 
cancers, whose low DNA repair capability contribute to their hypersensivitiy 
to cisplatin (Koberle et al, 1999). Overall, these mechanisms serve to reduce 
platinum-DNA adducts, and in so doing, prevent the activation of signalling 
cascades leading to apoptosis.  
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For the second category, a plethora of alterations, including defects in 
the signalling cascades that elicit apoptosis, defects in the apoptotic machinery 
itself, as well as the enhancements of pro-survival pathways, can prevent the 
occurrence of cisplatin-induced apoptosis (Galluzzi et al, 2012). Several 
dozens of proteins, including TP53, pro- and anti-apoptotic members of the 
BCL-2 protein family, caspase-inhibitory proteins, and many others are 
involved in the regulation and execution of apoptosis, and most of them have 
been shown to be modulator of response to cisplatin (Gadducci et al, 2002; 
Han et al, 2003; Nakamura et al, 2004). Moreover, platinum resistance needs 
not necessarily to be acquired through alterations in pathways directly engaged 
by cisplatin. Indeed, genes modulations that render cells less sensitive to cell 
death signals (prosurvival) have also been found to be associated with 
cisplatin resistance (Deng et al, 2009; Hu & Friedman, 2010). 
It must be noted that the mechanisms listed above is by no means 
exhaustive. Combination of these mechanisms and also many other 
undescribed mechanisms may be responsible for the acquired and intrinsic 
platinum resistance of cancers, reflecting the multi-factorial nature of cisplatin 
resistance. In view of these, combination therapies of cisplatin with drugs 
targeting these mechanisms may be a feasible strategy in circumventing 
platinum resistance.  
In the context of ovarian cancers, translation of the increased 
understanding of cisplatin resistance mechanisms into clinical practice is still 
lacking (Vaughan et al, 2011), and the optimal combination chemotherapies 
that can restore cisplatin sensitivity to therapeutic useful levels remain 
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undetermined (Sandler et al, 2006). The challenge is further compounded by 
the notion that most of these mechanisms modulate cisplatin response in a 
very restricted number of settings, and are likely to be context-dependent 
(Galluzzi et al, 2012). Moreover, most cisplatin-resistance studies are based on 
targeted gene approach, with few genome-wide functional studies. Hence, in 
the second part of the thesis, we propose using a genome-wide knockdown 
approach to identify functionally relevant molecular targets that could be used 









Figure 1.11 Mode of action of cisplatin. 
Cells can uptake cisplatin through transmembrane protein, such as the copper 
transporter 1 (CTR1). Intracellular cisplatin is aquated and form positively 
charged aquated species that can react with nucleophilic sites on intracellular 
macromolecules. In the cytosol, it binds with cytoplasmic substrates, such as 
reduced glutathione, methionine and metallothioneins. Such bindings deplete 
the reduced species and sustain the generation of reactive oxygen species. In 
the nucleus, the reaction with DNA yields inter- and intra-strand platinum-
DNA adducts that impedes cellular processes, such as replication and 
transcription. Adducts cause distortion in DNA that can be recognised by 
DNA damage-sensing machinery. If damage is limited, the cell may induce 
cell cycle arrest and remove adducts through DNA repair pathways, such as 
nucleotide excision repair (NER). Otherwise, the cell activates signalling 
cascades that ultimately leads to apoptosis. Multiple signalling pathways link 
cisplatin-induced DNA damage and apoptosis. Cisplatin resistance can be 
mediated through the downregulation (*) and upregulation (**) of these 
pathways.   
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1.4 Hypothesis and objective of the thesis 
Despite extensive research in ovarian cancer, in particular epithelial 
ovarian carcinomas (EOC), the disease remains the most lethal gynaecologic 
malignancy. For the past few decades, improvements in the 5-year relative 
survival are at best, modest. The possible reasons for these low survival rates 
are the high incidence of chemoresistance found with EOC and a lack of 
consideration of the high degree of heterogeneity of EOC in the current 
standard of care. Accordingly, the thesis is divided into two parts in an attempt 
to address these two concerns. 
EOC, like most cancers, is hallmarked by a high degree of 
heterogeneity, but it is still widely treated as a single disease entity. To address 
this heterogeneity, our group recently proposed a classification scheme based 
on transcriptional profiles to dissect EOC into five molecular subtypes. These 
subtypes exhibited significantly distinct clinicopathological characteristics, 
deregulated pathways and rates of overall survival. Hence, the proposed 
classification scheme confers new opportunities to devise effective therapeutic 
strategies, specific for each of the multiple subtypes. Therefore, for the first 
part of the thesis, we aim to identify subtype-specific targets, with particular 
focus on the poor prognosis Stem-A subtype. Such targets could be utilised for 
future therapy, and hopefully contribute to the improvement of targeted 
therapeutic regimens for EOC patients. The specific aims are as follows:  
1. To identify Stem-A subtype-specific growth-promoting genes and validate 
the subtype specificity of these genes on at least 5 representative cell lines 
of each subtype. 
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2. To identify the pathway that mediate cell growth and survival in Stem-A 
subtype and demonstrate the subtype specificity effect of drug inhibitors 
specific to the pathway.  
For the second part of the thesis, we attempt to improve patient 
survival via circumventing platinum resistance of EOC. Since the approval of 
cisplatin by the FDA in 1978, platinum-based therapy has been the standard of 
care for EOC patients, and majority of them respond well to the initial 
treatment. Unfortunately, a large fraction of the tumours eventually acquire 
resistance to cisplatin, leading to relapse and treatment failure. Hence, the 
clinical usefulness of cisplatin in EOC is limited by the high incidence of 
platinum-resistance. Extensive research has been carried out on strategies for 
circumventing platinum resistance, but as of now, none has been introduced 
into clinical practice. Therefore, for the second part, we intent to utilise a 
genome-wide knockdown approach, so as to identify target genes that can be 
used to enhance the sensitivity of resistant cells to cisplatin. The specific aims 
are as follows: 
1. To identify cisplatin resistance candidate genes through the use of 
genome-wide knockdown approach. 
2. To test whether drug inhibitors specific to these genes are able to sensitise 











The pooled library of shRNA-expressing lentiviruses (TRC1.0, 
#CSTVRS), pLKO.1-puro shRNA expressing vectors, lentiviral packaging 
mix (#SHP001), polybrene (hexadimethrine bromide, #H9268), puromycin 
(#P9620), dimethyl sulfoxide (DMSO, #D2650), radioimmunoprecipitation 
assay (RIPA) buffer (#R0278), paclitaxel (#T7402), vincristine (#V8879), 
vinorelbine (#V2264) and cisplatin (#C2210000) were purchased from Sigma 
Aldrich (St Louis, MA). SL0101 (#S560000) was purchased from Toronto 
Research Chemicals (Toronto, Canada). ChIP-Seq sample preparation kit 
(#IP-102-1001), and multiplexing index 6 and index 12 primers (#PE-400-
1001) were purchased from Illumina (San Diego, CA). KOD Plus ver. 2 
polymerase (#KOD-211) was purchased from Toyobo (Japan). Roswell Park 
Memorial Institute (RPMI) 1640 medium (#23400), Dulbecco’s Modified 
Eagle Medium (DMEM, #12800), PureLink genomic DNA kits (#K1820-01), 
10% Novex tris-borate-EDTA (TBE) gel (#EC6275BOX) and ProLong Gold 
Antifade reagent (#P36930) were purchased from Invitrogen (Carlsbad, CA). 
Fetal bovine serum (#S1810-500) was purchased from Biowest (Nuaillé, 
France). QIAQuick PCR Purification Kit (#28106), RNeasy Kit (#74104) and 
Omniscript RT Kit (#205111) were purchased from Qiagen (Hilden, 
 56 
 
Germany). SYBR Green PCR Master Mix (#4309155) was purchased from 
Applied Biosystems (Foster City, CA).  
 
All siRNA reagents used in the present study (Dharmacon SMART 
pool siGENOME siRNA; Dharmacon SMART pool ON-TARGETplus 
siRNA) and their transfection reagents (DF1, T-2001; DF2, T-2002, DF3, T-
2003; DF4, T-2004) were purchased from Thermo Scientific (Lafayette, CO). 
CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (#G5430) 
was purchased from Promega (Fitchburg, WI). Affymetrix Human Exon 1.0 
ST arrays were purchased from Affymetrix (Santa Clara, CA).  
The EB3-GFP expressing plasmid was a gift from Prof. Michael 
Sheetz and Dr. Pascale Monzo of the Mechanobiology Institute of Singapore. 
X-tremeGene HP DNA transfection reagent (#06-366-236-001) and FuGene6 
(#11 988 387 001) were purchased from Roche Applied Science (Basel, 
Switzerland). Protease inhibitor cocktail (#539134) was purchased from 
Calbiochem (Boston, MA). Pierce BCA protein assay (#23225) was purchased 
from Thermo Scientific (Rockford, IL). Immobilon-FL Transfer membrane 
(#IPFL00010) was purchased from Merck Millipore (Billerica, MA). 
Antibodies directed against PARP (#9542) and Caspase-3 (#9662) were 
purchased from Cell Signaling (Danvers, MA), antibody against pericentrin 
(#ab4448) was from Abcam (Cambridge, MA), while those against beta-actin 
(#A1978) and alpha-tubulin (#T6074) were purchased from Sigma Aldrich. 
The secondary antibodies for western blotting: secondary IRDye 800CW 
conjugated goat anti-rabbit (#926-32211) and IRDye 680 conjugated goat anti-
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mouse antibodies (#926-32220) were purchased from LI-COR Biosciences 
(Lincoln, NE), whereas those for immunofluorescence analysis: Cy2 
conjugated donkey anti-rabbit IgG (H&L) (#611-711-127) and Cy3.5 
conjugated donkey anti-mouse IgG (H&L) antibodies (#610-712-124) were 
from Rockland (Gilbertsville, PA).  
2.1.2 Cell lines 
Twenty-three ovarian cancer cell lines (OVCA429, OVCAR-8, 
OVCA433, PEO1, ovary1847, HEY, HeyA8, HeyC2, SKOV-3, A2780, CH1, 
PA-1, SKOV-4, SKOV-6, OVCAR-3, DOV 13, OVCA432, OVCA420, 
RMG-II, JHOS-2, IGROV-1, TOV-112D, OVCAR-10) were gifts from Dr. 
Noriomi Matsumura of Kyoto University, Kyoto, Japan. Other cell line, such 
as HEK-293 (#CRL-1573) was obtained from American Type Culture 
Collection (Manassas, VA). All ovarian cancer cell lines were cultured in 
RPMI 1640 medium, while HEK-293 was cultured in DMEM. All media were 
supplemented with 10% foetal bovine serum. All cell lines were maintained at 
37 °C in a humidified incubator containing 5% CO2. 
 
2.2 Genome-wide RNAi screen for subtype-specific growth 
determinants  
2.2.1 Lentiviral library infection 
Fourteen ovarian cancer cell lines representing Epi-A, Mes or Stem-A 
subtype were infected with the pooled library of shRNA-expressing 
lentiviruses (80,000 clones targeting 16,000 genes per library; Sigma Aldrich). 
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These cell lines were chosen based on the silhouette width for the subtype 
signature (Table 3.1), so as to have “more representative” cell lines for a given 
subtype. To ensure the highest probability of having single shRNA integration 
into the host genome in each cell, cells were infected at a multiplicity of 
interest (MOI) of 0.3 (Luo et al, 2008). Under selection pressure from 
puromycin (5 μg/ml; Sigma Aldrich), infected cells were allowed to propagate 
for ~14 days (~4 or 5 passages). 
2.2.2 shRNA retrieval by PCR of the genomic DNA 
At the endpoint of the incubation, genomic DNA was harvested from 
the resulting cells by PureLink Genomic DNA kits (Invitrogen), following the 
manufacturer’s recommendations. The integrated shRNA sequences were 
retrieved from the genomic DNA (100 ng) by PCR amplification using vector 
primers (shRNA Forward Primer: 5'-atcttgtggaaaggacgaaac-3' and shRNA 
Reverse Primer: 5'-tactgccatttgtctcgaggt-3') with KOD Plus ver. 2 polymerase 
(Toyobo). The PCR amplification conditions were as follow: 28-32 cycles of 
98°C for 10 sec, 56°C for 30 sec, and 68°C for 1 min. Products were purified 
with QIAQuick PCR Purification Kit (Qiagen), following the manufacturer’s 
recommendations. 
 
2.2.3 Next-generation sequencing analysis to count copy number of 
individual shRNAs 
Amplified DNA (20 ng) from PCR was used to construct a sequencing 
library using a ChIP-Seq sample preparation kit (Illumina). The two sample-
multiplexing sequencing method was used individually, with multiplexing 
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index 6 and index 12 primers for each sample (Illumina). Constructed libraries 
were subjected to a final size-selection step on a 10% Novex TBE gel 
(Invitrogen). DNA fragments of 205 bp were excised, recovered and 
quantified following Illumina’s qPCR quantification protocol and guides. 
Quantified libraries were then sequenced on the Genome Analyzer IIx 
(Illumina) using the multiplexing single-end sequencing protocol at a length of 
58 + 7 bp (#PE-400-2002, Illumina). Image analysis and base calls were 
performed using the default settings. After stripping off the PCR primer 
sequences, reads were then aligned to the shRNA library using Bowtie with 
the specified settings: --solexa1.3-quals –n 0 –l 5 -v 0 -k 1 -m 1 --best –strata -
y –nomaqround. The data are made available on Gene Expression Omnibus 
(GEO), with the accession of GSE45420. Concordance in the shRNA copy 
numbers among replicates was statistically evaluated by Spearman Correlation 
test. 
 
2.2.4 Statistical identification of subtype-specific growth determinants 
Using reads with a perfect match to the reference sequences (Sigma 
Aldrich), copy number was counted and normalised by total number of reads 
in a sample. RNAi gene enrichment ranking (RIGER) was used to find 
phenotype-specific, functionally relevant genes from the scale-normalised 
copy number count data (Luo et al, 2008). Among 80,000 hairpins included in 
the library, next-generation sequencing analyses detected 60,002 and 65,533 
shRNA hairpins in two independent screenings and 57,168 hairpins were 
intersected in both results. We compiled and subsequently standardised these 
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two datasets by ComBat (Johnson et al, 2007). Binary comparisons were 
performed on the three subtypes (e.g. Epi-A subtype versus the others). We 
adopted the signal-to-ratio as the metric for ranking hairpins, 1000 as the 
number of permutations, and Kolmogorov-Smirnov in the RIGER settings. 
The false discovery rate was computed using the Benjamini and Hochberg 
procedure. Genes were considered significant at q < 0.005 in Fig. 3.5 or q < 
0.03 for the subsequent validation study (Section 2.3).  
 
 
2.3 Validation of functional determinants in cell growth of 
Stem-A cell lines  
From the genome-wide RNAi screen (Section 2.2), 135 top hit genes 
(q < 0.03) were selected as Stem-A-specific growth-promoting genes for 
further validation using siRNAs. The validation experiments were performed 
via a process consisting of four steps (Fig. 3.7). Dharmacon SMART pool 
siGENOME siRNA (1st and 2nd steps) and Dharmacon SMART pool ON-
TARGETplus siRNA (3rd and 4th steps) formats (Thermo Scientific) were 
used to examine the effect of gene knockdown on the cell growth of ovarian 
cancer cell lines (Fig. 3.7). We used two negative controls (siGENOME Non-
Targeting Pools #1 and #2) for Dharmacon SMART pool siGENOME siRNA 
transfection, and one negative control (ON-TARGETplus Non-Targeting 
Pool) for Dharmacon SMART pool ON-TARGETplus siRNA transfection. 
PA-1 (1st, 2nd and 3rd steps) and CH1, A2780 and OVCAR-3 (4th step) were 
used as representative cell line(s) for the Stem-A subtype. As reference(s) for 
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the subtype, HeyA8 (1st step), HeyA8 and OVCA433 (2nd and 3rd steps), 
OVCA429, PEO1, ovary1847, SKOV-3 and HEY (4th step) were used (Fig. 
3.7). The reverse transfection method (Ziauddin & Sabatini, 2001) was used to 
transfect the cells with each individual siRNA per well in a 96-well format. 
The optimal transfection conditions of each cell line are shown in Table 2.1. 
The optimal conditions were previously determined, such that reverse 
transfection of siGAPDH into the cells at these conditions would cause the 
reduction of GAPDH activity by more than 80%. Assays were performed in 
quadruplicate. After 96 hour incubation, an MTS assay was used to measure 
cell growth using a CellTiter 96 AQueous Non-Radioactive Cell Proliferation 
Assay (Promega), following the manufacturer’s recommendations. Genes 
were identified as Stem-A-specific growth-promoting genes when their down-
regulation caused ≥ 20% growth suppression on the Stem-A cell line 
(Student's t-test, p < 0.001), and showed ≥ 20% more growth suppression on 
the Stem-A line than on the reference cell lines. For the fourth step of the 
validation process, differences in growth suppression between Stem-A and 








Table 2.1 siRNA reverse transfection conditions for ovarian cancer cell 
lines. 





Volume of  
Transfection Reagent 
PA-1 Stem-A 1200 cells/well DF2 0.22 μl 
CH1 Stem-A 1800 cells/well DF4 0.17 μl 
A2780 Stem-A 2000 cells/well DF1 0.16 μl 
OVCAR-3 Stem-A 4000 cells/well DF3 0.20 μl 
HeyA8 Mes 800 cells/well DF4 0.08 μl 
ovary1847 Mes 2500 cells/well DF2 0.12 μl 
SKOV-3 Mes 2500 cells/well DF2 0.12 μl 
HEY Mes 1000 cells/well DF4 0.08 μl 
OVCA433 Epi-A 2500 cells/well DF1 0.30 μl 
OVCA429 Epi-A 1500 cells/well DF4 0.22 μl 
PEO1 Epi-A 4000 cells/well DF4 0.24 μl 
 
 
2.4 Ovarian tumour gene expression data derived from 
publicly available databases  
Ovarian tumour gene expression datasets were downloaded from 
multiple data repositories: Gene Expression Omnibus (GEO), Array Express, 
Expression Project for Oncology (ExpO), and The Cancer Genome Atlas 
(TCGA) in February 2010. Microarray data on Affymetrix U133A or 
U133Plus2 platforms were collected, with no limit on patient race, pre-
treatment history or medical conditions, or on the stages, grades, and histology 
of the disease. Altogether, 1,538 ovarian tumour samples were assembled, of 
which, 1,142 samples were identified as core samples, based on their positive 
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silhouette width values for the subtype signature (Fig. 1.3B) (Tan et al, 2013). 
Note that ComBat was performed on the compiled expression data to remove 
batch effect while conserving meaningful variation (Tan et al, 2013).  
Of these datasets, only expression data from GSE3149 (Bild et al, 
2006) and TCGA (The Cancer Genome Atlas Research Network, 2011) have 
accompanying information regarding the patients’ clinical response to 
chemotherapy. Most patients in these datasets received platinum-based 
chemotherapy and had their clinical responses assessed per Response 
Evaluation Criteria in Solid Tumor (RECIST) (Kang et al, 2012).  
 
2.5 Expression data of cultured cell lines  
Microarray analyses for the gene expression of 142 ovarian cancer cell 
lines were previously assembled from four independent datasets: Duke 
University, Kyoto University, National University of Singapore and Lawrence 
Berkeley National Laboratory (Tan et al, 2013). Of these samples, 129 
samples were identified as core samples, based on their positive silhouette 
width values for the subtype signature (Fig. 1.8A) (Tan et al, 2013). 
 
2.6 Pathway analysis for Stem-A-specific gene knockdowns  
Dharmacon SMART pool ON-TARGETplus siRNA (Thermo 
Scientific) was used for the individual silencing of validated Stem-A-specific 
growth-promoting genes—TUBGCP4 and NAT10—in OVCA433 (Epi-A), 
HeyA8 (Mes), and PA-1 (Stem-A), with ON-TARGETplus Non-Targeting 
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Pool (Thermo Scientific) as a negative control. siRNA reverse transfections 
were performed in triplicate, in a 6-well plate, as recommended: OVCA433, 
32,000 cells with 3.0 μl of DF1; HEYA8, 19,000 cells with 0.7 μl of DF4; 
PA1, 18,000 cells with 2.5 μl of DF2. After 96 hour incubation, RNA were 
extracted, as recommended (RNeasy Mini Kit, Qiagen), and used for 
Affymetrix Human Exon 1.0 ST arrays (Affymetrix). There were a total of 9 
expression samples. 
Single sample-Gene set enrichment analysis (ss-GSEA) was performed 
to compute enrichment scores to the expression data (Molecular Signature 
Database, MSigDB version 3.0; 6,769 gene sets) (Subramanian et al, 2005). 
The ss-GSEA score fold-change of each individual gene knockdown clones 
were then computed by taking the difference of ss-GSEA scores between 
knockdown clones and the mean of the negative control. For each gene 
silencing, gene sets with standard deviation of <0.1 and maximum absolute 
fold change of > 0.3 across OVCA433, HeyA8 and PA-1 were denoted as 
commonly altered gene sets. These gene sets are shown in Appendix II. In 
addition, comparison of PA-1 against OVCA433 and HeyA8 was performed 
to identify pathways specifically down-regulated in PA-1 in each individual 
gene knockdown experiment. Gene sets with Significance Analysis of 
Microarrays (SAM; FDR q < 2.5%), Receiver Operation Curve (ROC >0.9) 
and showed at least 20% reduction in ss-GSEA score relative to negative 
control were selected as PA-1 (Stem-A) specific down-regulated gene sets. 
These gene sets are shown in Appendix III. 
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2.7 Stem-A-specific enrichment of microtubule/tubulin-related 
gene sets  
A total of 19 microtubule/tubulin-related gene sets were collected from 
MSigDB version 3.0 (Table 4.1). Enrichment scores for each gene set were 
computed using ss-GSEA to estimate the pathway activity in 1,142 core 
samples of ovarian clinical tumours and 129 core samples of cell lines 
samples. Differences in pathway activity between Stem-A and non-Stem-A 
subgroups were statistically evaluated by Mann Whitney U-test. 
 
2.8 Measurement of cell line drug sensitivity  
Eighteen ovarian cancer cell lines (12 non-Stem-A: OVCA433, 
OVCA429, OVCAR-8, PEO1, OVCA432, OVCA420, HeyA8, HEY, HeyC2, 
SKOV-3, ovary1847 and DOV 13; 6 Stem-A: PA-1, CH1, A2780, OVCAR-3, 
SKOV-4 and SKOV-6) were tested for their sensitivity to paclitaxel, 
vincristine and vinorelbine, as described previously (Bild et al, 2006). Cells 
were seeded in 96-well plates at an optimal density, which was determined for 
each cell line to ensure that it reached 80% confluence by the end of the assay. 
Following an overnight incubation, cells were treated with nine concentrations 
of each drug (2-fold dilution series over a 128-fold concentration range) for 48 
hour. The percentage of the cell population responding to the drug relative to 
the negative controls was measured using a CellTiter 96 AQueous Non-
Radioactive Cell Proliferation Assay, following the manufacturer’s 
recommendations (Promega). Dose-response curves were plotted using 
GraphPad Prism, to derive a growth inhibitory concentration of 50% (GI50; 
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drug concentration for 50% growth inhibitory effects on cells) for each cell 
line in at least three independent experiments of triplicates. Mann-Whitney U-
test of GraphPad Prism was used to statistically evaluate the averaged GI50s 
between non-Stem-A and Stem-A cell lines.  
Note that the procedure described above was also used for the 
measurement of cisplatin sensitivity of OVCA433 cells, but with slight 
modification: cells were cultured with increasing concentrations of cisplatin 
for 72 hour, instead of 48 hour. In addition, ten ovarian cancer cell lines 
(OVCA433, OVCA429, RMG-II, OVCAR8, JHOS-2, PA-1, CH1, IGROV-1, 
TOV-112D and OVCAR-10) were tested for their sensitivity to cisplatin, in 
the presence or absence of SL0101 (Toronto Research Chemicals). For this 
assay, cells treated with nine different concentrations of cisplatin were 
additionally treated with 40 μM SL0101 or its vehicle control (0.04% DMSO). 
After 72 hour incubation, MTS assay was similarly performed to measure the 
effect of the drug combination on cell growth, which was subsequently used to 
plot dose-response curves in GraphPad Prism. Cisplatin GI50 values of 
SL0101-treated cells or vehicle-treated cells were then determined from the 
dose-response curves. Assays were repeated in at least three independent 
experiments. For each cell line, differences in cisplatin GI50 values between 






2.9 Western blotting analysis  
Total cell lysates were prepared by direct lysis with RIPA buffer 
(Sigma Aldrich), supplemented with protease inhibitor cocktail (Calbiochem). 
Protein concentrations were determined using Pierce BCA protein assay 
(Thermo Scientific). Electrophoresis of the cell lysates were carried out with a 
BioRad Mini Protean II apparatus and transferred onto Immobilon-FL transfer 
membranes (Merck Millipore) with a BioRad Mini Trans-Blot apparatus, 
following the manufacturer’s recommendations. Membranes were 
immunoblotted with primary antibodies directed against PARP (Cell 
Signaling), Caspase-3 (Cell Signaling) or β-actin (Sigma Aldrich), followed 
by immunoblotting with secondary IRDye 800CW conjugated goat anti-rabbit 
or IRDye 680 conjugated goat anti-mouse antibodies (LI-COR Biosciences). 
The western blots were scanned using an Odyssey Infrared Imaging System 
from LI-COR Biosciences. 
 
2.10 Live-cell imaging of EB3-GFP comets 
Ovarian cancer cell lines—OVCA433 (Epi-A), HeyA8 (Mes) and 
A2780 (Stem-A)—were seeded on glass coverslips at low density, to ensure 
that the cells would only reach 30% confluence after overnight incubation. 
EB3-GFP expressing plasmid was then transfected into the cells using X-
tremeGene HP DNA transfection reagent (Roche Applied Science), according 
to the manufacturer’s recommendations. At 24 hour post-transfection, time-
lapse images of EB3-GFP comets were taken using Olympus total internal 
reflection fluorescence (TIRF)-iLas
2
 microscope system with 1 s time interval, 
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200 ms exposure time and 60X TIRF objective lens. For each cell line, at least 
180 EB3-RFP comets from 6 independent cells were manually tracked using 
the Fiji software (Schindelin et al, 2012). 
 
2.11 Immunofluorescence analysis 
Ovarian cancer cell lines—OVCA433 (Epi-A), HeyA8 (Mes) and 
A2780 (Stem-A)—were seeded on glass coverslips at a density, such that cells 
would reach 50% confluence after overnight incubation. Cells were then fixed 
with cold methanol for 5 mins at -20°C, and blocked in 0.5% BSA/0.1% 
Triton X in PBS for 10 min at room temperature. After which, cells were 
incubated with primary antibodies directed against pericentrin (Abcam) and 
alpha-tubulin (Sigma Aldrich), followed by incubating with secondary Cy2 
conjugated donkey anti-rabbit IgG (H&L) and Cy3.5 conjugated donkey anti-
mouse IgG (H&L) antibodies (Rockland). DNA staining was then performed 
by incubating the cells with DAPI in PBS for 5 min at room temperature. The 
glass coverslips were mounted on glass slides with ProLong Gold Antifade 
reagent (Invitrogen). Images were taken using Olympus cell^TIRF 
Illuminator, and analysed using the Fiji software (Schindelin et al, 2012). 
 
2.12 Genome-wide RNAi screen for cisplatin resistance 
candidate genes  
OVCA433 cells were infected with the pooled library of shRNA-
expressing lentiviruses (80,000 clones targeting 16,000 genes per library; 
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Sigma Aldrich) at a MOI of 0.3 (Luo et al, 2008), selected with puromycin (5 
μg/ml) and plated into two populations at a seeding density ratio of 2:1. The 
smaller population was left untreated, while the larger population was cultured 
in 11 μM cisplatin. After 5 days in culture, shRNA inserts were retrieved from 
the surviving cells in the untreated and treated populations following the 
procedure described in Section 2.2.2. Copy numbers of individual shRNA 
were determined through the next-generation sequencing analysis, as 
described in Section 2.2.3. Concordance in the shRNA copy numbers among 
replicates was statistically evaluated by Spearman Correlation test. 
Using reads with a perfect match to the reference sequences (Sigma 
Aldrich), copy number was counted and normalised by total number of reads 
in a sample. RIGER analysis was then performed on the scale-normalised 
copy number count data to find shRNAs relatively amplified or depleted in the 
cisplatin-treated population (Luo et al, 2008), and thereby identify genes that 
are functionally relevant to cisplatin sensitivity. We adopted the signal-to-ratio 
as the metric for ranking hairpins, 1000 as the number of permutations, and 
Kolmogorov-Smirnov in the RIGER settings. The false discovery rate was 
computed using the Benjamini and Hochberg procedure. Genes were 
considered significant at q < 0.005 in Fig. 5.2 and in the subsequent validation 





2.13 Validation of functional determinants in cisplatin 
sensitivity  
2.13.1 Custom siRNA library as a second screen for cisplatin resistance 
candidate genes  
The validation experiments were performed via a two steps process 
(Fig. 5.3). For the first step, a custom siRNA library based on the Dharmacon 
SMART pool siGENOME siRNA format (Thermo Scientific), was used to 
target the 96 top hit cisplatin resistance candidate genes from the genome-
wide RNAi screen (q < 0.005; Section 2.12). All siRNAs, including the two 
negative control siRNAs (siGENOME Non-Targeting Pools #1 and #2, 
Thermo Scientific) were individually seeded by the manufacturer in 96-well 
plates. siRNA transfections were performed by introducing OVCA433 cells 
(1500 cells/well) and DF1 (0.3 μl) into each siRNA-containing well. Each 
siRNA transfections were performed in eight replicates, which were split into 
two populations at 24 hour post-transfection. One population was left 
untreated, while the other population were cultured in 20 μM cisplatin. After 
72 hour in culture, effects of siRNAs on cell viability in the presence or 
absence of cisplatin were measured by MTS assay using CellTiter 96 
AQueous Non-Radioactive Cell Proliferation Assay (Promega). Each siRNA 
was assigned a viability ratio calculated as mean viability in cisplatin divided 
by mean viability in the absence of cisplatin. The viability ratios were 
determined in three independent experiments. Following which, differences 
between the viability ratios of each siRNA and those of negative control 
siRNAs, were statistically evaluated using Student's t-test. Genes, which upon 
siRNA silencing, further reduce cell viability in the presence of cisplatin 
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(Student’s t-test, cut-off p-value of 0.05), were retained for the second step of 
the validation process. 
 
2.13.2 Validation of cisplatin resistance candidate genes by shRNAs  
For the second step of the validation process (Fig. 5.3), stable 
integrants expressing shRNAs that target the 16 genes identified from the 
second screen (p < 0.05; Section 2.13.1), were used to ascertain whether 
inhibition of these genes sensitised cells to cisplatin. To establish stable 
integrants, lentiviruses were first generated by co-transfecting pLKO.1-puro 
shRNA expressing vector and Lentiviral Packaging Mix (Sigma Aldrich) into 
HEK-293 cells using FuGene6 (Roche Applied Science), following the 
manufacturer’s recommendations. Virus supernatants were harvested at 36 
hour after transfection and used to infect OVCA433 cells in the presence of 
polybrene (8 μg/ml; Sigma Aldrich). Stable integrants were then established 
through puromycin selection (5 μg/ml; Sigma Aldrich), and subsequently 
tested for their sensitivity to cisplatin, as described in Section 2.8. Stable 
integrant established from shRNA that targets Luciferase (shLuciferase), was 
used as a negative control. Differences between the cisplatin GI50 values of 
each stable integrant and those of shLuciferase were statistically evaluated 





2.13.3 Measurement of shRNA knockdown efficiency by quantitative RT-
PCR 
To measure the knockdown efficiency of shRNAs, quantitative RT-
PCR was performed on the stable integrants established in Section 2.13.2. 
Total RNA was isolated from cultured cells using RNeasy Kit (Qiagen), 
according to the manufacturer’s recommendations. RNA was reverse-
transcribed using Omniscript RT Kit (Qiagen), according to the 
manufacturer’s instructions. qPCR was then performed on 7000 Real-Time 
PCR system (Applied Biosystems), using SYBR Green PCR Master Mix 
(Applied Biosystems) and primers specific to the target genes, following the 
recommended condition of holding at 95°C for 10 min, followed by 40 cycles 
of 98°C for 5 sec and 72°C for 1 min. Primers were designed using Primer3 
software (http://frodo.wi.mit.edu/primer3/) and are listed in Table 2.2. The 
expression levels of target genes were determined based on standard curves, 
with GAPDH as the endogenous quantitative control. For each stable 
integrant, the shRNA knockdown efficiency was computed by normalising the 




















Forward tccatccggaagcagtacat 20 60 
101 
Reverse tgttccacagtccacttcca 20 60 
CATSPE
R3 
Forward gaccttgagccacactgacc 20 60 
169 
Reverse gggcaagtcttccagcatta 20 60 
TNPO3 
Forward cttgccctacagatgccttc 20 60 
167 
Reverse ataatttctgtgcgccgatt 20 60 
KCNN1 
Forward gctaacacgcttaccgacct 20 60 
120 
Reverse atccaagcggctttccag 18 60 
RIT2 
Forward ggtgctggtgggtaacaaaa 20 58 
112 
Reverse ggctgcagaggtctcaaaaa 20 58 
RPS6KA1 
Forward tcccaccaggacctacagc 19 58 
110 
Reverse gccaggatggatgactcg 18 57 
CYB5R3 
Forward gagcatgcagattggagaca 20 60 
139 
Reverse gatcatgcccacagacttca 20 60 
SLC22A6 
Forward tgttcggctaccttgcagac 20 58 
116 
Reverse gcagtagatggggaagttgg 20 57 
TNPO2 
Forward tggcagacttcatcaaaca 19 61 
94 
Reverse gcgatggtggtgatgagaat 20 61 
KCNH3 
Forward ttcctttatgggccagacac 20 60 
132 
Reverse atccaggagacaccagaacg 20 60 
ABCC3 
Forward gctcttcactgtggtcatcct 21 59 
220 
Reverse ctggttggcatccaccttag   20 60 
SLC23A2 
Forward gccagcatcatcgagtctatt 21 60 
128 
Reverse tgccatcaagaacacaggag 20 60 
ART4 







Forward tggctctgtacctggacataaa 22 59 
134 
Reverse ttctggcagttcctcttcatc 21 59 
AKAP13 
Forward attcctggagacggttgc 18 60 
123 
Reverse ggatcctgtgctgtcatcatt 21 60 
PODXL 
Forward accgataccccaaaacacct 20 60 
102 
Reverse ggacgagctgcttctcactc 20 60 
GAPDH 
Forward gacagtcagccgcatcttct 20 60 
127 










Despite recent drug development and numerous clinical trials, 
epithelial ovarian cancer (EOC) remains the deadliest of all gynaecologic 
cancers. For the past 30 years, there were limited improvements in the overall 
mortality rates (Siegel et al, 2013), and advanced stage EOC remains 
associated with low 5-year survival rates (Howlader et al, 2013). The standard 
chemotherapy for EOC has yet to progress beyond platinum-based therapy 
that was introduced in the late 1970s (Vaughan et al, 2011). Thus, there is still 
significant unmet need for women who have been diagnosed with ovarian 
cancer and new therapeutic strategies should be implemented for ovarian 
cancer patients.  
Paramount to the development of new drugs with higher efficacy is the 
realization of the fact that EOC represents a collection of molecularly distinct 
diseases and exhibit extensive heterogeneity (Bast et al, 2009; Coleman et al, 
2013; Gomez-Raposo et al, 2010). Thus, standardised chemotherapy regimens 
should not be identical to all EOC patients. In recognition of this fact, world 
leaders in ovarian cancer field have been advocating for a major shift in 
clinical trial design from all-inclusive Phase III trials to subtype-specific 
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(randomised) Phase II trials that are based on sound scientific rationale 
(Vaughan et al, 2011). Accordingly, clinical trials are being designed to 
exploit the specific pathway aberrations associated with histotypes, such as 
low-grade serous, clear cell and endometrioid ovarian carcinoma (Coleman et 
al, 2013). For example, low-grade serous ovarian carcinoma, which has a high 
incidence of RAS pathway mutations (Singer et al, 2003), is currently being 
investigated in relation to response to the MEK inhibitor, MEK162 
(http://www.clinicaltrials.gov/ct/show/NCT01849874).  
Besides tumour histopathology, the heterogeneity of EOC can be 
defined through high throughput molecular techniques. Rather than evaluating 
one factor or small panels of factors at a time, such techniques allow 
comprehensive assessment of complex biological samples at the DNA, RNA 
and protein levels. Of these techniques, gene expression profiling has been the 
most developed, and is now widely used by multiple groups in their search for 
molecular-phenotypic correlations (Denkert et al, 2009; Mok et al, 2009). 
Major efforts have been made by The Cancer Genome Atlas (TCGA) and the 
Australian Ovarian Cancer Study (AOCS) to extensively characterize EOC. 
Through analysis of genomic profiles from multiple tumour samples, they 
demonstrated the existence of recurrent subtypes defined by transcriptional 
patterns (The Cancer Genome Atlas Research Network, 2011; Tothill et al, 
2008). However, analysis of 285 serous and endometrioid EOC by AOCS 
identified six molecular subtypes (Tothill et al, 2008), whereas TCGA 
reported four molecular subtypes in their analysis of 489 high-grade serous 
EOC (The Cancer Genome Atlas Research Network, 2011). These differences 
are likely to arise because of varied histotype presentation, samples sizes and 
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analytical criteria. Using a much larger collection of ovarian tumour gene 
expression data, our group recently identified five molecular subtypes (Epi-A, 
Epi-B, Mes, Stem-A and Stem-B) (Fig. 1.3A) that exhibited distinct 
clinicopathological characteristics and rates of overall survival (Figs 1.5 and 
1.6) (Tan et al, 2013). In addition, our group was also able to identify 
representative ovarian cancer cell lines for each molecular subtypes (Fig. 
1.8A) (Tan et al, 2013). Though the cell lines may be divergent from their 
ancestral tumour and not wholly representative of the full diversity of ovarian 
cancer, the cell line classification represents a foundation for the development 
of personalised therapy.  
Personalised therapy refers to the matching of patients to appropriate 
therapy according to the biological features of the tumour and 
pharmacogenomics. With the increased emphasis on targeted treatments and 
precision medicine, molecular profiling is starting to influence cancer 
management, from prognostic classification to predicting the most efficacious 
treatment. Several clinical trials are being designed to evaluate the extent to 
which patients matched to therapeutic regimens by their molecular profiles can 
improve clinical outcome. A prominent example is the large, non-randomised 
trial, named WINTHER, in which all patients enrolled are assigned to a 
rational personalised therapeutic regimen based on the RNA profiles of their 
tumours (http://www.clinicaltrials.gov/ct/show/NCT01856296). In fact, 
personalised cancer therapies have already been used with success among 
others for chronic myelogenous leukemia, ER- or Her2-positive breast cancer 
and EGFR-mutated lung cancer (Quintas-Cardama et al, 2009; Rosell et al, 
2010; Yaziji et al, 2004).  
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In personalised therapy, it is critical that the drugs target critical 
pathways that are required for cancer cell viability, and have to be highly 
selective to a particular group of patients rather than broadly cytotoxic (Berns 
& Bernards, 2012). However, other than the standard platinum-taxane based 
regimen, there are little alternative therapeutic options for EOC. Consequently, 
for our proposed EOC classification scheme to be useful, it requires the 
parallel identification of molecular targets, which could be used to develop 
therapeutic options relevant for each molecular subtype.  
The recent success in suppressing the growth of cultured lung cancer 
cells with activating EGFR mutations by siRNA (Sordella et al, 2004) 
unveiled the sensitivity of RNA interference- (RNAi) based approaches in 
distinguishing drivers of tumour growth. As such, short duplex RNAs 
(siRNAs) and vector encoded short hairpin RNAs (shRNAs) libraries that 
cover almost the entire or subsets of the human genome have been generated 
to uncover genes that play a causal role in specific cancer phenotypes. Thus, 
one approach for the identification of specific targets for EOC subtypes is the 
use of such RNAi libraries to perform a genome-wide, systematic, functional 
assessment of genes for their contribution to each molecular subtype. 
Depending on the biological system and the choice of the RNAi 
reagent, the RNAi-based screen can be performed in arrayed or pooled format. 
The arrayed screen format involves the introduction of individual siRNAs or 
shRNAs into cultured cells, and can be used for the isolation of key regulators 
of cancer cell growth or other more diverse and complex phenotypes, such as 
DNA content, cell shape and protein localisation (Berns & Bernards, 2012). 
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However, single-well screen of the entire genome requires very large number 
of plates, a logistically complex and expensive procedure. In contrast, the 
pooled screening approach with shRNAs is primarily used to screen for cell 
growth phenotypes. Pools of shRNA-expressing vectors are introduced into 
cultured cells by transfection or infection such that a typical cell is subjected 
to only one integration event of an shRNA-expressing genome into the host. 
Cells are then allowed to proliferate for a period of time to permit the 
amplification or depletion of hairpins accordingly. Although the vast majority 
of shRNAs have minimal effects on cell proliferation and/or viability, an 
shRNA that silences the expression of a critical gene will be relatively 
depleted. Conversely, the relative amplification of a shRNA suggests that it 
targets a gene with an inhibitory role in cell growth. These integrated hairpins 
are then subsequently retrieved from the genomic DNA by PCR amplification, 
and the abundance of individual shRNA sequence can be measured with 
microarray hybridisation (Luo et al, 2008). Recently, next-generation 
sequencing (NGS) technology emerged as an alternative to microarray-based 
approach, and in comparison, NGS offers better sensitivity and unlimited 
dynamic range (Sims et al, 2011).  
Notably, large-scale genetic studies using RNAi libraries have enabled 
the unbiased identification of genes responsible for proliferation and viability, 
tumorigenicity, adhesion, migration and drug sensitivity in human cancer cell 
lines (Bajrami et al, 2013; Huang et al, 2008; Kolfschoten et al, 2005; Luo et 
al, 2008; Smolen et al, 2010), as well as in mouse models (Meacham et al, 
2009; Zender et al, 2008). For instance, the successful application of a pooled 
shRNA library led to the discovery of PAX8 as having a more essential role in 
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proliferation and survival in ovarian cancer cell lines than in cell lines from 
other tissues (Cheung et al, 2011). Furthermore, TBK1 was identified as a 
synthetic lethal partner of oncogenic KRAS in an earlier report using arrayed 
shRNA library (Barbie et al, 2009). Despite these successes, RNAi technology 
has not been used to identify subtype-specific growth-promoting genes, 
particularly in the context of ovarian cancer. 
 Here, we performed a genome-wide loss-of-function screen to identify 
molecular targets crucial for cell growth in a selected subtype (Stem-A). Upon 
extensive validation of the top hits, TUBGCP4 and NAT10 were identified as 
Stem-A-specific essential genes that can be used as potential therapeutic 
targets in EOC. Together with the proposed EOC molecular classification 
described in Introduction, the results presented in Chapter 3 and 4 were 
previously published in EMBO Molecular Medicine (Tan et al, 2013). 
 
3.2 Results 
3.2.1 Genome-wide functional screen for subtype-specific growth-
promoting genes 
Genes essential to each molecular subtype were investigated via 
genome-wide screens using the pooled The RNAi Consortium (TRC) 
lentiviral shRNA library (Moffat et al, 2006; Root et al, 2006), with the 
presumption that tumours within the same subtype would share molecular 
mechanisms for their growth (proliferation and/or survival). The genome-wide 
functional screen was performed on 14 ovarian cancer cell lines, representing 
Epi-A, Mes and Stem-A subtypes, that differ profoundly in gene expression 
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and clinical properties (Figs. 1.3A and 1.5A) (4 Epi-A: OVCA429, OVCAR-
8, OVCA433, PEO1; 5 Mes: ovary1847, HEY, HeyA8, HeyC2, SKOV-3; and 
5 Stem-A: A2780, CH1, PA-1, SKOV-4, SKOV-6). These 14 cell lines were 
selected based on their high silhouette width values for the subtype, 
acknowledging that PA-1 is a teratocarcinoma cell line (Table 3.1; Fig. 1.8A). 
Silhouette is a graphical aid for the identification of representative members of 
each cluster, wherein members with positive silhouette width values indicate 
higher similarity to members of their own cluster than to any members of 
other clusters, and vice versa for those with negative values (Rousseeuw, 
1987). Thus, the selection of cell lines with high silhouette width values 
allows screening with the more representative cell lines for a given subtype.   
The TRC library contains 80,000 lentivirally expressing short hairpin 
RNAs (shRNAs), with 4 or more independent shRNAs targeting each of 
16,000 human genes. In addition, each lentiviral vector encodes each shRNA 
expression cassette with the puromycin resistance gene, allowing the use of 
puromycin to isolate stable integrants.  
The experimental strategy of the screen is shown in Fig. 3.1. The cell 
lines were infected with the shRNA pools at a multiplicity of infection (MOI) 
of 0.3, to ensure the highest probability of having single shRNA integration 
into the host genome in each cell (Luo et al, 2008). Under puromycin pressure, 
infected cells were allowed to propagate for ~14 days, whereby cells 
expressing shRNAs that silence genes that are required for and known to 
suppress the cell growth were depleted from and enriched in the culture, 
respectively. Hence, the abundance of each shRNA (shRNA copy number) 
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reflects the effect of each shRNA on cell proliferation or viability. At the 
endpoint of the incubation, the genomic DNA was harvested from the 
resulting cells and integrated shRNA sequences were retrieved from the 
genome by PCR amplification using vector primers. PCR amplified DNAs 
were sequenced using highly parallel next generation sequencing and reads 
with perfect match to reference sequences that are provided by Sigma were 
used to retrieve the copy number of each shRNA for each cell line sample. 
Comparison of the shRNA copy numbers among cell lines from the three 
subtypes (Epi-A, Mes and Stem-A) consequently reveals the subtype-specific 
depletion or enrichment of cells expressing a given shRNA.   
To define subtype essential genes, RNAi gene enrichment ranking 
(RIGER) analysis was used to identify genes that have more than one 
independent shRNAs specifically depleted or amplified in a given subtype 
(Luo et al, 2008). RIGER takes into account all independent shRNAs targeting 
each gene in its analysis, and from there, calculates a normalised enrichment 
score (NES) for each gene with respect to the molecular subtypes or any other 
specific classifications. This analysis provides increased power to the screen, 
and compensates for any variation in gene silencing efficacy and possible ‘off-




Table 3.1 Description of ovarian cancer cell lines used. 
Cell Line Subtype 
Silhouette 
width 
Histology Original Repository Source Reference TP53 Status 
A2780 Stem-A 0.41 Undifferentiated ECACC, #93112519 Kyoto U. (Eva et al, 1982) Wild-type 
CH1 Stem-A 0.35 
Papillary 
cystadenocarcinoma 
-- Kyoto U. (Hills et al, 1989) Wild-type 
HEY Mes 0.46 Serous -- Kyoto U. (Buick et al, 1985) Wild-type 
HeyA8 Mes 0.44 Serous -- Kyoto U. (Mills et al, 1990) Wild-type 
HeyC2 Mes 0.44 Serous -- Kyoto U. (Mills et al, 1990) Wild-type 
ovary1847 Mes 0.26 Serous -- Kyoto U. (Eva et al, 1982) T125-K132 deletion 
OVCA429 Epi-A 0.28 Serous -- Kyoto U. (Bast et al, 1981) Wild-type 
OVCA433 Epi-A 0.22 
Papillary serous 
cystadenocarcinoma 
-- Kyoto U. (Bast et al, 1981) Wild-type 




ATCC, #HTB-161 Kyoto U. (Hamilton et al, 1983) R248Q 
OVCAR-8 Epi-A 0.12 Undifferentiated NCI-Frederick Kyoto U. (Schilder et al, 1990) L43 deletion 
PA-1 Stem-A 0.35 Teratocarcinoma ATCC, #CRL-1572 Kyoto U. (Zeuthen et al, 1980) Wild-type 
PEO1 Epi-A 0.22 
Poorly differentiated 
serous adenocarcinoma 
CRT Kyoto U. (Wolf et al, 1987) G244D 
SKOV-3 Mes 0.36 Serous ATCC, #HTB-77 Kyoto U. (Buick et al, 1985) Y126C 
SKOV-4 Stem-A 0.29 -- -- Kyoto U. -- R273C 






Figure 3.1 Experimental strategy of the genome-wide functional screen 
for subtype-specific growth-promoting genes. 
Schematic showing identification of functionally relevant genes for cell 
growth in a subtype-specific manner. Genome-wide collection of shRNA 
vectors are introduced into the cell lines in a pooled format. shRNAs that 
target growth-promoting genes will become depleted, while those that target 
growth suppressive genes are enriched. Copy numbers of shRNAs are 
retrieved by PCR amplification and subsequent sequencing approach. 
Subtype-specific depleted and amplified shRNAs can be identified by 
comparing the shRNA copy numbers among cell lines from the three subtypes 






3.2.2 Assessing the reliability of the genome-wide functional screen 
Two independent screens were performed to ensure reproducibility. 
The initial assay was designed to determine concordance among four 
experimental replicates of a single cell line per subtype (OVCA433, HeyA8 
and PA-1 was used to represent Epi-A, Mes and Stem-A subtypes, 
respectively). Spearman correlations revealed tight correlations among the 
quadruplicates in the screen (Fig. 3.2). The second screen was performed in 
the aforementioned 14 cell lines with the aim to detect differences across 
subtypes as well as concordance among different cell lines within a subtype. 
Fig. 3.3 illustrates highly distinctive genome-wide patterns in the copy number 
of subtype-specific shRNAs that were depleted or amplified. Since the 
screenings detected similarity in subtype-specific depletions or amplifications 
of hairpins, datasets from both independent screens were combined and used 
to identify subtype-specific growth-promoting genes. Though the correlations 
among the quadruplicates and different cell lines within a subtype may not be 
perfect, these observations demonstrate the capability of the system to identify 
shRNAs with differential role in proliferation in a subtype-specific manner.  
Next, to further assess the reliability of the shRNA screen, RIGER 
analysis was performed to identify genes that correlated with the TP53 status 
of the 14 cell lines (Table 3.1). TP53 is a well-known tumour suppressor gene 
that plays a crucial role in preventing tumour development and progression 
through transcriptional dependent and independent mechanisms. Downstream 
genes of TP53 include genes involved in the induction of cell cycle arrest or 
apoptosis after DNA damage, the maintenance of genomic stability, and the 
inhibition of angiogenesis (Nakamura, 2004). As such, the suppression of 
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TP53 should confer selective growth advantage to TP53 wild-type cells 
(Nakamura, 2004). Indeed, the systematic functional screening showed that 
TP53 is among the top ranked genes associated with TP53 genotype of the 
cultured cell lines. The copy numbers of all four TP53-targeting hairpins were 
specifically higher in TP53 wild-type cell lines than in mutant cell lines (Fig. 
3.4), indicating that TP53 suppression specifically increased the cell growth of 
wild-type cells. Subsequently, RIGER analysis was applied to identify genes 




Figure 3.2 Correlation among replicates in the initial genome-wide screen.  
Pair-wise comparisons of normalised read counts from quadruplicates of 
shRNA sequences amplified from genomic DNA of HeyA8, OVCA433 and 
PA-1 in the initial genome-wide functional screen. Numbers indicate 












Figure 3.3 Genome-wide patterns of shRNA copy number across different 
subtypes.  
Heatmaps of centred and normalised copy numbers of all shRNAs (57,168 
hairpins) retrieved from the 14 cell lines via next-generation sequencing 
analysis. The results are compiled from two independent screens. 
Quadruplicates of three cell lines (OVCA433; Epi-A, HeyA8; Mes and PA-1; 
Stem-A) were assayed in the initial screen, while the other screen regarded 
one experimental replicate of 14 different cell lines (Table 3.1). The cell lines 
were sorted according to their subtypes (Epi-A, Mes then Stem-A), whereas 
the shRNA copy numbers were sorted according to hairpin score in the 
RIGER analysis (Luo et al, 2008). Note that a clear genome-wide distinctive 
pattern of hairpins across subtypes was detected. Red = higher; green = lower 

















Figure 3.4 Correlation of shRNAs with cell lines TP53 status.  
Heatmap of centred and normalised copy numbers of all shRNAs (57,168 
hairpins) retrieved from the 14 cell lines via next-generation sequencing 
analysis. RIGER analysis (Luo et al, 2008) was performed to identify genes 
that correlated with the TP53 status. The cell lines were sorted according to 
TP53 wild-type and mutant (Table 3.1), whereas the shRNA copy numbers 
were sorted according to hairpin score in the RIGER analysis. Red arrows 
indicate positions of independent shRNAs targeting TP53. Note that the copy 
numbers of all four TP53-targeting hairpins were relatively higher in cells 









3.2.3 Identification of subtype-specific growth-promoting genes 
The primary aim of the screens was to identify genes that, when 
inhibited, would render growth suppression on a certain molecular subtype. 
Through RIGER analysis, we identified depleted shRNAs targeting 77 genes 
for Epi-A, 85 genes for Mes, and 88 genes for Stem-A subtypes (Fig. 3.5), 
with high significance in subtype enrichment (q < 0.005) and Hairpin Score (> 
0.2). These genes are potentially involved in growth promotion of the cells in 
a given subtype (Appendix I). Conversely, amplified hairpins targeting 43 
genes for Epi-A, 72 genes for Mes, and 44 genes for Stem-A (Fig. 3.5) that 
may have a suppressive effect on cell growth of the given subtype under 
conventional culture conditions were identified (Appendix I). The effect size 
was reasonably large (Cohen, 1988; Monk et al, 2012; Syrjanen & Syrjanen, 
2013): the mean effect sizes of depleted hairpins were Epi-A = -0.9098; Mes = 
-0.7681 and Stem-A = -0.7818, and those of amplified hairpins were Epi-A = 
0.8128, Mes = 0.8282 and Stem-A = 0.7486 (Fig. 3.6; Appendix I). For most 
of the growth-related functional genes, the abundance of shRNAs did not 
show significant correlation to gene expression, implying that the functional 















Figure 3.5 RIGER analysis of shRNA screen identifying subtype-specific 
functional relevance genes.  
Gene centred and normalized heatmap, compiled from two independent 
screens, shows hairpins selectively depleted or amplified in each subtype. The 
quadruplicates of three cell lines (OVCA433; Epi-A, HeyA8; Mes and PA-1; 
Stem-A) were assayed in the initial screen, while the second screen used one 
experimental replicate of 14 different cell lines (Table 3.1). The copy number 
of each hairpin was counted and normalized against the total number of reads 
in a sample and then rendered to RIGER analysis, with which binary 
comparisons were performed for each subtype to obtain subtype-specific cell 
growth determinant genes (e.g. Epi-A subtype versus the others) (Luo et al, 
2008). Top panel. Subtype-specific depleted hairpins in Epi-A, followed by 
Mes and Stem-A subtypes. Each row represents shRNA hairpin copy number 
and is sorted according to the hairpin score identified in RIGER (Luo et al, 
2008). Only hairpin scores ≥ 0.2 and genes significantly enriched in a subtype 
(q < 0.005) are shown. Bottom panel. Subtype-specific amplified hairpins 
arranged as in the top panel. Red = higher; green = lower copy number counts. 















Figure 3.6 Effect size distribution of subtype-specific amplified or 
depleted hairpins.  
Effect-size distribution of the subtype-specific amplified or depleted hairpins 
from the three binary comparisons in RIGER analysis. x-axis is the effect size, 
y-axis is the frequency. Green = subtype-specific depleted hairpins; subtype-











3.2.4 Validation of subtype-specific growth-promoting genes 
To validate the effects of the genes identified from the screens, we 
focused on the Stem-A subtype (given its worse clinical outcome; Fig. 1.5A) 
and targeted individual genes with siRNA (Fig. 3.7A). In addition, only 
growth-promoting genes (i.e. gene targets of depleted shRNAs) were 
subjected for validation, as most pharmacological agents inhibit rather activate 
protein function. Accordingly, 135 genes depleted in Stem-A subtype were 
chosen based on a less stringent q-value cut-off of 0.03 from RIGER analysis 
(note that a more stringent q-value was used in Fig. 3.5; Table 3.2).  
The validation of these 135 genes was performed in a process that 
consisted of four steps (Fig. 3.7B) in order to identify siRNAs that inhibited 
growth on Stem-A cells but had a minimal effect on other cells. Genes were 
individually silenced in ovarian cancer cell lines in 96-well format through the 
reverse transfection method (Ziauddin & Sabatini, 2001), whereby the cells, 
siRNAs and optimal transfection reagent were all added to the wells at the 
same time (see Materials and Methods section 2.3 for additional details). The 
effect of siRNA on cell growth was then measured with the MTS assay after 
96-hour incubation (Fig. 3.7A). For all four steps of validation, Stem-A-
specific essential genes were identified as positive hits based on the following 
comparisons using Student t-tests: 1) comparison between the growth 
inhibitory effect of silencing the gene of interest with that of the siRNA 
negative controls in the Stem-A cells; and 2) comparison between the effect on 
Stem-A cells with that on the references for the subtype (i.e. non-Stem-A 
cells) (Fig. 3.7B). Significance thresholds for the two comparisons were as 
follows: 1) ≥ 20% growth suppression in Stem-A cell with p < 0.001 in a 
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Student's t-test comparing negative control with the gene of interest, and 2) ≥ 





Figure 3.7 Schematics of subtype-specific functional relevance genes 
validation.  
A. Timeline of assay performed for the siRNA validation experiment. B. 
Schematic of siRNA experiments validating the identified Stem-A-specific 
growth-promoting genes. This analysis led to the identification of two 
functionally relevant genes specific to Stem-A: TUBGCP4 and NAT10. Green 




In the first step of validation, experiments were only performed in PA-
1 (Stem-A) and HeyA8 (Mes) cells, and 28 genes were found to be selective 
for PA-1 cell growth (Table 3.2). In the second step, we examined the effect of 
these 28 genes in PA-1 (Stem-A), HeyA8 (Mes) and OVCA433 (Epi-A), and 
further confirmed the growth suppressive effect of 14 of these 28 genes (Table 
3.2). For the third step, the platform was switched from “siGenome” to “On-
Target Plus siRNA” to further validate our observations using different sets of 
target sequences in the genes as well as to reduce possible off-target effects. 
After this step, five genes (TUBGCP4, NAT10, GTF3C1, BLOC1S1 and 
LRRC59) were validated as PA-1-relevant genes (Fig. 3.8; Table 3.2). 
Importantly, PA-1 (Stem-A) cells showed cleavage of Caspase-3 and PARP 
after treatment with siTUBGCP4, siNAT10, siGTF3C1 or siLRRC59, 
indicating activation of apoptosis in these cells (Fig. 3.8). On the contrary, 
cleavage of Caspase-3 and PARP was not detected in non-Stem-A cells 
(HeyA8 and OVCA433) (Fig. 3.9). 
Finally, as the fourth step of the validation process, the experiments 
were conducted with use of additional non-Stem-A (Mes: ovary1847, SKOV-3 
and HEY; Epi-A: OVCA429 and PEO1) and Stem-A (CH1, A2780 and 
OVCAR-3) cell lines to ensure its reproducibility and to exclude any possible 
impact of PA-1 cells being derived from a different cell-of-origin 
(teratocarcinoma), even though it had the highest silhouette width of the Stem-
A cell lines. TUBGCP4 or NAT10 siRNA treatment reproducibly resulted in a 
statistically significant reduction in cell growth for the Stem-A cell lines, 
whereas cell growth for non-Stem-A cell lines was minimally affected (Fig. 
3.10; Table 3.2). These multiple stages of rigorous validation confirmed the 
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dependence of Stem-A cell lines on TUBGCP4 and NAT10 in cell growth and 
ensured that this effect was not limited to PA-1 cells. Silencing of the other 
three genes (GTF3C1, BLOC1S1 and LRRC59), albeit not statistically 
significant, also exhibited a tendency toward differential toxicity in Stem-A 
cells (Fig. 3.10). These observations demonstrate that subtype classification 
based on gene expression is indeed mirrored by patterns of functional genetic 
determinants of cell viability. Moreover, the validated genes can provide us 













Table 3.2 List of Stem-A-selective growth-promoting genes identified for validation.  
Subtype Step No. of Genes Genes 
Stem-A 
Candidates identified by 
shRNA screen 
135 
ACAB, ACER3, ACVR2A, ATIC, BAI2, BEX1, BLOC1S1, C12orf10, C16orf71, 
C2CD2, CA8, CAB39L, CAP2, CASC1, CCL3L1, CDKL3, CHD9, CHPT1, 
CRELD1, CTTNBP2, CUL7, DBNDD1, DDX11, DGKB, ECSIT, EGFR, EIF2S3, 
EPN2, ETFA, ETV2, FAM32A, FIGNL1, FLCN, FOXRED2, FRS2, GNPDA1, 
GOLIM4, GORASP2, GP1BB, GPSM2, GRIK5, GRWD1, GTF3C1, GUF1, HAX1, 
HIF3A, HIPK2, HIST1H2AI, HIST1H4J, HMGN2, HNRNPUL1, HS3ST4, INTS12, 
IQCC, ISCU, JUP, KIAA1012, KIAA1772, KIF2C, KLHL2, KREMEN2, LANCL1, 
LCMT1, LIPT1, LMNB2, LRRC59, MAD2L1, MAR6, MAZ, MED17, MINPP1, 
MRPS14, MTHFD2L, NAALAD2, NAB2, NANOG, NAT10, NCAM2, NONO, NPY, 
NQO2, NUP210, NXPH4, OR2T4, OR5T3, OXCT1, PBX2, PCOLCE2, PIAS4, PIR, 
PNPLA4, POLR2J, PPP1R10, PPP1R3C, PRDX4, PRKD3, PTPRD, QRICH1, 
RAB33B, REEP1, RFC3, RNF4, ROBO1, RPL3L, SERTAD3, SFRS2, SMUG1, 
SNRPN, SSRP1, SSX2IP, TBCC, TEX14, TFAM, TMEM121, TNFRSF4, TRAF5, 
TRPM8, TSPYL2, TTC3, TTLL7, TUBGCP4, UBB, UBL5, UNC119, PGCP, 
UTP14A, WNT10B, ZFP2, ZFR, ZNF35, ZNF573, ZNF652, ZNF770, ZNF804A, 
ZZZ3 
Candidates identified by 
validation step 1 
28 
ACVR2A, BAI2, BLOC1S1, C16orf71, C2CD2, CA8, CCL3L1, CHPT1, GP1BB, 
GTF3C1, HIF3A, HIST1H2AI, ISCU, KLHL2, LRRC59, NANOG, NAT10, NONO, 
PIAS4, PIR, QRICH1, SFRS2, TEX14, TMEM121, TRPM8, TUBGCP4, UBL5, 
WNT10B 
Candidates identified by 
validation step 2 
14 
QRICH1, CHPT1, LRRC59, CA8, NONO, TUBGCP4, BLOC1S1, KLHL2, 
HIST1H2AI, TMEM121, GP1BB, TEX14, GTF3C1, NAT10 
Candidates identified by 
validation step 3 
5 LRRC59, TUBGCP4, BLOC1S1, GTF3C1, NAT10 
Candidates verified in 
11 Ovarian Cell Lines 
(7 non-Stem-A VS 4 
Stem-A) 











Figure 3.8 Validation of PA-1 (Stem-A) functional relevance genes.  
Validation of subtype-selective effect of the genes on cell growth by siRNAs. 
Effect of gene knockdown on cell growth (bar plots) as a percentage ratio of 
growth suppression, normalized against the negative controls. Error bar 
indicates the SEM of three independent quadruplicate experiments. Stem-A-
selective growth suppression effect is shown for the inhibition of the five 
validated PA-1 (Stem-A)-specific growth-promoting genes in OVCA433, 
HeyA8 and PA-1, respectively. Green = OVCA433 (Epi-A); red = HeyA8 









Figure 3.9 Detection of apoptotic activity initiated by the five PA-1 (Stem-A) functional relevance gene knockdowns.  
The five PA-1 selective genes were silenced individually by siRNA in OVCA433 (Epi-A), HeyA8 (Mes) and PA-1 (Stem-A) and 
examined for the presence of apoptotic activity by immunoblotting for cleaved PARP and Caspase 3. Arrows indicate cleavage of 
PARP and Caspase 3. Suppression of LRRC59, NAT10, GTF3C1 and TUBGCP4 was linked with the induction of apoptosis only 
in PA-1 cells, albeit a slight apoptotic response was also detected using the siRNA negative control in PA-1. Green = Epi-A cell 









Figure 3.10 Effect of silencing PA-1 (Stem-A) selective genes on cell 
growth in other ovarian cancer cell lines.  
The five PA-1-selective genes were silenced individually by siRNA in non-
Stem-A (OVCA433, OVCA429, PEO1, HeyA8, ovary1847, SKOV-3 and 
HEY) and Stem-A (PA-1, CH1, A2780 and OVCAR-3) cell lines in three 
independent quadruplicate experiments, and examined for their effect on cell 
growth relative to the negative control. Averaged percentages of growth 
suppression in each group are shown as a box plot and were statistically 
evaluated using Mann-Whitney U-test with GraphPad Prism. Bottom, middle 
and top lines of each box represent the 25th percentile, median and 75th 
percentile, respectively, and whiskers extend to the most extreme values of the 
group. Inhibition with siTUBGCP4 or siNAT10 significantly suppressed cell 
growth of Stem-A cell lines as compared to non-Stem-A cell lines. Grey = 








The consensus clustering of a large collection of epithelial ovarian 
carcinoma (EOC) samples presented previously by our group identified five 
molecular subtypes (Epi-A, Epi-B, Mes, Stem-A and Stem-B) that exhibited 
distinct clinicopathological characteristics and rates of overall survival (Tan et 
al, 2013). As a complement to the proposed classification scheme, we 
performed an unbiased genome-wide RNAi screen for genes that modulate 
cell growth (proliferation and/or viability) in a subtype-specific manner and 
illustrated that subtype-matched cell lines have distinct vulnerabilities. In 
particular, TUBGCP4 and NAT10 were proven as specific growth-promoting 
genes for the poor-prognosis Stem-A subtype. These results offer possible 
opportunities in developing therapeutic strategies that could be matched with 
the characteristics of individual patients. 
The functional screen reported here confers opportunities to recognize 
molecular vulnerabilities as well as particular drug sensitivities relevant for 
each molecular subtypes of EOC. In the current era of molecular targeted 
therapies, there has been an increased appreciation of the importance of 
individual diversity in cancer biology (De Palma & Hanahan, 2012; Vaughan 
et al, 2011). This comes with a shift in clinical trials design from all-inclusive 
Phase III trials to subgroup-specific Phase II trials (Vaughan et al, 2011), so as 
to connect particular patient subgroups to therapies with the highest likelihood 
of benefit. Of note, such concept is only useful when therapeutic alternatives 
are available. Thus far, therapeutic options for EOC are rather limited and no 
studies have been able to reveal molecular subtype-specific dependencies in 
EOC. It is thus our intention to uncover subtype-specific targets, and for the 
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first time, we utilised the pooled shRNA library, in combination with next-
generation sequencing technology as the detection platform (Sims et al, 2011), 
to identify key subtype-specific regulators of cancer cell proliferation and/or 
survival. Importantly, we have demonstrated that specific growth determinants 
can be distinguished amongst the ovarian cancer subtypes at the genome-wide 
as well as gene level. This observation supports the potential for subtype-
specific therapeutic options in treating ovarian carcinoma and reinforces the 
clinical importance of the classification scheme proposed previously (Tan et 
al, 2013). 
As an initial approach, we elected to explore essential genes belonging 
to the poor prognosis Stem-A subtype of EOC. Our results showed that Stem-
A cell lines exhibit selective sensitivity to the suppression of TUBGCP4 and 
NAT10. On the other hand, the silencing of these genes had minimal growth 
suppression effect on non-Stem-A cell lines, and thus, suggesting that new 
therapeutics targeting these genes could prove useful in the therapy of Stem-A 
EOC tumours.  
The relevance of such subtype-specific targets has been exemplified by 
oestrogen receptor 1 (ESR1) for luminal-subtype breast cancers; these cancers 
share not only clinical features such as prognosis and the response to 
hormonotherapy, but also the pattern of gene expression (Sorlie et al, 2001). 
ESR1 has been used not only for diagnosis but also as a molecular target to 
treat cancer patients with this subtype (Chia et al, 2012; Howell, 2013). In 
another example, associations of epidermal growth factor receptor (EGFR) 
mutations and echinoderm microtubule associated protein like 4 - anaplastic 
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lymphoma kinase (EML4-ALK) translocations in non-small cell lung cancer 
(NSCLC) patients with improved response to EGFR (gefitinib, erlotinib and 
afatinib) and ALK (crizotinib) tyrosine kinase inhibitors, respectively 
(Gaughan & Costa, 2011) are paving the way for individualised care of 
NSCLCs. In fact, poly (ADP) ribose polymerase (PARP) inhibitors, such as 
olaparib, have been shown in several clinical trials to exhibit selective toxicity 
to EOC tumours with BRCA1/2 germline mutations (Farmer et al, 2005; Fong 
et al, 2009). Most recently, cyclin E1 (CCNE1) over-expressing ovarian 
cancer cell lines were found to be selectively sensitive to BRCA1 gene 
suppression, suggesting that inhibition of BRCA1 represents a potential 
therapeutic approach for CCNE1-amplified EOC tumours (Etemadmoghadam 
et al, 2013). Similarly, we hoped that our findings will help in the 
improvement of therapeutic regimens for EOC patients.  
It should be pointed out that the functional screen was conducted using 
ovarian cancer cell lines, which were assigned to unique ovarian tumour 
subtypes by expression data (Tan et al, 2013). We acknowledge that cell lines 
may be divergent from their ancestral tumour and not wholly representative of 
the full diversity of EOC. For instance, tumour-associated non-epithelial cells, 
such as blood vessels, fibroblasts and inflammatory cells are not recapitulated 
in the cell line model. Nonetheless, the subtype-representative cell line models 
were previously identified based on their similarity in transcriptional profile 
with their primary tumour counterparts (Tan et al, 2013). These similarities 
were illustrated by the spearman correlation map in gene expression (Fig. 
1.8B; average spearman rho = 0.80), as well as by the shared subtype-specific 
gene sets enrichment in tumours and cell lines (Figs. 1.7 and 1.9). While the 
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correlations between primary tumour subtypes and cell line subtypes are 
admittedly not perfect, subtype-representative cell lines are thus far, the most 
representative models readily available for molecular subtype study. In fact, 
subtype-matched cultured breast cancer cell lines have been used by several 
groups to represent their in vivo counterparts (Gatza et al, 2010; Neve et al, 
2006; Perou et al, 2000). Subsequent integration of our findings with the 
transcriptional, copy number, structural or epigenomic analyses of cancer 
genomes by The Cancer Genome Atlas (TCGA) and other such efforts would 
further validate the clinical relevance of our two Stem-A candidate genes; 
TUBGCP4 and NAT10 (Garay & Gray, 2012). 
Towards the end of this thesis, Domcke et al. (2013) published an 
important study, in which they compared the genomic profiles of high-grade 
serous ovarian cancer (HGSOC) samples in TCGA with those of human 
ovarian cancer cell lines in Broad-Novartis Cancer Cell Line Encyclopedia 
(CCLE) and then, ranked the cell lines according to their suitability as 
HGSOC models. Based on their ranking, majority of the ovarian serous cell 
lines utilised (Table 3.1), as representative models for our proposed molecular 
subtypes of epithelial ovarian carcinoma (EOC), were listed as ‘bad’ cell line 
models of HGSOC (Domcke et al, 2013). However, it is also clear that these 
cell lines share common transcriptional signatures with their corresponding 
EOC molecular subtypes; in particular, those of serous carcinoma (Tan et al, 
2013). Nevertheless, it is true that the lack of good HGSOC models could 
have an impact on the results. To exclude this possible impact, further 
verification using cell lines that are highly representative of the EOC 
molecular subtypes and are also good models of HGSOC, is still required. 
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Interestingly, the biological functions of both TUBGCP4 and NAT10 
are associated with microtubules. TUBGCP4 (tubulin, gamma complex 
associated protein 4) is a component of the gamma-tubulin ring complex 
(γTuRC), which is involved in the nucleation of microtubules from 
centrosome, chromatin and spindle microtubules (Fava et al, 1999; Goshima et 
al, 2008; Guillet et al, 2011; Moritz et al, 1995). Of note, TUBGCP4 is 
evolutionarily conserved (Fava et al, 1999), implying that it performs 
functions that confer selective advantage. Depletion of the gene ortholog leads 
to the reduction of γTuRC in sucrose gradients, as well as an increase in the 
frequency of chromosome mis-segregation in the filamentous fungi 
Aspergillus nidulans, thus suggesting that TUBGCP4 has a role in the 
assembly or stability of the ring complex and in ensuring the fidelity of 
chromosomal segregation (Xiong & Oakley, 2009). Even so, TUBGCP4 has 
been shown to be non-essential for viability in yeast and in Drosophila 
melanogaster (Anders et al, 2006; Verollet et al, 2006), and also non-critical 
for the correct organization of cytoplasmic microtubules in Aspergillus 
nidulans (Xiong & Oakley, 2009). This is perhaps less puzzling in light of 
recent findings that the sub-complex of γTuRC, gamma-tubulin sub-complex 
(γTuSC) forms ring structure even in the absence of other γTuRC components 
and nucleates microtubules from the centrosome, albeit at a much lower 
efficiency (Kollman et al, 2010; Oegema et al, 1999). Conversely, microtubule 
nucleation from non-centrosomal sites, such as within the mitotic spindle, 
depends largely on γTuRC-specific components, which includes TUBGCP4 
(Kollman et al, 2011; Verollet et al, 2006). NAT10 (N-acetyltransferase 10), 
on the other hand, is a protein with lysine acetyltransferase activity, and thus 
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far, has been implicated in diverse processes, including telomerase activity, 
cell survival, cell cytokinesis and nuclear architecture (Larrieu et al, 2014; Liu 
et al, 2007; Lv et al, 2003; Shen et al, 2009). Briefly, NAT10 was first 
identified as an activator of telomerase activity through the transactivation of 
the hTERT promoter (Lv et al, 2003). In addition, NAT10 was found to be 
involved in DNA damage response and enhanced cell survival in the presence 
of genotoxic agents (Liu et al, 2007). Recent reports showed that the 
knockdown of NAT10 led to morphological changes in nuclear shape and also 
induced defective cytokinesis (Larrieu et al, 2014; Shen et al, 2009). Notably, 
NAT10 is known to acetylate α-tubulin, and in turn regulates microtubule 
stability (Perdiz et al, 2011; Shen et al, 2009). Inhibition of its 
acetyltransferase activity by the specific chemical inhibitor, Remodelin, 
indeed caused reorganisation of the microtubule network (Larrieu et al, 2014). 
Given that both genes are associated with microtubules, it may be worth 
examining microtubule-related pathways in Stem-A EOC tumours and/or cell 
lines. Such pathway analysis could possibly allow us to move from targeting 
individual genes to pathway-targeted therapeutic approach. 
Generally, our findings add on to those of previous studies that used 
pooled shRNA libraries in loss-of-function studies to identify essential genes 
in specific human cancer cell lines in the context of synthetic lethality 
(Bajrami et al, 2013; Luo et al, 2008; Scholl et al, 2009) and lineage-
specificity (Cheung et al, 2011). However, a major issue to date remains the 
off-target effects of siRNAs and shRNAs, resulting in the inhibition of genes 
that are not the intended target (Ashworth & Bernards, 2010). As such, it is 
commonly accepted that extensive validation of hits identified is required for 
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any RNAi-based screens. Another critical consideration for pooled shRNA 
screening is the extent to which each shRNA construct is accurately and 
sufficiently represented during the hairpin retrieval by PCR amplification 
(Sims et al, 2011; Strezoska et al, 2012). PCR amplification has been 
demonstrated to be a substantial source of data variability, and so, 
optimisation of amplification conditions would help to avoid introduction of 
bias (Strezoska et al, 2012). Besides PCR optimisation, location of PCR 
primers away from the stem of hairpin also substantially improved the 
uniformity of PCR amplification, compared to primers that amplify the hairpin 
stem (Strezoska et al, 2012). Accordingly, data reproducibility could be 
improved by the use of pooled barcoded-shRNA libraries, in which each 
independent shRNA is tagged with a unique barcode sequence. Unfortunately, 
such libraries were not available to us at the time of our screening, which 
possibly account for our less than perfect correlations among the technical 
replicates. At the same time, we also cannot eliminate the possibility that other 
factors were missed in our screen.  
In addition, a major shortcoming of RNAi screens is the current lack of 
standardisation, and thus, making it difficult for individual laboratories to 
compare their data (Berns & Bernards, 2012). Attempts to integrate the results 
from our screen with that of another published screen using the same shRNA 
library (Cheung et al, 2011) were not feasible because of the differences in 
experimental design and detection platforms. Even so, the power of RNAi 
screens in discovering underlying relationships between genotype and 
essential genes should not be discounted, and can be a valuable tool to extend 




MICROTUBULES AS TARGETS IN STEM-A 
EPITHELIAL OVARIAN CARCINOMA TUMOURS 
 
4.1 Introduction 
As mentioned in Section 1.1.5, epithelial ovarian carcinoma (EOC) is 
hallmarked by a high degree of heterogeneity that arises as a consequence of 
varied somatic mutations and epigenetic changes acquired during the process 
of tumorigenesis and tumour progression. In addition, genomic 
characterization of EOC has revealed the existence of molecular subtypes that 
are associated with distinct clinicopathological characteristics (Tan et al, 2013; 
The Cancer Genome Atlas Research Network, 2011; Tothill et al, 2008). As a 
result, world-leading ovarian cancer researchers and clinician scientists have 
been advocating for the need to recognise EOC as a series of molecularly and 
etiologically distinct diseases (Bast et al, 2009; Vaughan et al, 2011). This 
realisation has opened the frontier of personalised cancer medicine for EOC, 
where the unique biology and genetics of a patient’s tumour is incorporated 
into the decisions on optimal treatment strategies. However, therapeutic 
options for EOC have yet to progress beyond the standard platinum-taxane 
based chemotherapy.  
To improve current therapeutic options, extensive efforts have been 
made in surveying EOC for actionable genomic and epigenomic events. In 
some instances, molecular-based knowledge gained from these genome-wide 
analytical approaches has already an impact on developing personalised 
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therapies. For instance, the discovery that many high-grade serous ovarian 
carcinomas are BRCA1 or BRCA2 defective (Press et al, 2008) has prompted 
the investigation into the efficacy of PARP inhibitors towards such tumours 
(Banerjee et al, 2010; Farmer et al, 2005). Studies have shown that the loss of 
PARP-1 function (a critical DNA damage sensor protein in base excision 
repair pathway) results in the generation of DNA lesions that are normally 
repaired by the homologous recombination DNA repair pathway (Farmer et al, 
2005). Since both BRCA1 and BRCA2 proteins are part of the homologous 
recombination pathway, PARP inhibitors are, thus, selectively lethal to 
BRCA1/2 defective cells (Banerjee et al, 2010). Indeed, a Phase I study of the 
orally active PARP inhibitor, olaparib, reported that only BRCA1/2 mutation 
carriers were associated with objective anti-tumour activity (Fong et al, 2009). 
These promising results as well as those of other randomised Phase II studies 
(Audeh et al, 2010; Ledermann et al, 2012) provided preliminary vindication 
of using PARP inhibitors against BRCA1/2 defective advanced ovarian cancer.  
Adding on to these findings, our group recently reported the 
identification of two subtype-specific growth-promoting genes (TUBGCP4 
and NAT10) that hopefully could be used as therapeutic targets for our 
proposed poor-prognosis Stem-A subtype (Tan et al, 2013). In addition, the 
association of both genes to microtubule suggests that it may be worth 
investigating the relevance of microtubule-targeted agents to Stem-A EOC 
tumours. 
Such microtubule-targeted agents comprise of chemically diverse 
compounds, such as taxanes, epothilones, vinca alkaloids, halichondrins, 
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maytansinoids and colchicine-site binding agents, which bind to tubulin and/or 
microtubule, and alter microtubule polymerisation and dynamics in diverse 
ways (Dumontet & Jordan, 2010). Given the importance of microtubules in 
cell proliferation, such alterations induce mitotic arrest, and thus, mediate anti-
tumour activity. Unsurprisingly, these agents have been part of the 
pharmacopoeia of anticancer therapy for decades, where they are often 
incorporated in combination chemotherapy regimens for a broad range of solid 
tumours and haematological malignancies (Dimitroulis & Stathopoulos, 2005; 
Gridelli et al, 2005; Markman, 2008). Even so, extensive research is still being 
devoted to understanding the role of the extremely diverse microtubule-
targeted agents in different cancer cells and also the mechanisms of resistance 
to these agents (Dumontet & Jordan, 2010). Hopefully, our investigation of 
their clinical relevance to Stem-A EOC tumours may lead to a better 
understanding and utilisation of microtubule-targeted agents in anticancer 
therapy in EOC. 
In this chapter, the clinical relevance of the Stem-A specific growth-
promoting genes, TUBGCP4 and NAT10, and their associated pathway(s) 
were evaluated using the expression data of clinical tumours and cell lines. 
Next, expression microarray analyses were performed to identify pathways 
affected by the Stem-A specific growth-promoting genes. Finally, we 
evaluated the relevance of the various microtubule-targeted agents to Stem-A 






4.2.1 Analysis of TUBGCP4 and NAT10 expression in ovarian tumours 
and cell lines expression data 
Genome-wide transcriptional analysis of the expressed mRNAs has 
been widely used to search for molecular-phenotypic correlations in cancer 
research, with the presumption that correlatively up- and down-regulated gene 
transcripts are hinting of their respective roles as cancer driver and suppressor 
genes. And so, to integrate our findings in Chapter 3 with the transcriptional 
analyses of cancer genomes, we examined the expression level of the two 
Stem-A specific growth-promoting genes, TUBGCP4 and NAT10 in publicly 
available datasets. For this purpose, we utilised the expression data from the 
core samples of ovarian clinical tumours (n = 1,142) and ovarian cancer cell 
lines (n = 129), which were identified in our proposed molecular subtyping to 
be “more representative” for a given subtype (Figs. 1.3B and 1.8A) (Tan et al, 
2013). To eliminate any possible technical differences inherent among the 
different collection sites, the strong batch-effect among the independent 
datasets was removed by ComBat (Fig. 1.1).  
On average, the expression level of both TUBGCP4 and NAT10 is 
significantly, but only slightly higher in Stem-A clinical tumours than in non-
Stem-A clinical tumours (Figs. 4.1A and 4.1B). In ovarian cancer cell lines, 
similar findings were observed for TUBGCP4 (Fig. 4.1C), but no significant 
enrichment of NAT10 was observed (Fig. 4.1D). Though these observations 
suggest the relevance of TUBGCP4 and NAT10 in Stem-A EOC tumours, the 
differences in expression were modest. Moreover, drugs that can alter the 
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function of these two proteins are currently not available, and thus, we should 






Figure 4.1 Comparison of Stem-A specific genes expression in non-Stem-
A and Stem-A subgroups of ovarian cancer. 
Expression level of the two Stem-A specific growth-promoting genes, 
TUBGCP4 and NAT10 were examined in 1,142 core samples of ovarian 
clinical tumours (A and B) and 129 core samples of cell lines samples (C and 
D). Differences in the gene expression between non-Stem-A and Stem-A 
subgroups were statistically evaluated with Mann-Whitney U-test in Graphpad 






4.2.2 Identification of pathways that mediate effects of Stem-A specific 
genes 
Identification of TUBGCP4 and NAT10 as Stem-A specific genes 
prompted us to explore the mechanisms, through which the growth-promoting 
effects are mediated in Stem-A subtype (Figs. 3.10 and 4.2). Each of the Stem-
A specific genes was silenced by siRNAs in 3 ovarian cancer cell lines, 
representing Epi-A, Mes and Stem-A subtypes (Epi-A: OVCA433; Mes: 
HeyA8; and Stem-A: PA-1). Following which, changes in the transcriptome 
resulting from the gene silencing were analysed to identify which pathways 
were affected.  
Quantitative analyses confirmed that all siRNA transfection 
experiments produced significant and appropriate knockdown of these two 
genes with 71.0 ~ 92.6 (median 84.8) % efficacy (Fig. 4.3). Using 6,769 gene 
sets that were downloaded from Molecular Signature Database (MSigDB) 
version 3.0 (Subramanian et al, 2005), single sample gene set enrichment 
analysis (ss-GSEA) was utilised to compute enrichment scores for all samples 
(Verhaak et al, 2010). The enrichment score indicates the degree of 
enrichment of genes in a gene set as compared to those genes outside the gene 
set (Verhaak et al, 2010), and thus, reflects the activity of the associated 
pathway in a sample. As such, changes in enrichment scores reveal the effect 
of gene silencing on a pathway. From this pathway analysis, we detected 425 
gene sets to be commonly altered across the three cell lines (Fig. 4.4; 
Appendix II). As one of the components required for microtubule nucleation 
(Fava et al, 1999), gene targeting of TUBGCP4 resulted in down-regulation of 
the “Microtubule” gene set in the transcriptome (Fig. 4.4), indicating that this 
 112 
 
approach can connect a gene with a pathway as expected from the biological 
function of the gene. 
We next focused on differential pathway alterations as a consequence 
of gene silencing among the three cell lines. The pathway analysis revealed 
several PA-1 specific down-regulation gene sets with notable enrichment in 
metabolism-related gene sets (Fig. 4.5). To better identify pathways that link 
these two genes with PA-1 growth promotion, we surveyed for PA-1-specific 
down-regulated gene sets that overlapped with the ones that were distinctly 
enriched in the cell lines expression data of Stem-A subtype (Fig. 1.9). In 
total, 91 gene sets were found overlapped, and of these, 23 gene sets recurred 
between the two genes (Fig. 4.5; Appendix III). Unfortunately, apart from the 
recurrence of some mitochondria-related pathways such as “Mitochondria 
Membrane” and “Heme Biosynthetic Process”, no other notable regulatory 


















Figure 4.2 Experimental strategy for the identification of pathways 
affected by silencing Stem-A specific genes. 
A schematic of the experiment to identify pathways linked to the growth-
promoting effects of Stem-A specific genes, TUBGCP4 and NAT10. Genes 
were individually silenced in OVCA433 (Epi-A), HeyA8 (Mes) and PA-1 
(Stem-A) by siRNAs. Changes in mRNA transcription were measured by 
expression microarray, and subsequently subjected to pathway analysis to 
identify common and PA-1 specific altered pathways. Green = OVCA433 







Figure 4.3 Quantitative analysis of Stem-A specific genes silencing by siRNAs. 
Effect of silencing each of the two Stem-A specific genes on the relative gene expression in the three cell lines (OVCA433, 
HeyA8 and PA-1). Bar plots indicate the expression of genes of interest with Non-Targeting siRNA (negative control) (white bar) 
and siRNA targeting the gene of interest (si“Gene”; black bar), and the averaged expression of house-keeping genes (ACTB, 
B2M, GAPDH, HPRT1, PGK1, PGK2, PPP1CA, RPL13A, TBP, TFRC) with Non-Targeting siRNA (negative control) (pink bar) 
and siRNA targeting the gene of interest (brown bar). Error bar indicates SEM of three independent triplicate experiments. Green 










Figure 4.4 Common altered pathways arisen from individual Stem-A specific growth-promoting genes knockdown. 
Common pathways in response to knockdown of the two Stem-A specific genes, TUBGCP4 (Left panel) and NAT10 (Right 
panel). Heatmaps show the relative change in ss-GSEA enrichment scores (si“Gene” versus siNon-Targeting negative control). 
Position of the Microtubule gene set is indicated to the right. List of commonly altered pathways can be found in Appendix II. 
Red = increased activity; green = decreased activity. The bar on top of the heatmap indicates triplicates or quadruplicates of 










Figure 4.5 PA-1 specific altered pathways arisen from individual Stem-A specific growth-promoting genes knockdown. 
PA-1 specific down-regulated pathways in response to knockdown of the two Stem-A specific genes, TUBGCP4 (Left panel) and 
NAT10 (Right panel). Heatmaps show the relative change in pathway activities of ss-GSEA enrichment scores (si“Gene” versus 
siNon-Targeting negative control). Positions of the recurrent gene sets, Mitochondria membrane and Heme biosynthetic process 
are indicated to the right. List of PA-1 specific down-regulated pathways that were also distinctly enriched in the cell lines 
expression data of Stem-A subtype can be found in Appendix III. Red = increased activity; green = decreased activity. The bar on 
top of the heatmap indicates triplicates or quadruplicates of OVCA433, HeyA8 and PA-1 cells. Green = OVCA433 (Epi-A), Red 
= HeyA8 (Mes), Blue = PA-1 (Stem-A).  
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4.2.3 Analysis of microtubule/tubulin-related pathway activity in ovarian 
tumours and cell lines  
As mentioned in Section 3.3, TUBGCP4 is a component of γ-tubulin 
ring complex that is involved in the nucleation of tubulin dimers in the cell 
(Fava et al, 1999; Goshima et al, 2008; Guillet et al, 2011; Moritz et al, 1995), 
while NAT10 is reported as a possible acetyl transferase of γ-tubulin that may 
be involved in the stabilisation of microtubules (Hubbert et al, 2002; Shen et 
al, 2009). In addition, silencing of the Stem-A specific gene, TUBGCP4 also 
resulted in a down-regulation of the Microtubule gene set in the transcriptome 
across Epi-A, Mes and Stem-A cell lines (Fig. 4.4; Appendix II). As such, the 
selective effect of siTUBGCP4 or siNAT10 on Stem-A cell lines (Fig. 3.10) 
may suggest that pathways related to microtubules may be significantly 
relevant to Stem-A subtype as compared to other subtypes.  
To investigate this possibility, we compiled all microtubule/tubulin-
related gene sets (n = 19; Table 4.1) from Molecular Signature Database 
version 3.0 (Subramanian et al, 2005) and utilised them for ss-GSEA on 
ovarian clinical tumours and cell lines expression data. Again, the ss-GSEA 
was performed to estimate the activity of a gene set in a sample (Verhaak et al, 
2010). Comparison of the ss-GSEA enrichment scores between Stem-A and 
non-Stem-A subgroups of clinical tumours, as well as cell lines revealed 
higher activity of microtubule/tubulin-related pathways in Stem-A than that in 
non-Stem-A subgroups (p = 6.6x10
-67 
and p = 2.1x10
-6
 by Mann-Whitney U-
test, respectively; Fig. 4.6; Table 4.1). Of note, in our previous analysis of 
subtype-specific pathway enrichment, microtubule/tubulin-related gene sets 
were also found to be distinctly enriched in the Stem-A subtype (Figs. 1.7 and 
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1.9). Taken together, these observations suggested the possible importance of 




Table 4.1 Microtubule/tubulin-related gene sets. 
    
Stem-A vs Rest,  
Mann Whitney p - value 
Index Gene set Clinical Sample Cell Line 
1 BETA_TUBULIN_BINDING 5.2 x 10
-17
 0.0242 
2 TUBULIN_BINDING 3.0 x 10
-54
 1.1 x 10
-06
 
3 MICROTUBULE 2.0 x 10
-51
 8.6 x 10
-05
 
4 MICROTUBULE_ASSOCIATED_COMPLEX 1.8 x 10
-63
 0.0043 
5 MICROTUBULE_BASED_MOVEMENT 2.2 x 10
-53
 8.4 x 10
-06
 
6 MICROTUBULE_BASED_PROCESS 4.0 x 10
-34
 0.0003 
7 MICROTUBULE_BINDING 1.7 x 10
-49
 2.2 x 10
-06
 
8 MICROTUBULE_CYTOSKELETON 3.3 x 10
-67
 0.0004 
9 MICROTUBULE_CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS 6.6 x 10
-42
 0.0079 
10 MICROTUBULE_MOTOR_ACTIVITY 8.8 x 10
-49
 5 x 10
-07
 
11 MICROTUBULE_ORGANIZING_CENTER 2.6 x 10
-45
 0.0003 
12 MICROTUBULE_ORGANIZING_CENTER_ORGANIZATION_AND_BIOGENESIS 1.3 x 10
-36
 3.4 x 10
-05
 
13 MICROTUBULE_ORGANIZING_CENTER_PART 3.0 x 10
-36
 3.0 x 10
-06
 
14 MICROTUBULE_POLYMERIZATION_OR_DEPOLYMERIZATION 9.4 x 10
-44
 9.9 x 10
-07
 
15 BIOCARTA_AKAPCENTROSOME_PATHWAY 2.2 x 10
-19
 0.0022 
16 CENTROSOME 1.7 x 10
-43
 0.0005 
17 CENTROSOME_CYCLE 2.4 x 10
-19
 0.9382 
18 CENTROSOME_ORGANIZATION_AND_BIOGENESIS 1.5 x 10
-30
 2.6 x 10
-05
 











Figure 4.6 Comparison of microtubule/tubulin-related pathways in non-Stem-A and Stem-A subgroups of ovarian cancer. 
Estimated microtubule activity in non-Stem-A and Stem-A subgroups of ovarian cancer. Microtubule activity in 1,142 core 
samples of ovarian clinical tumours (Left panel) and 129 core samples of cell lines samples (Right panel) was estimated based on 
the average single sample gene set enrichment analysis (ss-GSEA) enrichment score of 19 microtubule/tubulin-related gene sets 
(Table 4.1) acquired from GSEA databases. Differences in microtubule activity between non-Stem-A and Stem-A subgroups 
were statistically evaluated with Mann-Whitney U-test in Graphpad Prism. Grey = non-Stem-A subgroup; blue = Stem-A 
subgroup. Tan et al (2013). 
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4.2.4 Investigation of the susceptibility of Stem-A cells to microtubule-
targeted agents 
The dependencies of Stem-A cell lines to genes associated with 
microtubules— TUBGCP4 and NAT10 (Fig. 3.10), as well as the 
comparatively high microtubule activity in Stem-A tumours and cell lines 
(Fig. 4.6), may suggest that the Stem-A cells are more susceptible to mitotic 
inhibition than cells of other subtypes. These findings prompted us to examine 
the in vitro sensitivity of Stem-A cells to microtubule-targeted agents such as 
paclitaxel, vincristine and vinorelbine. For this purpose, a panel of 18 ovarian 
cancer cell lines (12 non-Stem-A: OVCA433, OVCA429, OVCAR-8, PEO1, 
OVCA432, OVCA420, HeyA8, HEY, HeyC2, SKOV-3, ovary1847 and DOV 
13; 6 Stem-A: PA-1, CH1, A2780, OVCAR-3, SKOV-4 and SKOV-6) was 
assayed for their growth inhibitory concentration of 50% (GI50; drug 
concentration for 50% growth inhibitory effects on cells) in at least three 
independent experiments. The Stem-A cell lines were found to be more 
sensitive to inhibitors of tubulin polymerisation, vincristine and vinorelbine 
(Lobert et al, 1996), than non-Stem-A cell lines (Figs. 4.7B and 4.7C). In 
contrast, paclitaxel, a drug that stabilizes microtubules (Manfredi & Horwitz, 
1984), resulted in no significant distinction between the two subgroups (Fig. 
4.7A).  
The results were further confirmed by western blot analysis, whereby 
cells were treated with increasing concentrations of vincristine for 48-hours, 
and subsequently, immunoblotted for the presence of apoptotic activity 
(cleavage of PARP and Caspase 3). As expected, 48-hour vincristine treatment 
caused apoptosis in Stem-A cell lines at 1.2 nM (Fig. 4.8), whereas minimal or 
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no apoptosis was observed in non-Stem-A cell lines, even at 10 nM 
concentration (Fig. 4.8). Therefore, these findings provided evidence that 
drugs targeting tubulin polymerisation may be useful in treating patients with 




Figure 4.7 Susceptibility of Stem-A cells to microtubule assembly 
inhibitors. 
Specificity of microtubule-targeted agents sensitivity in ovarian cancer cell 
lines. A panel of 18 ovarian cancer cell lines was classified into non-Stem-A 
(OVCA433, OVCA429, OVCAR-8, PEO1, OVCA432, OVCA420, HeyA8, 
HEY, HeyC2, SKOV-3, ovary1847 and DOV 13) or Stem-A (PA-1, CH1, 
A2780, OVCAR-3, SKOV-4 and SKOV-6) groups and analysed for their 
sensitivity to paclitaxel (A), vincristine (B) and vinorelbine (C). GI50 values 
were calculated with the results from cell proliferation assays for each cell 
type in three independent triplicate experiments, and the mean GI50s are 
shown as dot plots. A non-parametric Mann-Whitney U-test in Graphpad 
Prism was used to evaluate the results statistically. A higher value along the y-
axis indicates increased sensitivity to the drugs. Stem-A cell lines were 
significantly more sensitive to vincristine and vinorelbine, but not to 









Figure 4.8 Western blot analysis of Stem-A cells sensitivity to microtubule assembly inhibitors. 
Detection of apoptotic activity upon vincristine treatment. Six non-Stem-A (Upper panel) and four Stem-A (Lower panel) cell 
lines were subjected to increasing concentrations of vincristine (0 to 10 nM) for 48 h. The presence of apoptotic activity was 
determined by immunoblotting for cleaved PARP and Caspase 3, as indicated by arrows. Induction of apoptotic activity was only 
detected in Stem-A cell lines. Grey = non-Stem-A subgroup; blue = Stem-A subgroup. Tan et al (2013). 
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4.2.5 Correlation of Stem-A specific dependency with properties of Stem-
A cell lines 
All, if not most, microtubule-targeted agents are anti-mitotic agents 
that inhibit cell proliferation by binding to microtubules and suppressing 
microtubule dynamics (Dumontet & Jordan, 2010). And so, modifications of 
tubulin-microtubule complex that influence drug binding or the effects of drug 
binding, as well as alterations that perturb microtubule dynamics are likely to 
influence sensitivity to microtubule-targeted agents (Dumontet & Jordan, 
2010; Gan et al, 2010). Thus, we sought to understand how the vulnerabilities 
of Stem-A cell lines to tubulin polymerisation inhibitory drugs (Figs. 4.7B and 
4.7C) relate to various properties, such as the intrinsic dynamics of 
microtubules and microtubule structure.  
To examine the intrinsic microtubule dynamics, we transfected EB3-
RFP expressing plasmid into 3 ovarian cancer cell lines, representing Epi-A, 
Mes and Stem-A subtypes (Epi-A: OVCA433; Mes: HeyA8; and Stem-A: 
A2780). The expressed microtubule plus end binding fusion protein, EB3-RFP 
accumulated at the ends of growing microtubules, and served as a marker for 
visualising microtubule growth in live cells (Stepanova et al, 2003). Time-
lapse images were acquired by total internal reflection fluorescence (TIRF) 
microscope, from which the movements of the RFP-fused protein along each 
individual microtubule were manually tracked. The results showed no 
significant differences in the average velocity of RFP-fused protein 
movements among the 3 cell lines (Figs. 4.9A and 4.9B), indicating that the 
susceptibility of Stem-A cells to tubulin polymerisation inhibitory drugs is 
probably not influenced by the intrinsic dynamics of microtubules.  
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We next investigated the integrity of microtubule and centrosome by 
immunofluorescent staining with alpha-tubulin and pericentrin antibodies, 
respectively. As an initial approach, only 3 ovarian cancer cell lines were 
examined (Epi-A: OVCA433; Mes: HeyA8; and Stem-A: A2780). In general, 
we did not observe any differences in microtubule structure or distribution 
among the 3 cell lines (Fig. 4.10). Conversely, abnormally-shaped or large 
centrosomes were observed in the Stem-A representative cell line, A2780, but 
not in the other 2 non-Stem-A cell lines (Fig. 4.10). These preliminary 
observations suggested a possible association between tubulin polymerisation 
inhibitory drugs sensitivity and centrosome abnormalities, but more studies 





Figure 4.9 Analysis of microtubule dynamics in ovarian cancer cell lines. 
A. Representative time-lapse sequences of EB3-RFP comets in OVCA433 (Epi-A; Top panels), HeyA8 (Mes; Middle panels) and 
A2780 (Stem-A; Bottom panels) cell lines. Cells expressing EB3-RFP, a plus end microtubule marker, were imaged with total 
internal reflection fluorescence (TIRF) microscope, at a 1 s time interval. Arrows indicate positions of marked EB3-RFP comets. 
Scale bars, 2μm. B. Quantifications of microtubule dynamics. The life history of at least 180 EB3-RFP comets (extracted from 6 
independent cells) was manually tracked to determine the dynamic parameters for each cell lines. Bar plots indicate average 
velocity of EB3-RFP comets movements. Error bar represents the SEM of three independent experiments. No significant 
differences in microtubule dynamics was observed among the 3 cell lines. Green = OVCA433 (Epi-A); red = HeyA8 (Mes); blue 









Figure 4.10 Immunofluorescence analysis of microtubule and centrosome 
integrity in ovarian cancer cell lines. 
Representative immunofluorescence images for microtubule and centrosome 
in OVCA433 (Epi-A; Top panels), HeyA8 (Mes; Middle panels) and A2780 
(Stem-A; Bottom panels) cell lines. Cells were fixed and immunostained with 
antibodies against α-tubulin (green) and pericentrin (red). DNA staining was 
performed with DAPI (blue). Images were taken using a laser scanning 
confocal microscope. Centrosome abnormalities were only observed in A2780 










In the previous chapter, we identified TUBGCP4 and NAT10 in an 
unbiased genome-wide RNAi screen for genes that modulate proliferation 
and/or survival in a subtype-specific manner. In addition, the interrogation of 
these Stem-A specific genes across multiple ovarian cancer cell lines provided 
further evidences of the subtype-specific dependence. Therefore, we 
proceeded to evaluate the relevance of these genes and their associated 
pathway in ovarian clinical tumours. In particular, the poor-prognosis Stem-A 
subtype was found to exhibit elevated microtubule activity. Upon further 
investigation, Stem-A representative cell lines were found to be significantly 
more sensitive to several tubulin polymerisation inhibitor drugs, such as 
vincristine and vinorelbine than cell lines of other subtypes. Hopefully, these 
findings offer possible opportunities to improve therapeutics for epithelial 
ovarian carcinoma (EOC). 
With the development of genome-wide analysis tools, bewilderingly 
large numbers of different epigenomic and genomic aberrations, which can be 
targeted for therapeutic benefit, are now being discovered. Such findings offer 
unprecedented opportunities for accelerating improvement of cancer 
therapeutics, but at the same time, presents a significant challenge for therapy 
development. It is not financially or logistically feasible to develop therapies 
targeting all these aberrations and also carry out clinical trials for them. This is 
especially true for EOC given the relatively low prevalence of the disease. 




An ideal therapeutic target would be a driver protein or pathway that is 
uniquely up-regulated in target tumour with poor clinical outcomes (Garay & 
Gray, 2012). In addition, the target should also be druggable (Garay & Gray, 
2012). Indeed, our present data provide evidence that TUBGCP4 and NAT10 
are functionally relevant to the poor-prognosis Stem-A subtype (Chapter 3). 
Integrated analysis of the functional dependencies and the transcriptional 
profiles of ovarian clinical tumours revealed significant up-regulation of 
TUBGCP4 and NAT10 in the Stem-A subtype. However, it should be pointed 
out that the differences in expression were not convincingly high, and together 
with the lack of readily available specific drug inhibitors, TUBGCP4 and 
NAT10 are unlikely to be prioritised for therapy development. Therefore, in 
the next step, we switched from targeting individual genes to targeting 
pathway(s) that mediate the effects of TUBGCP4 and NAT10.  
In the integrated genomic analyses of high-grade serous ovarian 
carcinoma, the high frequency of de-regulated RB1 and PI3K/RAS signalling 
pathways were found to be driven by a diverse array of low prevalence 
genomic and epigenomic aberrations that vary between patients (The Cancer 
Genome Atlas Research Network, 2011). These observations indicate that 
pathway-targeted therapeutics could be a powerful alternative to target 
tumours or tumour subtypes. Unfortunately, attempts to identify effector 
pathway(s) of TUBGCP4 and NAT10 through the genome-wide transcriptional 
analysis were unsuccessful. On the other hand, the association of TUBGCP4 
and NAT10 with microtubules prompted us to examine the 
microtubule/tubulin-related pathway, and we indeed found significantly high 
microtubule activity in the Stem-A subtype. Of note, Stem-A representative 
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cell lines were found to be specifically more susceptible to tubulin 
polymerisation inhibitory drugs, vincristine and vinorelbine, but not to the 
tubulin stabilising drugs, paclitaxel.  
Both vincristine and vinorelbine are well-established chemotherapeutic 
agents that block cell proliferation by inhibiting microtubule assembly through 
its interaction with microtubule ends (Lobert et al, 1996). On the other hand, 
paclitaxel enhance microtubule polymerisation by binding to the inside surface 
of microtubule (Desai & Mitchison, 1997). As such, their diverse mechanisms 
of action could possibly account for their differential responses in EOC 
subtypes. In fact, these drugs have been approved for different cancer types. 
Paclitaxel is primarily employed in solid cancers, such as breast, ovarian and 
gastro-oesophageal, while vincristine and vinorelbine are most often used for 
haematological malignancies, such as lymphomas and leukaemia (Stanton et 
al, 2011).  
Further investigations on cellular properties found a Stem-A cell line 
with centrosomal abnormalities, suggesting a possible association with tubulin 
polymerisation inhibitory drugs sensitivity. Centrosomal abnormalities have 
been identified in many different tumours, including ovarian carcinoma, and 
their prominence often correlates with poor clinical outcome (Chan, 2011; 
Nigg, 2006). However, it remains unclear whether these abnormalities can 
account for the Stem-A susceptibility to vincristine and vinorelbine, and also 
whether these abnormalities can also be found in other Stem-A cells. Hence, it 




So far, the molecular mechanisms linking TUBGCP4 or NAT10 with Stem-A 
growth remains to be elucidated. Nevertheless, the susceptibility to vincristine 
and vinorelbine underscores the possible importance of tubulin polymerisation 
in Stem-A cells. However, they are not standard chemotherapeutic reagents for 
the treatment of EOC, unlike paclitaxel (Armstrong et al, 2006; McGuire et al, 
1996). The molecules implicated in the tubulin polymerisation pathway may 
provide us with a potential platform to more effectively target Stem-A ovarian 





GENOME-WIDE FUNCTIONAL SCREEN FOR 
CISPLATIN RESISTANCE CANDIDATE GENES 
 
5.1 Introduction 
Although therapeutic strategies that could be matched with the 
characteristics of individual patients are promising, progression free survival 
of epithelial ovarian carcinoma (EOC) could also be improved by 
circumventing platinum resistance. Hence, in this second part of the thesis, we 
attempt to address the critical issue of chemoresistance in EOC. 
Platinum derivatives, such as cisplatin and carboplatin, play a central 
role as a first-line treatment option in EOC, and are usually administered 
together with taxanes. Although EOC is a relatively chemosensitive disease, 
approximately 20% of patients present platinum-refractory disease (Cannistra, 
2004). Moreover, a large fraction of the patients who initially experience 
therapeutic success, suffer from relapse within a window of months to years, 
and the relapsed tumours typically acquire resistance to platinum (Coleman et 
al, 2013; Vaughan et al, 2011). Thus, intrinsic and acquired platinum 
resistance are among the major reasons for the low survival of EOC, and 
overcoming platinum resistance will allow patients to achieve more durable 
response to therapy. 
Previous studies have classified the mechanisms of cisplatin resistance 
into two main categories: the first, prevention of platinum-DNA adducts 
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formation and the second, impairment in activation of apoptotic response 
following adducts formation (Galluzzi et al, 2012). The former category can 
be mediated through decreased uptake, increased detoxification and export of 
platinum and elevated DNA repair, while the latter category can occur as a 
consequence of defective apoptotic signal transduction and activation of pro-
survival pathways. At present, this knowledge is yet to be translated into 
clinical practice (Vaughan et al, 2011). Hence, circumventing platinum 
resistance remains a critical goal for ovarian cancer therapeutics. 
One approach for the identification of novel combination therapies that 
can circumvent platinum resistance is the use of a genome-wide RNAi screen. 
Such RNAi screens have proven to be a powerful approach in identifying both 
drug resistance mechanisms and enhancers of drugs activity, from which 
strategies to counter resistance can be developed (Berns & Bernards, 2012). 
The use of these screens to identify novel drug enhancers has been 
exemplified by the discovery that suppression of ATP6V0D2, a subunit of the 
vacuolar ATPase led to enhanced sensitivity of non-small cell lung cancer 
(NSCLC) cell lines to paclitaxel (Whitehurst et al, 2007). In particular, 
treatment of NSCLC lines with a vacuolar ATPase inhibitor, RTA203 in 
combination with paclitaxel revealed a significant collaborative impact on 
viability (Whitehurst et al, 2007). Moreover, the genome-wide RNAi screen 
that we presented in Chapter 3 also illustrated the strong predictive power of 
such screens for identification of potential therapeutic targets. 
Therefore, in this chapter, we performed a genome-wide loss-of-
function screen to identify molecular targets that, when inhibited, would 
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enhance the sensitivity of cells to cisplatin. Following extensive validation of 
the top hits, we identified six genes, including ABCC3, KCNH3, KCNN1, 
MLH1, MRPL3 and RPS6KA1 as cisplatin resistance candidate genes. In 
addition, combination of a RPS6KA1 specific inhibitor, SL0101 with cisplatin 
was shown to render cells more sensitive to cisplatin. 
 
5.2 Results 
5.2.1 Genome-wide functional screen for cisplatin resistance candidate 
genes 
Similar to our screen for subtype-specific growth-promoting genes 
(Chapter 3), genes relevant to cisplatin resistance were also investigated via 
genome-wide screens using the pooled The RNAi Consortium (TRC) 
lentiviral shRNA library (Moffat et al, 2006; Root et al, 2006). Compared to 
the functional screen in Chapter 3, the screen presented herein was designed to 
identify gene targets that upon suppression by shRNA further reduce cell 
viability as otherwise expected at a sub-lethal cisplatin concentration. Such 
genes are likely to be involved in cisplatin resistance mechanisms, and can be 
targeted to increase the cisplatin sensitivity of resistant cells. Hence, these 
genes will be denoted as cisplatin resistance candidate genes. 
Growth inhibitory concentration of 50% (GI50; drug concentration for 
50% growth inhibitory effects on cells) of cisplatin for a panel of 46 ovarian 
cancer cell lines spanned a wide range of concentrations, from 0.38 μM to 
41.43 μM (Matsumura et al, 2011). Given its high GI50 value (22.58 μM; 
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median GI50 is 9.29 μM) and ease of handling, the cell line, OVCA433 was 
selected from this panel for the genome-wide functional screen.  
The TRC library, as described in Section 3.2.1, contains 80,000 
lentivirally expressing shRNAs, with 4 or more independent shRNAs targeting 
each of 16,000 human genes. In addition, each lentiviral vector encodes each 
shRNA expression cassette with the puromycin resistance gene, allowing the 
use of puromycin to isolate stable integrants.  
The experimental strategy for this screen is shown in Fig. 5.1. 
OVCA433 cells were infected with the shRNA pools at a multiplicity of 
infection (MOI) of 0.3, to ensure the highest probability of having single 
shRNA integration into the host genome in each cell (Luo et al, 2008). 
Puromycin was then used to select for the presence of shRNA vectors. After 
selection, infected cells were split into two populations at a ratio of 1:2, of 
which the former population was left untreated and used as reference, while 
the latter population was treated with 11 μM cisplatin. This cisplatin dosage 
was previously known to inhibit OVCA433 cell growth by 50% after 5 days of 
culture, thus implying that the number of cells expressing shRNAs that are of 
no relevance to cisplatin would be the same in both populations. In particular, 
shRNAs that silence genes involved in cisplatin resistance mechanism(s), 
would upon cisplatin treatment, further limit the growth or viability of the 
cells into which they were introduced, resulting in the relative depletion of 
such shRNAs. Conversely, relative amplification of shRNAs suggests that 
they target genes that help to mediate the anticancer effect of cisplatin. Such 
genes will be denoted as cisplatin sensitizing genes. Therefore, by comparing 
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the abundance of each shRNA (shRNA copy number) in the cisplatin 
treatment population to that in the reference population, we can identify 
shRNAs that decreased or increased cell growth or viability in the presence of 
cisplatin, but to ignore shRNAs that were inherently toxic and have no 
synergistic relationship with cisplatin.  
At the endpoint of the incubation, the genomic DNA was harvested 
from the resulting cells and integrated shRNA sequences were retrieved from 
the genome by PCR amplification using vector primers. PCR amplified DNAs 
were sequenced using highly parallel next generation sequencing and reads 
with perfect match to reference sequences that are provided by Sigma, were 
used to retrieve the copy number of each shRNA for each population. 
Comparison of the shRNA copy numbers between the two populations 
consequently reveals the relevance of each shRNA to cisplatin. 
To define genes relevant to cisplatin, RNAi gene enrichment ranking 
(RIGER) analysis was used to identify genes that have more than one 
independent shRNAs relatively depleted or amplified in the cisplatin treatment 
population (Luo et al, 2008). RIGER takes into account all independent 
shRNAs targeting each gene in its analysis, and from there, calculates a 
normalised enrichment score (NES) for each gene. This analysis provides 
increased power to the screen, and compensates for any variation in gene 








Figure 5.1 Experimental strategy of the genome-wide functional screen 
for cisplatin resistance candidate genes. 
Schematic design showing the identification of genes with relevance to 
cisplatin. Genome-wide collection of shRNA vectors are introduced into 
OVCA433 cells in a pooled format. Infected cells were split into two 
populations: Reference and Cisplatin treatment. shRNAs that increase 
sensitivity of OVCA433 to cisplatin (Resistance genes) will be relatively 
depleted, while those that decrease cisplatin sensitivity (Sensitizing genes) are 
relatively amplified. Copy numbers of shRNAs are retrieved by PCR 
amplification and subsequent sequencing approach. Depleted and amplified 




5.2.2 Identification of cisplatin resistance candidate genes  
The primary aim of the screen presented herein was to identify genes 
that, when inhibited, would render OVCA433 cells more sensitive to cisplatin. 
Figure 5.2 showed the abundance of the shRNA vectors in both the reference 
and cisplatin treatment cell populations. To determine the concordance among 
the technical replicates, we employed spearman correlation analysis in the 
reference (Spearman rho = 0.6059) and the cisplatin treatment populations 
(Spearman rho = 0.6551). Similar to our previous screen (Section 3.2.2), the 
concordance was not perfect; this approach would need further improvement. 
Nevertheless, distinct differences in the shRNA copy numbers can still be 
observed between the two cell populations. 
Through RIGER analysis, we identified relatively depleted shRNAs 
targeting 96 genes (Fig. 5.2; Appendix IV), with high significance (q < 0.005) 
and Hairpin Score (> 0.5). These indicated that shRNA silencing of these 
genes decreased cell viability in the presence of cisplatin. It is possible that 
these genes are involved in cisplatin resistance mechanisms, and are thus, 
denoted as cisplatin resistance candidate genes. Conversely, relatively 
amplified hairpins targeting 78 genes (Fig. 5.2; Appendix IV) that may be 
involved in cisplatin response were identified. Viability of cisplatin-treated 
cells increased when these genes were silenced, implying that their increased 
abundance might augment the sensitivity of OVCA433 to cisplatin. These 













Figure 5.2 RIGER analysis of shRNA screen identifying cisplatin 
resistance candidate genes. 
Heatmaps of centred and normalised copy numbers of all shRNAs retrieved 
after next-generation sequencing analysis (Left panel) and shRNAs with high 
significance (q < 0.005) and hairpin Score (> 0.5) in RIGER analysis (Right 
panel). Each row represents shRNA hairpin copy number and is sorted 
according to the hairpin score identified in RIGER (Luo et al, 2008). Red = 











5.2.3 Validation of cisplatin resistance candidate genes 
The cisplatin resistance genes and the sensitizing candidate genes 
identified from our genome-wide screen (Fig. 5.2) are both potential targets 
for therapy. However, it is more difficult to develop therapies that enhance the 
function of a sensitizing gene than it is to suppress the activity of a cisplatin 
resistance candidate gene. In addition, most pharmacological agents inhibit 
rather than activate protein function. Therefore, we elected to focus on the 
cisplatin resistance candidate genes, of which 96 genes were chosen based on 
the q-value cut-off of 0.005 from RIGER analysis (Fig. 5.2). 
To confirm that inhibition of these genes indeed sensitises cells to 
cisplatin, we performed the validation in a process that consisted of two steps 
(Fig. 5.3). First, we performed a second screen on OVCA433 cells using 
siRNAs, targeting each of the 96 cisplatin resistance candidate genes (Fig. 
5.4A). Specifically, genes were individually silenced by siRNAs in 96-well 
format through the reverse transfection method (Ziauddin & Sabatini, 2001). 
Transfections were performed in octuplicate for quadruplicate analysis in the 
presence and the absence of cisplatin. A 72-hour exposure to 20 μM cisplatin 
was used as a sub-lethal dose that should only inhibit OVCA433 cell growth 
by approximately 50%. Cell viability was subsequently measured with the 
MTS assay after 72-hour cisplatin treatment (Fig. 5.4A). Each siRNA was 
assigned a viability ratio calculated as mean viability in cisplatin divided by 
mean viability in the absence of cisplatin. Cisplatin resistance candidate genes 
were identified as positive hits based on the p-value cut-off of 0.05 in a 
Student's t-test analysis comparing the viability ratio of silencing the gene of 
interest with that of the siRNA negative controls. Thus, in this second screen, 
 141 
 
silencing of 16 genes was found to increase the sensitivity of OVCA433 cells 
to cisplatin (Fig. 5.4B; Table 5.1). 
Finally, for the next step of the validation process (Fig. 5.3), we 
switched from siRNA to shRNA to further validate our observations using 
different sets of target sequences in the genes as well as to reduce possible off-
target effects. OVCA433 cells were lentivirally transduced with individual 
shRNAs to establish stable integrants for each of the 16 genes identified from 
the second screen (Fig. 5.4B). Stable integrant established from shRNA 
targeting Luciferase (shLuciferase) was used as a negative control. These 
stable integrants were exposed to a range of doses of cisplatin, and assessed 
for viability after 3 days. Six of the stable integrants showed a shift in their 
dose-response curves (Fig. 5.5A-F), indicating that the expression of shRNAs 
targeting ABCC3, KCNH3, KCNN1, MLH1, MRPL3 and RPS6KA1, sensitised 
OVCA433 cells to cisplatin. Indeed, GI50 values for these six stable integrants 
were at least twice lower than that of the shLuciferase control (Fig. 5.6A). The 
reliability of these six shRNAs to reduce expression of their respective genes 
was confirmed by quantitative RT-PCR analysis (Fig. 5.6B). Overall, these 
multiple stages of validation confirmed that silencing of ABCC3, KCNH3, 
KCNN1, MLH1, MRPL3 and RPS6KA1 rendered OVCA433 cells more 
sensitive to cisplatin. 
Moreover, in the absence of cisplatin, expression of shRNAs targeting 
these six genes caused no more than 15% reduction in cell viability as 
compared to the negative control (shLuciferase) (Fig. 5.7), and also did not 
lead to changes in cell morphology. These observations suggested that the 
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increase in cisplatin sensitivity is unlikely to be indirectly caused by the 
effects of gene silencing on cell health. 
Our finding of a member of the ATP binding cassette (ABC) 
transporter superfamily, ABCC3 as a cisplatin resistance candidate gene is 
consistent with earlier reports which demonstrated their contributions to 
chemoresistance through the efflux of anticancer drugs from cancer cells 
(Borst et al, 2000; Gottesman et al, 2002; Januchowski et al, 2013). However, 
the discovery of six genes with seemingly diverse biological functions reflects 
the multi-factorial nature of cisplatin resistance (Coleman et al, 2013). Since 
all experiments were conducted in a single cell line, OVCA433, we have no 
idea whether the inhibition of these six genes can also render other ovarian 
cancer cell lines more sensitive to cisplatin, and thus, raising the possibility 
that the relevance of these genes to cisplatin resistance could be cell line-























Figure 5.3 Schematics of cisplatin resistance candidate genes validation. 
Schematic of experiments validating the cisplatin resistance candidate genes 
identified from the genome-wide functional screen. This analysis led to the 
identification of six genes involved in the cisplatin resistance of OVCA433 










Figure 5.4 Second screen for cisplatin resistance candidate genes using 
siRNAs. 
A. Timeline of assay performed for the second screen. B. Effects of individual 
siRNAs on the cisplatin sensitivity of OVCA433 cells. 96 cisplatin resistance 
candidate genes (Fig. 5.2) were silenced individually by siRNAs, and exposed 
to the presence and the absence of cisplatin. Each siRNA was assigned a 
viability ratio calculated as mean viability in cisplatin divided by mean 
viability in the absence of cisplatin. Bar plot indicates the viability ratio of 
siRNA relative to that of negative control siRNAs. Error bar indicates the 
SEM of three independent quadruplicate experiments. siRNAs with 
statistically significant relative viability (p-value < 0.05) in Student's t-test 
were shown as green. The second screen identified 16 siRNAs that enhanced 















SLC5A1, RB1, PABPC4, SLC6A13, ANAPC11, SLC22A6, CAV3, AKR1B10, KCND1, ATP6V0A1, 
SLC22A1, TNFRSF8, NF2, TBL3, KCNN1, CLDN14, EXOC3, HIST1H4F, RIT2, RPS6KA1, MLH1, 
CATSPER3, VTI1A, KRTHA1, AP1M1, RPL7L1, XRCC4, SLC6A17, TNPO3, SLC23A2, CTAG2, 
CYB5R3, SLC27A5, ZNF510, FKSG30, MRPL3, LOC393062, SPTBN4, DUOX2, KIFC3, SLC5A12, 
ABCC3, MR1, VKORC1, RAB3GAP2, PPL, SLCO4C1, PEX5, SLC35E2, SLCO2A1, BIN1, 
ATP6V0D2, TRPC3, ATP6V0A2, CLCN1, AKAP8, KCNJ3, ST3GAL6, SLC35B1, RBM15, CKAP1, 
ZNF694, SLC25A17, ZNF546, ATP1B3, SCN4A, CKS1B, TRPV3, DUOX1, TPCN2, WDR57, 
HIST1H4B, KCNH3, CACNA2D1, INCENP, NMRAL1, AKAP13, TMEM16A, CBR1, DPP10, 
MYO15A, TNPO2, GPC3, ZNF418, SLC26A4, ACE, ART4, PODXL, SARS2, ARL6, AOF1, NDST3, 





MLH1, CATSPER3, TNPO3, KCNN1, RIT2, RPS6KA1, CYB5R3, SLC22A6, TNPO2, KCNH3, ABCC3, 











Figure 5.5 Dose-response curves of stable integrants expressing shRNAs against cisplatin resistance candidate genes. 
Stable integrants of OVCA433 established from shRNAs targeting ABCC3 (A), KCNH3 (B), KCNN1 (C), MLH1 (D), MRPL3 (E) 
and RPS6KA1 (F) were exposed to a range of cisplatin concentrations, and assessed for viability after 3 days. All six shRNAs, in 
comparison to control shRNA targeting luciferase, sensitised OVCA433 cells to cisplatin. Representative dose-response curves of 






Figure 5.6 Effect of silencing cisplatin resistance candidate genes on cisplatin sensitivity. 
A. Assessment of cisplatin sensitivity of stable integrants expressing shRNAs against ABCC3, KCNH3, KCNN1, MLH1, MRPL3 
and RPS6KA1. Averaged GI50 values of cisplatin for each stable integrants are shown as a bar plot and were statistically 
evaluated using Student’s t-test. Error bar indicates SEM of three independent triplicate experiments. A higher value along the y-
axis indicates decreased sensitivity to cisplatin. All six stable integrants were significantly more sensitive to cisplatin than control. 
White bar = control shRNA targeting luciferase (shLuciferase), Black bar = shRNA targeting gene of interest (sh“Gene”). B. 
Quantitative analysis of cisplatin resistance candidate genes silencing by shRNAs. Bar plots indicate the expression of genes of 
interest with control shRNA targeting luciferase (shLuciferase; white bar) and shRNA targeting the gene of interest (sh“Gene”; 












Figure 5.7 Effect of gene silencing on cell health. 
Assessment of cell viability of stable integrants expressing shRNAs against 
ABCC3, KCNH3, KCNN1, MLH1, MRPL3 and RPS6KA1. Bar plots indicate 
the cell viability of stable integrants (sh“Gene”; black bar), normalised against 
the negative control (shLuciferase; white bar). Error bar indicates SEM of 
three independent triplicate experiments. In the absence of cisplatin, none of 




5.2.4 RPS6KA1 as a target in cisplatin resistance 
The availability of a specific RPS6KA1 inhibitor, SL0101 prompted us 
to further validate the relevance of RPS6KA1 to cisplatin resistance across 
multiple ovarian cancer cell lines. SL0101 is a flavonoid glycoside 
(kaempferol 3-O-(3”,4”-di-O-acetyl-α-L-rhamnopyranoside)) which was 
isolated from the extract of the tropical plant Forsteronia refracta (Smith et al, 
2005). Its ability to inhibit RPS6KA1 kinase activity was initially discovered 
through a high throughput ELISA screen (Smith et al, 2005). Subsequent in 
vitro kinase assays with a panel of 71 protein kinases demonstrated the 
specificity of SL0101 to RPS6KA1, as well as to another member of the p90 
ribosomal S6 kinase (RSK) family, RPS6KA3 (Bain et al, 2007). Conversely, 
AURKB and PIM3 were inhibited with slightly lower potency and other 
protein kinases in the panel were unaffected (Bain et al, 2007). The interaction 
of SL0101 with RSK was further shown by the crystallographic model of 
SL0101 in complex with the amino-terminal kinase domain of RPS6KA3 
(Utepbergenov et al, 2012). Of note, SL0101 was proven to be an effective 
RPS6KA1 inhibitor in intact cells (Smith et al, 2005). Moreover, MCF-7 cells 
that are dependent on the RSK pathway were found to be susceptible to 
growth inhibition by SL0101, in accordance with its function as a RSK-
specific inhibitor (Smith et al, 2005). Taken together, SL0101 can be a useful 
tool for analysing the role of RPS6KA1 in cisplatin resistance. 
Accordingly, the GI50 values of cisplatin for a panel of 10 ovarian 
cancer cell lines (OVCA433, OVCA429, RMG-II, OVCAR8, JHOS-2, PA-1, 
CH1, IGROV-1, TOV-112D and OVCAR-10) was determined in the presence 
of vehicle or 40 μM SL0101. Though SL0101 exhibited high affinity for 
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RPS6KA1 in in vitro kinase assay (Smith et al, 2007), it was observed that 
such high concentration of SL0101 is required to elicit phenotypic responses 
of intact cells to SL0101-induced RSK inhibition (Smith et al, 2005). 
Inhibition of RPS6KA1 kinase activity by SL0101 indeed sensitised 5 cell 
lines in the panel, including OVCA433 to cisplatin (Fig. 5.8A). Moreover, the 
reduction in GI50 values for SL0101-treated OVCA433 cells was comparable 
with our previous findings using RPS6KA1-specific shRNA (Figs. 5.6A and 
5.8A). These results confirmed RPS6KA1 as a cisplatin resistance candidate 
gene and showed that its relevance to cisplatin resistance was not limited to 
OVCA433 cells. At the same time, the fact that only 5 out of 10 cell lines 
showed reduction in their GI50 values (Figs 5.8A and 5.8B), suggested that 
the relevance of RPS6KA1 to cisplatin resistance is likely to be context-
dependent, which is consistent with the multi-factorial nature of cisplatin 
resistance (Galluzzi et al, 2012).  
Intriguingly, the 5 sensitized cell lines were previously identified to be 
representative of our proposed Epi-A subtype, whereas other cell lines in the 
panel that did not show increase in cisplatin sensitivity (Fig. 5.8B) were 
representatives of the proposed Stem-A subtype (Tan et al, 2013). In view of 
these observations, it is tempting to speculate that the role of RPS6KA1 is 
dependent on the molecular subtype status of the cells. At present, the 
relevance of the proposed molecular classification of EOC in circumventing 
cisplatin resistance remains to be determined.  
Next, we sought to assess the validity of our in vitro findings by 
extending our study to clinical ovarian tumour samples. We took advantage of 
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ovarian tumour gene expression data that have accompanying information 
about the patients’ clinical response to chemotherapy (GSE3149 and TCGA) 
(Bild et al, 2006; The Cancer Genome Atlas Research Network, 2011). Most 
patients in these data sets received standard platinum-based chemotherapy 
with carboplatin, another platinum drug that has an equivalent mode of action 
as cisplatin (Knox et al, 1986). Based on Response Evaluation Criteria In 
Solid Tumour (RECIST), clinical samples were first subdivided into two 
populations; those with complete response (CR) and those with partial 
response (PR), stable disease or progressive disease (non-responder; NR). 
Following which, the average expression of RPS6KA1 was compared between 
the two populations. We found that the average level of RPS6KA1 in 
partial/non-responders is significantly higher than the expression level in 
complete-responders (Fig. 5.9), suggesting the possible role of RPS6KA1 in 
rendering patients to respond poorly to platinum-based chemotherapy. 
However, we are also aware that RPS6KA1 is unlikely to be the main reason 
for poor clinical response to chemotherapy, as shown by the modest difference 
in its average expression between the two patient populations (Fig. 5.9), as 
well as the modest increase in cisplatin sensitivity of ovarian cancer cell lines 









Figure 5.8 Effect of RPS6KA1-specific inhibitor, SL0101 on cisplatin 
sensitivity. 
A panel of 10 ovarian cancer cell lines (OVCA433, OVCA429, RMG-II, 
OVCAR8, JHOS-2, PA-1, CH1, IGROV-1, TOV-112D and OVCAR-10) was 
treated with increasing concentration of cisplatin for 72 hour in the presence of 
vehicle or 40 μM SL0101. GI50 values of cisplatin were then determined 
using Graphpad Prism, and shown as mean ± SE of three independent 
triplicate experiments. Effect of SL0101 on GI50 values of cisplatin was 
statistically evaluated using Student’s t-test. A higher value along the y-axis 
indicates decreased sensitivity to cisplatin. SL0101 treatment rendered cell 
lines that are representative of Epi-A subtype (A) to be more sensitive to 
cisplatin, whereas Stem-A cell lines (B) showed no significant change in 













Figure 5.9 Relevance of RPS6KA1 expression in clinical response to 
standard chemotherapy.  
Dot plot of RPS6KA1 expression retrieved from clinical ovarian tumour 
samples that have accompanying information about the patients’ clinical 
response to chemotherapy (GSE3149 and TCGA) (Bild et al, 2006; The 
Cancer Genome Atlas Research Network, 2011). Classification of samples 
was based on Response Evaluation Criteria In Solid Tumour (RECIST): blue 
= complete response (CR); red = partial response (PR), stable disease and 
progressive disease (non-responder; NR). Differences in RPS6KA1 expression 
was statistically evaluated with Mann-Whitney U-test in Graphpad Prism. 






In this second part of the thesis, we took advantage of the genome-
wide pooled shRNA library to perform an unbiased screen for genes that 
modulate the cisplatin sensitivity of a resistant cell line, OVCA433. Inhibition 
of six genes, ABCC3, KCNH3, KCNN1, MLH1, MRPL3 and RPS6KA1 were 
found to enhance the activity of cisplatin in OVCA433 cells. In particular, 
combination treatment of cisplatin with a RPS6KA1-specific inhibitor, 
SL0101 rendered Epi-A representative cell lines, including OVCA433, more 
sensitive to cisplatin. These results revealed the value of targeting RPS6KA1 
in countering cisplatin resistance, and further investigation of its function may 
lead to increased understanding of cisplatin resistance mechanisms. On the 
other hand, cisplatin sensitivities of Stem-A representative cell lines were 
unaffected by SL0101 treatment. 
Platinum resistance is a major obstacle in the treatment of EOC. EOC 
can be intrinsically resistant to or rapidly acquire resistance to platinum-based 
chemotherapy, leading to therapeutic failure (Cannistra, 2004; Coleman et al, 
2013; Vaughan et al, 2011). Thus, circumventing platinum resistance is one of 
the main research goals in the ovarian cancer field. Combination 
chemotherapy strategies targeting resistance mechanisms have been proposed 
to have the best chance in significant chemosensitisation (Galluzzi et al, 
2012). So far, multiple mechanisms have been described (see Section 1.3.3 for 
details), but which of these mechanisms should be preferentially targeted 
remains to be determined. Hence, the unbiased functional screen represented 
herein confers opportunities to recognise combination strategies relevant for 
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all or subsets of EOC patients (Ashworth & Bernards, 2010; Berns & 
Bernards, 2012).  
As an initial approach, we utilised a cisplatin resistant cell line, 
OVCA433 to identify enhancers of cisplatin activity. The cell line was 
established by Bast et al. (1981) from a patient with serous papillary 
cystadenocarcinoma, and so far, has been used as a model of HGSOC by at 
least five publications (Cai & Xu, 2013; Creighton et al, 2010; Liu et al, 
2010; Rauh-Adelmann et al, 2000; Yang et al, 2010). However, due to the 
lack of the DNA copy-number profile for OVCA433 in the CCLE database, 
the suitability of OVCA433 as a HGSOC model cannot be verified 
(Domcke et al, 2013).  
Nevertheless, we uncovered six cisplatin resistance candidate genes—
ABCC3, KCNH3, KCNN1, MLH1, MRPL3 and RPS6KA1—from the screen. 
These genes may not only be useful in future chemosensitisation strategies, 
but also in development of new predictive and prognostic biomarkers of 
clinical response to platinum drugs. Even so, further investigation is required 
to examine their clinical relevance.  
RPS6KA1 is a member of the p90 ribosomal S6 kinase (RSK) family, 
which are downstream effectors of the RAS-mitogen-activated protein kinase 
(MAPK) signalling cascade (Anjum & Blenis, 2008). The structure of 
RPS6KA1 consists of two non-identical kinase domains (Jones et al, 1988). 
The carboxyl-terminal kinase domain contains a docking site for extracellular 
signal-regulated kinase-1/-2 (ERK1/2) (Gavin & Nebreda, 1999) while the 
amino-terminal kinase domain is responsible for the phosphorylation of many 
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cytosolic and nuclear targets (Leighton et al, 1995). Substrates of RPS6KA1 
include transcription factors, such as cyclic AMP response element-binding 
protein (CREB), serum response factor (SRF), oestrogen receptor 1 (ESR1) 
and nuclear factor-ĸB (NF-ĸB) (Anjum & Blenis, 2008; Frodin & 
Gammeltoft, 1999), as well as kinases, such as tumour suppressor death-
associated protein kinase (DAPK), BUB1 mitotic checkpoint serine/threonine 
kinase and membrane-associated tyrosine- and threonine-specific CDC2-
inhibitory kinase 1 (PKMYT1) (Anjum et al, 2005; Palmer et al, 1998; 
Schwab et al, 2001). The functions of these substrates associate RPS6KA1 
with diverse cellular processes, including transcriptional regulation, cell cycle 
regulation and cell survival. In fact, RPS6KA1 has been implicated in several 
cancers, including breast and lung cancer as driver of proliferation and 
metastasis (Doehn et al, 2009; Lara et al, 2011; Smith et al, 2005). Though 
RPS6KA1 has yet to be directly associated with platinum resistance, inhibition 
of its activators, ERK1/2 has been reported to sensitise ovarian cancer cell 
lines to cisplatin (Hayakawa et al, 1999; Lee et al, 2007). On the other hand, 
there are also reports demonstrating that ERK1/2 activation potentiates 
platinum-induced apoptosis in ovarian cancer cell lines (Gupta et al, 2013; 
Nonaka et al, 2012). These conflicting reports illustrated that the roles of 
ERK1/2 in the cellular response to cisplatin is likely to depend on the 
individual cellular context (Wang & Lippard, 2005). Similarly, we found that 
inhibition of RPS6KA1 activity by the small molecule inhibitor, SL0101 led 
to differential changes in the cisplatin sensitivities of ovarian cancer cell lines. 
Despite so, the value of targeting RPS6KA1 or its associated pathway in 
chemosensitisation strategies may worth further investigation. In addition, 
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development of a predictive framework that could align such strategies to 
appropriate patients will be beneficial. Preliminary observations suggested that 
the proposed molecular classification of EOC presented in Section 1.2.3 may 
be useful for this purpose. 
ABCC3 is a member of the ATP binding cassette (ABC) transporter 
superfamily that is known to mediate multidrug resistance (Gottesman et al, 
2002). Like other members of its family, ABCC3 is also an organic anion 
transporter with broad drug specificity, and is able to confer resistance to 
anticancer drugs, such as etoposide, teniposide, methotrexate, cisplatin and 
doxorubicin (Gottesman et al, 2002; Januchowski et al, 2013; Kool et al, 1999; 
Szakacs et al, 2006). Currently, agents that can modulate ABCC3 function are 
not known, as much focus has instead been given to other members of the 
family, ABCB1, ABCC1 and ABCG2 (Szakacs et al, 2006). However, clinical 
trials evaluating the inhibition of these ABC transporters have met with little 
success, as the inhibitors often have pharmacokinetic interactions with other 
drugs and are associated with adverse side-effects (Szakacs et al, 2006). Even 
so, researchers remain optimistic that multidrug resistance mediated by ABC 
transporters can one day be vanquished (Gottesman et al, 2002; Saneja et al, 
2014; Szakacs et al, 2006). 
Both KCNN1 and KCNH3 are potassium channels that are involved in 
the regulation of potassium ion concentration. Though both genes have not 
been implicated in platinum resistance, changes in extracellular potassium ion 
concentration have been shown to influence the intracellular accumulation of 
cisplatin, which in turn, affects the formation of platinum-DNA adducts 
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(Andrews et al, 1991; Gately & Howell, 1993). It remains to be determined 
whether inhibition of KCNN1 and KCNH3 also modulate the intracellular 
accumulation of cisplatin. 
MRPL3 is a ribosomal protein that is exclusively found in 
mitochondria (Gruschke et al, 2010). Recent reports have associated MRPL3 
with mitochondrial cardiomyopathy (Galmiche et al, 2011) and common 
familial colorectal cancer (Gylfe et al, 2013), but none showed its involvement 
in platinum resistance. As a result, we have no clue how inhibition of MRPL3 
sensitises OVCA433 cells to cisplatin. 
Lastly, MLH1 is a component of the DNA mismatch repair (MMR) 
process that is normally responsible for the recognition and repair of erroneous 
insertions and deletions by DNA replication and recombination (Kunkel & 
Erie, 2005). It is widely described that the MMR system is able to detect but 
fail to repair platinum-induced DNA damage, and thus, lead to the induction 
of cell cycle arrest and apoptosis (Vaisman et al, 1998). In fact, components of 
MMR system, including MLH1 are often found to be mutated or under-
expressed in cells selected for cisplatin resistance (Aebi et al, 1996; 
Drummond et al, 1996; Strathdee et al, 1999). Moreover, higher number of 
relapsed ovarian tumours had MLH1 promoter methylation, as compared to 
matched chemo-naïve tumours (Gifford et al, 2004). Unfortunately, this is 
contrary to our findings, where silencing of MLH1 rendered OVCA433 cells 
more sensitive to cisplatin. On the other hand, compelling data showing the 
relationship between MMR pathway and cisplatin-induced cytotoxicity in 
clinical settings have yet to be reported (Galluzzi et al, 2012; Wang & 
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Lippard, 2005). For instance, immuno-histochemical staining for MLH1 in 
ovarian tumours revealed no association between MLH1 expression and 
overall survival (Samimi et al, 2000). Hence, doubts over the contributions of 
defective MMR pathway to cisplatin resistance remain, and more in-depth 
studies are still required. 
It should be pointed out that the aforementioned genes are by no means 
the principal cause of cisplatin resistance. Though shRNA silencing of each of 
the six genes resulted in significant decrease in GI50 values of cisplatin, 
cisplatin sensitivities were only increased by two-fold. Moreover, these genes 
are functionally diverse, with no clear connection among them. Taken 
together, these findings reinforced the notion that not one mechanism can 
solely explain for the presence of a platinum resistance phenotype (Galluzzi et 
al, 2012; Kartalou & Essigmann, 2001). As such, any future combination 
chemotherapy strategies will have to target platinum resistance at multiple 
levels (Galluzzi et al, 2012). Additionally, we are also aware that cell lines 
may be divergent from their ancestral tumours and the extent to which the data 
presented herein mirror the situation in human tumours is still uncertain.  
Nevertheless, our study can serve as an initial screen for modulators of 
cisplatin sensitivity that could be used to better understand cisplatin resistance 
and facilitate the development of strategies for circumventing resistance. 
Given the heterogeneity of EOC and the multi-factorial nature of platinum 
resistance, the low survival of EOC patients could be improved by tailoring 








GENERAL DISCUSSION AND FUTURE WORK 
 
6.1 General discussion 
The increased awareness of a high degree of heterogeneity in EOC 
cries out for an urgent need to replace current standard of care with treatments 
specifically designed for the different histological or molecular subtypes of 
EOC (Vaughan et al, 2011). Unfortunately, aside from the classical 
platinum/taxane-based chemotherapy, gyne-oncologists have limited access to 
other therapeutic options. Thus, the challenge is to develop a classification 
scheme that can define EOC into molecularly homogeneous subgroups, with 
each benefiting from novel therapeutic strategies.  
In a previous study, we reported the identification of five molecular 
subtypes (Epi-A, Epi-B, Mes, Stem-A and Stem-B) that exhibited distinct 
clinicopathological characteristics (Tan et al, 2013). This classification scheme 
is in good agreement with other classification schemes published by TCGA 
(The Cancer Genome Atlas Research Network, 2011) and AOCS (Tothill et al, 
2008), yet reveals novel biological features.  
As a complementary approach, the first part of the study conducted an 
unbiased RNAi-based genetic screen for genes that are essential for each 
molecular subtype. In particular, the screen demonstrated that specific growth 
determinants can be distinguished amongst the molecular subtypes, thus 
supporting the feasibility of developing subtype-specific therapeutics for EOC. 
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Subsequent validation experiments confirmed TUBGCP4 and NAT10 to be 
functionally relevant for the cell growth of the poor-prognosis Stem-A 
subtype. At present, the molecular mechanisms accounting for the preferential 
growth suppression of Stem-A cells by TUBGCP4 or NAT10 knockdown are 
unknown. Since both genes are associated with microtubules, one would 
expect that pathways related to microtubules may somehow be relevant to the 
Stem-A subtype. Indeed, our present data provide evidence that the Stem-A 
subtype exhibits gene signatures associated with microtubule dynamics and 
are sensitive to drugs interfering with tubulin polymerisation, such as 
vincristine and vinorelbine. These findings underscore the possible importance 
of tubulin polymerisation in Stem-A cells. Thus, further studies on the 
molecules implicated in tubulin polymerisation may allow a deeper 
understanding of the differences amongst the molecular subtypes, and in turn, 
facilitate the development of driver-/mechanism-targeted therapies or drugs 
combinations of higher efficacy in Stem-A tumours.  
To date, a few targeted therapies have already been incorporated into 
the standard of care of other cancers, such as chronic myeloid leukemia 
(CML), breast and NSCLC (Ma & Adjei, 2009). A classic example is the 
specific inhibitor of BCR-ABL tyrosine kinase, imatinib for CML (Druker et 
al, 2006). In fact, PARP inhibitors, such as olaparib have already been 
proposed to be effective against EOC with defective homologous 
recombination repair pathway (BRCA-like) (Banerjee et al, 2010; Fong et al, 
2009). Thus, it is hoped that relative successes of targeted therapies obtained 
in other cancers would also occur for EOC.  
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On the other hand, the clinical usefulness of platinum-based drugs in 
treating EOC is limited by the high incidence of chemoresistance, and thus, 
circumventing platinum resistance is also a critical goal in the ovarian cancer 
research field. In this context, the unbiased RNAi-based genetic screen 
performed in the second part of the thesis, identified ABCC3, KCNH3, 
KCNN1, MLH1, MRPL3 and RPS6KA1 as genes that can modulate the 
sensitivity of ovarian cancer cell line to cisplatin. These findings suggest that 
these genes could possibly be involved in the cisplatin resistance mechanisms 
of ovarian cancer cell lines. Although studies showing the relevance of these 
genes to the platinum resistance in established tumours are necessary, these 
genes may represent potential targets for chemosensitisation strategies.  
However, given the multi-factorial nature of platinum resistance, it is 
highly likely that a particular resistance mechanism may only be relevant in a 
restricted number of settings (Galluzzi et al, 2012). Thus, there is also the need 
to identify patients that would benefit from particular chemosensitisation 
strategies. This notion is also evident in the present study, where the 
combinatorial treatment of cisplatin and a RPS6KA1-specific inhibitor, 
SL0101 only rendered Epi-A representative cell lines, but not Stem-A 
representative cell lines more sensitive to cisplatin. Although the influence of 
the molecular subtype status on SL0101-induced chemosensitisation remains 
to be determined, it is clear that the role of RPS6KA1 in cisplatin resistance is 
dependent on the individual cellular content. Taken together, the challenges 
are to identify promising candidates that should be modulated for optimal 
chemosensitisation, as well as to discover predictive biomarkers that would 
allow patient stratification.  
 164 
 
More generally, the present study illustrates the usefulness of RNAi-
based genetic screens in identifying subtype-specific regulators of cancer cell 
proliferation and/or survival, as well as regulators of cisplatin sensitivity. 
Together with other studies (Bajrami et al, 2013; Barbie et al, 2009; Berns et 
al, 2007; Cheung et al, 2011; Lam et al, 2008; Luo et al, 2008), we showed 
that RNAi-based genetic screen is a feasible strategy to systematically identify 
key players involved in cancer progression and drug responsiveness, and also 
identify potential targets for therapeutic intervention. Although we only 
assessed a single phenotype (cell viability), the approach may be extended to 
other phenotypes, and thus, provides insights into a wide range of biological 
processes in mammalian cells.  
However, RNAi-based genetic screens are still in need of further 
improvements. For instance, the methodology outlined in the thesis can be 
further improved through thorough optimisation of conditions for virus 
transduction and PCR amplification. Current RNAi reagents can be enhanced 
to provide more efficient suppression of the intended targets, while lowering 
possibility of off-targets effects. In addition, the genetic screens have to be 
standardised by the scientific community, so as to ensure reliable and 
reproducible data (Berns & Bernards, 2012). Such efforts would give 
researchers high confidence in the biological significance of hit genes, and 





6.2 Future work 
Though findings from the present study suggest possible therapeutic 
approaches for EOC, further studies are still needed before such approaches 
can become clinically applicable. Therefore, in the following paragraphs, we 
shall discuss some of these future works.  
The susceptibility of Stem-A cells to tubulin polymerisation inhibitor 
drugs, as shown in the first part of the thesis (Chapter 4), is a potential 
platform for Stem-A-specific therapeutics. This finding may be further 
examined to elucidate the mechanisms by which tubulin polymerisation 
regulate the viability of Stem-A cells, with focus on ascertaining the 
molecule(s) involved and how to exploit them for therapy development. List 
of genes implicated in the tubulin polymerisation pathway would have to be 
curated from literature reviews, and then systematically examined for their 
relevance to Stem-A cell growth. The gene list may include those involved in 
microtubule nucleation, dynamics and interaction with chromosomes or 
cellular organelles. In fact, some of them have already been proposed as 
potential therapeutic targets in cancer cells (Dumontet & Jordan, 2010). In 
addition, substantial efforts are still being devoted to the identification and 
evaluation of new microtubule-targeted agents that are insensitive to resistance 
mechanisms, increase tumour selectivity or have reduced toxicity (Bailly et al, 
2003; Hamel et al, 1999; Kita et al, 2013; Romagnoli et al, 2013). Thus, 
examination of these new agents in regard to their relevance to Stem-A cells, 
might allow us to further validate our findings and more effectively target 
Stem-A ovarian cancer. 
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However, a crucial challenge facing the use of subtype-specific 
therapeutics is the paucity of biomarkers to identify patients who are most 
likely to benefit from particular targeted therapies. A predictive model based 
on BinReg was previously reported by us as a potential diagnostic tool for 
subtype assignment (Tan et al, 2013), but that will require the use of genome-
wide expression arrays on every cancer specimen. Moreover, it will be a 
financial burden on the patients. Hence, it would be worth exploring the 
feasibility of characterising each subtype with a small subset of genes or 
immunohistochemistry of selected biomarkers.  
Next, in the second part of the thesis, we uncovered six genes—
ABCC3, KCNH3, KCNN1, MLH1, MRPL3 and RPS6KA1—as possible targets 
for chemosensitisation strategies. Though inhibitions of these genes were 
found to enhance cisplatin sensitivity, their involvement in resistance 
mechanisms remains to be precisely determined. Thus, the mechanisms by 
which these genes modulate cisplatin sensitivity would be investigated and 
any positive findings will lead to increased understanding of cisplatin 
resistance. This knowledge will not only provide us with new insights for 
developing improved therapeutic strategies for circumventing platinum 
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Appendix I. The genes for subtype-specific depleted and amplified shRNAs. 




Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 




2 AQP12A 1.82 0.0001 TRCN0000060249,TRCN0000060252 0.85, 0.47 -1.55, -0.86 Epi-A Depleted 




4 LIX1L 1.8 0.0004 TRCN0000135165,TRCN0000138619 0.65, 0.46 -1.05, -0.74 Epi-A Depleted 
5 SH3TC1 1.8 0.0004 TRCN0000062609,TRCN0000062608 0.51, 0.46 -0.92, -0.93 Epi-A Depleted 




7 LIN7A 1.79 0.0005 TRCN0000116868,TRCN0000116871 0.64, 0.49 -1.24, -0.97 Epi-A Depleted 
8 NIP7 1.79 0.0014 
TRCN0000145541,TRCN0000139190,TRCN0000144658
,TRCN0000122000 





9 FAM26E 1.78 0.0007 TRCN0000122216,TRCN0000142408 0.58, 0.48 -1.03, -0.82 Epi-A Depleted 
10 MRAS 1.78 0.0014 TRCN0000036992,TRCN0000036990 0.70, 0.51 -1.34, -1.02 Epi-A Depleted 
















15 LEP 1.77 0.002 
TRCN0000058357,TRCN0000058355,TRCN0000058353
,TRCN0000058354 





16 NCAM1 1.77 0.0008 TRCN0000073460,TRCN0000073462 0.62, 0.41 -0.91, -0.79 Epi-A Depleted 
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Appendix I. The genes for subtype-specific depleted and amplified shRNAs. (continued) 




Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 




18 HELB 1.76 0.0008 TRCN0000152487,TRCN0000152488 0.47, 0.46 -0.79, -0.77 Epi-A Depleted 




20 RAB1B 1.75 0.0009 TRCN0000047216,TRCN0000047217 0.56, 0.53 -1.10, -0.91 Epi-A Depleted 








23 DLAT 1.74 0.0033 TRCN0000035922 1.06 -1.93 Epi-A Depleted 
















28 COX10 1.73 0.0015 TRCN0000034557,TRCN0000034558 0.67, 0.40 -1.28, -0.60 Epi-A Depleted 












Appendix I. The genes for subtype-specific depleted and amplified shRNAs. (continued) 




Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 
32 C13orf27 1.72 0.0018 TRCN0000072335,TRCN0000072333 0.55, 0.37 -0.83, -0.61 Epi-A Depleted 
33 CRLF3 1.72 0.004 
TRCN0000063378,TRCN0000063380,TRCN0000063379
,TRCN0000063381 













36 TTK 1.72 0.0048 TRCN0000006358,TRCN0000006356 0.48, 0.38 -0.83, -0.63 Epi-A Depleted 
37 GRID1 1.71 0.0048 TRCN0000063035,TRCN0000063036 0.53, 0.28 -1.01, -0.56 Epi-A Depleted 
38 DCTN1 1.7 0.0024 TRCN0000063971,TRCN0000063968 0.53, 0.46 -0.89, -0.74 Epi-A Depleted 
39 LMNB1 1.7 0.0024 
TRCN0000029270,TRCN0000029271,TRCN0000029269
,TRCN0000029272 





40 MRGPRF 1.7 0.0024 TRCN0000011771,TRCN0000011770 0.35, 0.35 -0.59, -0.62 Epi-A Depleted 








43 TMEM38A 1.69 0.0027 TRCN0000127540,TRCN0000129632 0.41, 0.35 -0.67, -0.59 Epi-A Depleted 
44 WDR72 1.69 0.0002 TRCN0000137006,TRCN0000134128 0.84, 0.69 -1.47, -1.15 Epi-A Depleted 
45 KCNS1 1.68 0.0031 TRCN0000044214 0.59 -1.17 Epi-A Depleted 
46 LASS6 1.68 0.0031 TRCN0000128857,TRCN0000128836 0.52, 0.46 -1.02, -0.73 Epi-A Depleted 










Appendix I. The genes for subtype-specific depleted and amplified shRNAs. (continued) 




Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 
49 SARNP 1.68 0.0035 TRCN0000151631,TRCN0000152985 0.54, 0.50 -0.86, -0.79 Epi-A Depleted 
50 SEC13 1.68 0.0033 TRCN0000064985,TRCN0000064983 0.46, 0.38 -0.92, -0.72 Epi-A Depleted 








53 GPR176 1.67 0.0042 TRCN0000011490,TRCN0000011491 0.53, 0.53 -0.94, -0.92 Epi-A Depleted 
54 LRRFIP2 1.67 0.0042 TRCN0000061978,TRCN0000061980 0.52, 0.51 -0.89, -0.93 Epi-A Depleted 




56 MYO1C 1.66 0.0005 TRCN0000122927,TRCN0000122926 0.58, 0.45 -0.97, -0.76 Epi-A Depleted 
57 SEMG2 1.65 0.0049 TRCN0000154196,TRCN0000156481 0.71, 0.46 -1.08, -0.74 Epi-A Depleted 
58 WDR67 1.65 0.0049 TRCN0000143325,TRCN0000142816 0.53, 0.41 -0.82, -0.69 Epi-A Depleted 
59 MYH10 1.64 0.001 TRCN0000123075 0.49 -0.86 Epi-A Depleted 
60 SIM2 1.63 0.0017 TRCN0000015150,TRCN0000015148 0.57, 0.51 -1.01, -0.90 Epi-A Depleted 
61 C1orf14 1.62 0.0024 TRCN0000136159,TRCN0000159649 0.82, 0.56 -1.29, -0.88 Epi-A Depleted 
62 PRAMEF7 1.62 0.0021 TRCN0000130745,TRCN0000128088 0.57, 0.41 -0.98, -0.64 Epi-A Depleted 
63 CASP10 1.61 0.0028 TRCN0000003586,TRCN0000003588 0.50, 0.47 -0.87, -0.88 Epi-A Depleted 
64 OR51T1 1.61 0.0029 TRCN0000061471,TRCN0000061469 0.99, 0.54 -1.94, -1.08 Epi-A Depleted 
65 SFRS8 1.61 0.0027 TRCN0000017226,TRCN0000017224 0.52, 0.48 -0.97, -0.90 Epi-A Depleted 
66 SAMSN1 1.6 0.0034 TRCN0000136656,TRCN0000138187 0.47, 0.41 -0.82, -0.65 Epi-A Depleted 
67 MAP2K2 1.59 0.0037 TRCN0000007007 0.72 -1.34 Epi-A Depleted 
68 PALLD 1.59 0.0035 TRCN0000073463 0.55 -0.86 Epi-A Depleted 
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Appendix I. The genes for subtype-specific depleted and amplified shRNAs. (continued) 




Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 
69 CLDND1 1.58 0.0044 TRCN0000146451 0.59 -0.89 Epi-A Depleted 
70 KLHL17 1.58 0.0044 TRCN0000155542 0.61 -0.91 Epi-A Depleted 
71 EYS 1.57 0.0046 TRCN0000040249 0.59 -1.15 Epi-A Depleted 
72 PAX6 1.57 0.0046 TRCN0000016126,TRCN0000016127 0.55, 0.37 -0.98, -0.73 Epi-A Depleted 
73 C20orf19 1.53 0.0011 TRCN0000133823 0.57 -0.85 Epi-A Depleted 
74 SLC15A1 1.52 0.0013 TRCN0000043300 0.74 -1.32 Epi-A Depleted 
75 LZTS2 1.51 0.0021 TRCN0000021124,TRCN0000021126 0.51, 0.50 -0.90, -0.85 Epi-A Depleted 
76 MAD1L1 1.49 0.0041 TRCN0000006563 0.49 -0.86 Epi-A Depleted 
77 WFDC12 1.49 0.0039 TRCN0000073672 0.5 -0.82 Epi-A Depleted 








80 PRAMEF3 1.88 0 
TRCN0000129627,TRCN0000128569,TRCN0000128976
,TRCN0000130446 





81 FATE1 1.86 0 
TRCN0000130192,TRCN0000128985,TRCN0000146597
,TRCN0000128805,TRCN0000149011 














84 GNPTG 1.8 0.0006 
TRCN0000036051,TRCN0000036052,TRCN0000036050
,TRCN0000036053,TRCN0000036049 








Appendix I. The genes for subtype-specific depleted and amplified shRNAs. (continued) 




Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 
85 GAL3ST2 1.79 0.0007 TRCN0000035072,TRCN0000035071 0.42, 0.34 -0.68, -0.66 Mes Depleted 
86 HEBP2 1.79 0.0002 TRCN0000151159,TRCN0000158096 0.75, 0.57 -1.12, -0.94 Mes Depleted 
87 KCNG1 1.79 0.0007 TRCN0000045112,TRCN0000045108 0.53, 0.51 -1.04, -0.86 Mes Depleted 
88 SPEG 1.79 0.0007 
TRCN0000037429,TRCN0000037432,TRCN0000037431
,TRCN0000037430 





89 ZC3HC1 1.79 0.0008 
TRCN0000037541,TRCN0000037540,TRCN0000037543
,TRCN0000037539 





90 APOF 1.77 0.0004 TRCN0000146962,TRCN0000148916 0.50, 0.38 -0.88, -0.67 Mes Depleted 





















95 LRP5 1.75 0.0017 TRCN0000033403,TRCN0000033399 0.75, 0.48 -1.20, -0.89 Mes Depleted 




97 APC2 1.74 0.0006 TRCN0000154929 0.59 -1 Mes Depleted 











Appendix I. The genes for subtype-specific depleted and amplified shRNAs. (continued) 




Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 




101 LRRC15 1.73 0.0025 
TRCN0000144278,TRCN0000139477,TRCN0000143971
,TRCN0000139627,TRCN0000140863 






102 TACC1 1.73 0.0024 TRCN0000155122 0.4 -0.63 Mes Depleted 
103 YEATS2 1.73 0.0025 
TRCN0000142732,TRCN0000144134,TRCN0000144252
,TRCN0000139940 













106 SLC37A2 1.71 0.001 
TRCN0000043324,TRCN0000043323,TRCN0000043325
,TRCN0000043326 









108 FRMD6 1.7 0.0013 TRCN0000142296,TRCN0000145454 0.53, 0.41 -0.94, -0.64 Mes Depleted 
109 GRM7 1.7 0.0013 TRCN0000009033 0.48 -0.86 Mes Depleted 




111 MRPS23 1.7 0.0013 TRCN0000155167,TRCN0000154022 0.57, 0.54 -0.86, -0.82 Mes Depleted 




113 ABCC2 1.69 0.0037 TRCN0000059307,TRCN0000059304 0.59, 0.43 -1.06, -0.71 Mes Depleted 
114 CTTN 1.69 0.0015 TRCN0000040274,TRCN0000040276 0.56, 0.48 -1.10, -0.87 Mes Depleted 
115 DEFB118 1.69 0.0018 TRCN0000149422,TRCN0000149580 0.58, 0.42 -1.05, -0.76 Mes Depleted 
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Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 
116 LGI2 1.69 0.0042 TRCN0000138972,TRCN0000145222 0.59, 0.34 -0.90, -0.62 Mes Depleted 




118 PTPN3 1.69 0.0018 TRCN0000002788,TRCN0000010741 0.42, 0.40 -0.69, -0.68 Mes Depleted 
119 UFSP2 1.69 0.0038 
TRCN0000130335,TRCN0000149929,TRCN0000149702
,TRCN0000150139 




























122 USE1 1.69 0.0036 
TRCN0000157187,TRCN0000156767,TRCN0000158060
,TRCN0000157522 













125 CBLL1 1.68 0.0043 TRCN0000033939,TRCN0000033942 0.33, 0.32 -0.65, -0.64 Mes Depleted 
126 GPR63 1.68 0.0042 TRCN0000011637,TRCN0000011639 0.64, 0.39 -1.15, -0.65 Mes Depleted 
127 PLB1 1.68 0 TRCN0000157010,TRCN0000155628 0.52, 0.51 -0.90, -0.85 Mes Depleted 
128 TBC1D20 1.68 0.0043 
TRCN0000148772,TRCN0000130793,TRCN0000148575
,TRCN0000129790 
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131 COMMD8 1.66 0 TRCN0000137729,TRCN0000134226 0.66, 0.46 -1.28, -0.77 Mes Depleted 












135 RMND1 1.65 0.0042 TRCN0000135089,TRCN0000135730 0.53, 0.42 -0.88, -0.69 Mes Depleted 
136 ALKBH5 1.64 0 TRCN0000064785,TRCN0000064787 0.53, 0.46 -0.81, -0.82 Mes Depleted 
137 KRT72 1.64 0.0045 TRCN0000116779 0.47 -0.94 Mes Depleted 
138 NANS 1.64 0.0042 TRCN0000045438,TRCN0000045439 0.48, 0.45 -0.91, -0.79 Mes Depleted 








141 PYCR1 1.64 0.0049 TRCN0000038982,TRCN0000038983 0.41, 0.41 -0.77, -0.74 Mes Depleted 
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1.64 0 TRCN0000021590 0.54 -0.94 Mes Depleted 
144 VSX2 1.64 0.0048 TRCN0000018065,TRCN0000018067 0.65, 0.43 -1.16, -0.76 Mes Depleted 
145 GLRB 1.63 0.0006 TRCN0000061708,TRCN0000061710 0.61, 0.42 -1.18, -0.70 Mes Depleted 
146 CLEC3B 1.62 0.0008 TRCN0000062475,TRCN0000062474 0.40, 0.40 -0.77, -0.73 Mes Depleted 
147 MRC1 1.62 0.0006 TRCN0000029669 0.69 -1.27 Mes Depleted 
148 PYGB 1.62 0.0008 TRCN0000153819 0.47 -0.71 Mes Depleted 




1.61 0.0009 TRCN0000046591,TRCN0000046590 0.71, 0.39 -1.41, -0.78 Mes Depleted 
151 SLC7A5 1.6 0.0012 TRCN0000043010,TRCN0000043011 0.47, 0.42 -0.72, -0.80 Mes Depleted 






Appendix I. The genes for subtype-specific depleted and amplified shRNAs. (continued) 















1.59 0.0018 TRCN0000002413,TRCN0000002412 0.58, 0.46 -1.04, -0.91 Mes Depleted 
154 GLP2R 1.58 0.0031 TRCN0000008795 0.4 -0.72 Mes Depleted 











1.57 0.0039 TRCN0000146604 0.42 -0.75 Mes Depleted 
157 ZNF619 1.57 0.0035 TRCN0000017793,TRCN0000017796 0.43, 0.36 -0.70, -0.64 Mes Depleted 




159 SMYD5 1.51 0.0011 TRCN0000155095,TRCN0000155068 0.68, 0.49 -1.16, -0.83 Mes Depleted 
160 ZNF264 1.5 0.0016 TRCN0000019141,TRCN0000019143 0.53, 0.46 -0.91, -0.88 Mes Depleted 
161 FAM129B 1.49 0.0019 TRCN0000122833 0.51 -0.82 Mes Depleted 
162 LMX1B 1.48 0.0037 TRCN0000017514,TRCN0000017517 0.46, 0.42 -0.88, -0.75 Mes Depleted 




0.68, 0.57, 0.34, 
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Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 
164 MESDC2 1.91 0 TRCN0000131214,TRCN0000146350 0.79, 0.56 -1.50, -0.94 Stem-A Depleted 
165 VPS13B 1.89 0 
TRCN0000083955,TRCN0000083953,TRCN0000083956
,TRCN0000083954 













0.46, 0.35, 0.35, 







168 FAM153A 1.85 0.0003 
TRCN0000148967,TRCN0000147331,TRCN0000148441
,TRCN0000127581 









170 TAPBP 1.81 0.0002 TRCN0000118833,TRCN0000118835 0.57, 0.50 -0.99, -0.96 Stem-A Depleted 




172 CHPT1 1.79 0.0012 TRCN0000035937,TRCN0000035938 0.43, 0.34 -0.84, -0.66 Stem-A Depleted 
173 DAZL 1.79 0.0014 TRCN0000083433,TRCN0000083436 0.59, 0.50 -1.14, -0.94 Stem-A Depleted 
174 MUC15 1.79 0.0014 TRCN0000128034,TRCN0000128885 0.45, 0.43 -0.79, -0.77 Stem-A Depleted 
175 C1orf187 1.78 0.0008 TRCN0000136368,TRCN0000134037 0.41, 0.41 -0.75, -0.65 Stem-A Depleted 
176 LGR6 1.78 0.0016 TRCN0000063622,TRCN0000063618 0.53, 0.37 -0.85, -0.71 Stem-A Depleted 
177 ZFR 1.78 0.0007 TRCN0000016964,TRCN0000016965 0.45, 0.40 -0.77, -0.69 Stem-A Depleted 
178 ZNF827 1.78 0.0017 TRCN0000144574,TRCN0000144745 0.48, 0.43 -0.77, -0.86 Stem-A Depleted 
179 COX5A 1.77 0.0019 
TRCN0000045961,TRCN0000045958,TRCN0000045962
,TRCN0000045960 
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181 ZIC2 1.77 0.0019 TRCN0000062368,TRCN0000062369 0.37, 0.32 -0.73, -0.64 Stem-A Depleted 
182 CCL3L1 1.76 0.0023 
TRCN0000058044,TRCN0000058045,TRCN0000058046
,TRCN0000058047 

























1.75 0.0008 TRCN0000152683 0.53 -0.76 Stem-A Depleted 
187 WDR5 1.75 0.0008 TRCN0000118048,TRCN0000118047 0.40, 0.36 -0.64, -0.61 Stem-A Depleted 
188 KLHL2 1.74 0.0033 TRCN0000064966,TRCN0000064964 0.77, 0.42 -1.49, -0.82 Stem-A Depleted 
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Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 
193 DGKH 1.72 0.0016 TRCN0000001359,TRCN0000001360 0.39, 0.37 -0.76, -0.60 Stem-A Depleted 
194 GLB1 1.72 0.0039 TRCN0000083273,TRCN0000083275 0.65, 0.31 -1.15, -0.57 Stem-A Depleted 












198 CALML4 1.71 0.0044 
TRCN0000053533,TRCN0000053537,TRCN0000053535
,TRCN0000053536 





199 FETUB 1.71 0.0044 TRCN0000073617,TRCN0000073615 0.54, 0.40 -0.92, -0.78 Stem-A Depleted 




201 LRRC59 1.71 0.0018 TRCN0000078740,TRCN0000078739 0.59, 0.47 -1.06, -0.92 Stem-A Depleted 




203 C1orf105 1.7 0.0022 TRCN0000140677,TRCN0000142864 0.76, 0.43 -1.25, -0.81 Stem-A Depleted 
204 C22orf25 1.7 0.0024 TRCN0000129777,TRCN0000130981 0.47, 0.43 -0.80, -0.79 Stem-A Depleted 
205 FAM38B 1.7 0.0024 TRCN0000123251 0.79 -1.3 Stem-A Depleted 
206 GORASP2 1.7 0.0024 TRCN0000130898,TRCN0000127975 0.67, 0.53 -1.29, -0.80 Stem-A Depleted 
207 HIPK2 1.7 0.0022 TRCN0000003202,TRCN0000003204 0.41, 0.40 -0.79, -0.68 Stem-A Depleted 








Appendix I. The genes for subtype-specific depleted and amplified shRNAs. (continued) 




Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 
210 VPS41 1.7 0.0024 TRCN0000034324,TRCN0000034326 0.36, 0.34 -0.62, -0.68 Stem-A Depleted 
211 AGPAT4 1.69 0.0026 TRCN0000035163,TRCN0000035161 0.35, 0.34 -0.66, -0.66 Stem-A Depleted 
212 BIK 1.69 0.0024 TRCN0000033528,TRCN0000033526 0.46, 0.32 -0.85, -0.57 Stem-A Depleted 








215 PIR 1.69 0.0024 TRCN0000019258,TRCN0000019257 0.70, 0.49 -1.29, -0.84 Stem-A Depleted 
216 SPATA1 1.69 0.0024 
TRCN0000136814,TRCN0000135064,TRCN0000137509
,TRCN0000134784 








1.69 0.0026 TRCN0000035090,TRCN0000035091 0.69, 0.40 -1.37, -0.77 Stem-A Depleted 
218 PCDHB5 1.68 0.0026 TRCN0000056218,TRCN0000056222 0.68, 0.55 -1.23, -1.06 Stem-A Depleted 
219 MAD2L1 1.67 0.0041 TRCN0000006564,TRCN0000006565 0.49, 0.39 -0.83, -0.74 Stem-A Depleted 
220 RALGPS1 1.67 0.0038 TRCN0000154931,TRCN0000152217 0.43, 0.40 -0.73, -0.79 Stem-A Depleted 
221 REEP1 1.67 0.0035 TRCN0000061733,TRCN0000061736 0.41, 0.39 -0.78, -0.71 Stem-A Depleted 








224 HEXIM1 1.66 0.0046 TRCN0000074176,TRCN0000074174 0.55, 0.30 -0.85, -0.54 Stem-A Depleted 
225 RFC3 1.66 0.0005 TRCN0000072650,TRCN0000072649 0.57, 0.52 -0.93, -0.86 Stem-A Depleted 
226 VWA1 1.66 0.0044 TRCN0000117178,TRCN0000117177 0.44, 0.44 -0.81, -0.77 Stem-A Depleted 
227 FBXO16 1.65 0.0049 TRCN0000149016,TRCN0000147114 0.67, 0.44 -0.99, -0.76 Stem-A Depleted 
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Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 














230 CREBZF 1.63 0.0019 TRCN0000017687 0.44 -0.82 Stem-A Depleted 
231 PPP1R13L 1.63 0.0015 TRCN0000022212,TRCN0000022210 0.56, 0.50 -0.97, -0.86 Stem-A Depleted 
232 MAP3K7IP2 1.62 0.002 TRCN0000004453,TRCN0000004456 0.42, 0.39 -0.71, -0.66 Stem-A Depleted 
233 TCERG1L 1.62 0.0021 TRCN0000015482,TRCN0000015480 0.42, 0.40 -0.78, -0.70 Stem-A Depleted 




235 ZNF548 1.61 0.0027 TRCN0000015379,TRCN0000015380 0.45, 0.37 -0.80, -0.74 Stem-A Depleted 
236 BLOC1S1 1.6 0.0034 TRCN0000107374,TRCN0000107372 0.51, 0.36 -1.02, -0.69 Stem-A Depleted 
237 UBXN1 1.6 0.003 TRCN0000004112,TRCN0000004111 0.43, 0.42 -0.76, -0.77 Stem-A Depleted 
238 C6orf165 1.59 0.0035 TRCN0000134261,TRCN0000135274 0.50, 0.47 -0.89, -0.84 Stem-A Depleted 
239 SCGB1A1 1.59 0.0034 TRCN0000083113,TRCN0000083117 0.58, 0.36 -1.12, -0.71 Stem-A Depleted 
240 ZNF577 1.59 0.0038 TRCN0000016695,TRCN0000016696 0.36, 0.35 -0.64, -0.60 Stem-A Depleted 
241 KBTBD4 1.58 0.0039 TRCN0000141375,TRCN0000139228 0.53, 0.52 -0.77, -0.89 Stem-A Depleted 




243 DTX2 1.57 0.0049 TRCN0000004560,TRCN0000004561 0.44, 0.37 -0.73, -0.69 Stem-A Depleted 
244 HLA-DMA 1.57 0.0045 TRCN0000057332 0.46 -0.93 Stem-A Depleted 
245 OR56B1 1.57 0.0049 TRCN0000060669,TRCN0000060672 0.40, 0.36 -0.69, -0.69 Stem-A Depleted 
246 INSC 1.51 0.0016 TRCN0000138732 0.48 -0.82 Stem-A Depleted 
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Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 
247 NPY 1.5 0.0034 TRCN0000009207 0.5 -0.96 Stem-A Depleted 
248 AFG3L1 1.49 0.0039 TRCN0000006680,TRCN0000006677 0.50, 0.42 -0.86, -0.71 Stem-A Depleted 
249 PRKAG2 1.49 0.0042 TRCN0000003145 0.42 -0.79 Stem-A Depleted 
250 RAB25 1.49 0.0049 TRCN0000021851 0.43 -0.73 Stem-A Depleted 
1 HRAS 1.76 0.0013 TRCN0000033265,TRCN0000040090 0.57, 0.47 0.90, 0.94 Epi-A Amplified 








4 SLC38A10 1.73 0.0009 
TRCN0000151835,TRCN0000154868,TRCN0000155811
,TRCN0000155211 





5 ZNF804A 1.72 0.0003 TRCN0000128318,TRCN0000128661 0.44, 0.43 0.83, 0.84 Epi-A Amplified 
6 PROZ 1.71 0.0016 TRCN0000056028,TRCN0000056029 0.56, 0.32 0.91, 0.11 Epi-A Amplified 




8 CA4 1.7 0.001 TRCN0000158178,TRCN0000157938 1.21, 0.58 2.01, 1.04 Epi-A Amplified 
9 RGPD5 1.7 0.0021 
TRCN0000155995,TRCN0000153068,TRCN0000150710
,TRCN0000155941 





10 ECM2 1.69 0.0025 TRCN0000157144,TRCN0000150882 0.30, 0.30 0.59, 0.60 Epi-A Amplified 




12 ZFP106 1.68 0.0028 TRCN0000107376,TRCN0000107377 0.70, 0.35 1.37, 0.69 Epi-A Amplified 




14 DEFB118 1.67 0.0013 TRCN0000149422 0.63 1.16 Epi-A Amplified 
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Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 








17 B3GNT1 1.66 0.003 TRCN0000035909,TRCN0000035911 0.43, 0.37 0.79, 0.71 Epi-A Amplified 




19 WDR75 1.66 0.0017 TRCN0000152085,TRCN0000156084 0.40, 0.39 0.76, 0.73 Epi-A Amplified 








1.65 0.0021 TRCN0000128607 0.79 1.57 Epi-A Amplified 
22 ZNF180 1.65 0.0021 TRCN0000013002,TRCN0000013000 0.52, 0.43 0.95, 0.79 Epi-A Amplified 








25 LHX4 1.63 0.0037 TRCN0000017492,TRCN0000017488 0.39, 0.32 0.70, 0.63 Epi-A Amplified 
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Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 




29 H2AFJ 1.61 0.0048 TRCN0000106749,TRCN0000106746 0.80, 0.32 1.42, 0.62 Epi-A Amplified 
30 EGR1 1.6 0.0007 TRCN0000013837 0.51 0.8 Epi-A Amplified 
31 CXCR6 1.58 0.0017 TRCN0000011323,TRCN0000011319 0.57, 0.36 1.03, 0.66 Epi-A Amplified 




33 ZNF33A 1.57 0.0028 TRCN0000014950 0.44 0.83 Epi-A Amplified 
34 PPP1R13L 1.56 0.0028 TRCN0000022210,TRCN0000022212 0.50, 0.44 0.94, 0.86 Epi-A Amplified 




36 CTSD 1.48 0.0022 TRCN0000003661,TRCN0000003660 0.46, 0.45 0.80, 0.83 Epi-A Amplified 
37 RAX 1.48 0.0019 TRCN0000018085 0.48 0.89 Epi-A Amplified 
38 ZYG11A 1.48 0.0013 TRCN0000135348,TRCN0000137844 0.61, 0.48 1.22, 0.82 Epi-A Amplified 
39 C12orf66 1.47 0.0025 TRCN0000137567 0.47 0.83 Epi-A Amplified 
40 HCRTR1 1.47 0.0024 TRCN0000004747 0.5 0.94 Epi-A Amplified 
41 MARK2 1.47 0.0024 TRCN0000001585,TRCN0000001582 0.47, 0.44 0.77, 0.83 Epi-A Amplified 
42 ATF5 1.46 0.0033 TRCN0000017638,TRCN0000017641 0.47, 0.42 0.86, 0.78 Epi-A Amplified 
43 ZNF773 1.46 0.0031 TRCN0000107859 0.54 1.08 Epi-A Amplified 
44 C11orf60 1.94 0 
TRCN0000074374,TRCN0000074375,TRCN0000074376
,TRCN0000074377 





45 TSPAN7 1.89 0 
TRCN0000118808,TRCN0000118807,TRCN0000118809
,TRCN0000118810,TRCN0000118811 






46 AKAP8L 1.84 0.0001 TRCN0000038003,TRCN0000037999 0.58, 0.48 1.12, 0.90 Mes Amplified 
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Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 




48 PIPOX 1.82 0.0002 
TRCN0000046134,TRCN0000046133,TRCN0000046136
,TRCN0000046135 













51 DGKB 1.77 0.001 TRCN0000000764,TRCN0000000767 0.64, 0.49 1.18, 0.91 Mes Amplified 
52 PRR16 1.77 0.0011 
TRCN0000123216,TRCN0000123217,TRCN0000123215
,TRCN0000123214 

















1.77 0.001 TRCN0000082444 0.69 1.3 Mes Amplified 




56 ITIH5 1.76 0.0005 
TRCN0000118263,TRCN0000118266,TRCN0000118265
,TRCN0000118264 





57 CEPT1 1.75 0.0018 TRCN0000035969,TRCN0000035971 0.65, 0.37 1.30, 0.74 Mes Amplified 
58 HKR1 1.75 0.0015 
TRCN0000017636,TRCN0000017637,TRCN0000017635
,TRCN0000017633 
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Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 




60 PNPT1 1.74 0.0019 
TRCN0000035908,TRCN0000035906,TRCN0000035905
,TRCN0000035907 





61 RPL5 1.74 0.0018 
TRCN0000074994,TRCN0000074995,TRCN0000074996
,TRCN0000074993 





62 SEMA3D 1.74 0.0019 
TRCN0000063213,TRCN0000063215,TRCN0000063217
,TRCN0000063214 





63 MS4A14 1.73 0.002 
TRCN0000060356,TRCN0000060357,TRCN0000060355
,TRCN0000060353 









65 ATP6V0E1 1.72 0.0009 TRCN0000038520,TRCN0000038522 0.78, 0.50 1.54, 0.93 Mes Amplified 
66 C6orf130 1.72 0.0024 TRCN0000129418,TRCN0000128685 0.54, 0.30 1.05, 0.61 Mes Amplified 
67 IL1F7 1.72 0.0026 
TRCN0000058176,TRCN0000058177,TRCN0000058174
,TRCN0000058173 





68 LY6K 1.72 0.0023 TRCN0000117955,TRCN0000117956 0.62, 0.39 1.22, 0.73 Mes Amplified 
69 MYCT1 1.72 0.0022 TRCN0000135843,TRCN0000136533 0.38, 0.30 0.73, 0.59 Mes Amplified 
70 WNT8B 1.72 0.0009 TRCN0000062095,TRCN0000062096 0.46, 0.37 0.89, 0.74 Mes Amplified 








73 BTNL2 1.7 0.0015 TRCN0000156514,TRCN0000155485 0.58, 0.48 1.09, 0.85 Mes Amplified 
74 CD151 1.69 0.0017 TRCN0000057643,TRCN0000057646 0.56, 0.39 1.08, 0.77 Mes Amplified 
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Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 
75 FAM160B1 1.69 0.0019 TRCN0000129856,TRCN0000130062 0.65, 0.54 1.10, 1.02 Mes Amplified 
76 FBXL3 1.69 0.0017 TRCN0000004283,TRCN0000004281 0.60, 0.42 0.98, 0.69 Mes Amplified 
77 UTP3 1.69 0.004 
TRCN0000134646,TRCN0000134895,TRCN0000136463
,TRCN0000135598,TRCN0000133824 










79 CASC3 1.68 0.0024 TRCN0000059920,TRCN0000059921 0.68, 0.44 1.35, 0.88 Mes Amplified 
80 GSTM3 1.68 0.0019 TRCN0000149566 0.41 0.68 Mes Amplified 
81 NKX3-1 1.68 0.0025 TRCN0000040122,TRCN0000040119 0.35, 0.34 0.69, 0.67 Mes Amplified 
82 NPSR1 1.68 0.0045 TRCN0000063361,TRCN0000063358 0.27, 0.27 0.55, 0.53 Mes Amplified 




84 TMEM123 1.68 0.0021 TRCN0000061730,TRCN0000061729 0.52, 0.40 0.91, 0.75 Mes Amplified 
85 DTX2 1.67 0 TRCN0000004560 0.69 1.14 Mes Amplified 




87 ERN1 1.66 0.0002 TRCN0000000532,TRCN0000000528 0.61, 0.50 1.00, 0.98 Mes Amplified 
88 KBTBD6 1.66 0.0031 TRCN0000138270,TRCN0000135111 0.52, 0.43 0.97, 0.84 Mes Amplified 
89 AIMP2 1.65 0.0002 TRCN0000072468 0.51 0.97 Mes Amplified 
90 CENPL 1.65 0.0038 TRCN0000136105,TRCN0000134136 0.42, 0.29 0.80, 0.57 Mes Amplified 
91 SLITRK5 1.65 0.0042 TRCN0000078706,TRCN0000078707 0.34, 0.30 0.65, 0.57 Mes Amplified 
92 TAS2R60 1.65 0.0041 
TRCN0000014138,TRCN0000014141,TRCN0000014140
,TRCN0000014142 
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Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 




94 SHANK1 1.64 0.0003 TRCN0000138405,TRCN0000136791 0.57, 0.43 1.09, 0.81 Mes Amplified 




96 SLITRK6 1.62 0.0008 TRCN0000153177 0.69 1.13 Mes Amplified 
97 THNSL1 1.59 0.0017 TRCN0000045420,TRCN0000045419  0.65, 0.43 1.29, 0.87 Mes Amplified 
98 SDAD1 1.58 0.0032 TRCN0000129836 0.51 0.77 Mes Amplified 














1.57 0.0039 TRCN0000060268,TRCN0000060271  0.53, 0.38 1.00, 0.76 Mes Amplified 
103 S1PR5 1.56 0.0042 TRCN0000004749,TRCN0000004748  0.61, 0.44 0.99, 0.86 Mes Amplified 
104 SEMA3G 1.56 0.0045 TRCN0000060855 0.38 0.71 Mes Amplified 
105 TAS2R7 1.56 0.0044 TRCN0000014152,TRCN0000014148  0.53, 0.34 0.97, 0.53 Mes Amplified 
106 TMEM128 1.52 0.0006 TRCN0000128524 0.58 1.08 Mes Amplified 
107 LDHAL6B 1.51 0.0007 TRCN0000028399 0.51 0.82 Mes Amplified 
108 FBXO25 1.5 0.0017 TRCN0000004317,TRCN0000004320  0.50, 0.45 0.89, 0.71 Mes Amplified 
109 RFXANK 1.5 0.0017 TRCN0000013263,TRCN0000013267  0.50, 0.45 0.87, 0.72 Mes Amplified 
110 RHO 1.5 0.0012 TRCN0000003752 0.68 1.29 Mes Amplified 
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Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 
111 WFDC2 1.5 0.0012 TRCN0000073678,TRCN0000073682  0.60, 0.47 0.94, 0.73 Mes Amplified 
112 CHRM4 1.49 0.0019 TRCN0000011268 0.54 1 Mes Amplified 
113 MT3 1.49 0.0023 TRCN0000072598,TRCN0000072599  0.48, 0.44 0.88, 0.80 Mes Amplified 






1.48 0.0036 TRCN0000073950 0.49 0.92 Mes Amplified 




117 SLC4A9 1.8 0.0002 
TRCN0000038251,TRCN0000038253,TRCN0000038252
,TRCN0000038250,TRCN0000038249 






118 IRAK1BP1 1.78 0.0003 
TRCN0000052533,TRCN0000052534,TRCN0000052535
,TRCN0000052537 





119 SPTLC1 1.77 0.0004 TRCN0000035013,TRCN0000035012 0.62, 0.43 1.07, 0.83 Stem-A Amplified 
120 CHEK1 1.75 0.0032 
TRCN0000000501,TRCN0000000499,TRCN0000039854
,TRCN0000039856,TRCN0000009827 














123 SLC22A15 1.73 0.0011 
TRCN0000038257,TRCN0000038256,TRCN0000038258
,TRCN0000038255 











Appendix I. The genes for subtype-specific depleted and amplified shRNAs. (continued) 




Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 
125 KDELC1 1.72 0.0015 TRCN0000152313,TRCN0000152479 0.61, 0.49 1.21, 0.99 Stem-A Amplified 
126 TMCO1 1.72 0.0005 
TRCN0000062123,TRCN0000062126,TRCN0000062125
,TRCN0000062124 















128 B3GNT8 1.69 0.0028 
TRCN0000035776,TRCN0000035777,TRCN0000035774
,TRCN0000035775 













131 C22orf34 1.67 0.0028 
TRCN0000147028,TRCN0000148869,TRCN0000149311
,TRCN0000149153 









1.67 0.0028 TRCN0000043185,TRCN0000043187 0.45, 0.38 0.88, 0.75 Stem-A Amplified 
134 
UNK_simil
ar to FK506 
binding 
protein 52 












Appendix I. The genes for subtype-specific depleted and amplified shRNAs. (continued) 






















138 LRRC15 1.65 0.0041 
TRCN0000139627,TRCN0000144278,TRCN0000143971
,TRCN0000139477 












1.65 0.0026 TRCN0000062254,TRCN0000062256 0.57, 0.43 1.14, 0.86 Stem-A Amplified 
140 ANO1 1.64 0 TRCN0000040264 0.48 0.86 Stem-A Amplified 




142 CLN6 1.63 0.0038 TRCN0000083612,TRCN0000083610 0.63, 0.33 1.26, 0.62 Stem-A Amplified 
143 SCG5 1.62 0.0046 TRCN0000060172 0.39 0.72 Stem-A Amplified 
144 LNX1 1.61 0.0005 TRCN0000073124,TRCN0000073126 0.49, 0.39 0.80, 0.74 Stem-A Amplified 
145 PLEKHO2 1.6 0.0005 TRCN0000138801 0.78 1.23 Stem-A Amplified 
146 GAK 1.59 0.0015 TRCN0000002156,TRCN0000002157 0.55, 0.37 1.06, 0.74 Stem-A Amplified 
147 IFNA1 1.58 0.0017 TRCN0000005874,TRCN0000005875 0.47, 0.40 0.74, 0.78 Stem-A Amplified 
148 PTGDS 1.57 0.0024 TRCN0000045506,TRCN0000045503 0.46, 0.33 0.80, 0.66 Stem-A Amplified 
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Hairpin ID Hairpin score Effect size Subtype 
Depleted/
Amplified 
149 ITGA5 1.56 0.0037 TRCN0000029652,TRCN0000029651 0.51, 0.36 0.95, 0.67 Stem-A Amplified 








152 FTL 1.49 0.0008 TRCN0000029434 0.61 1.04 Stem-A Amplified 
153 NDUFS8 1.49 0.001 TRCN0000036669 0.46 0.89 Stem-A Amplified 
154 ATOH8 1.48 0.0018 TRCN0000016994,TRCN0000016995 0.43, 0.43 0.66, 0.71 Stem-A Amplified 
155 NFIL3 1.48 0.0023 TRCN0000014742 0.61 0.98 Stem-A Amplified 
156 TLE1 1.48 0.0021 TRCN0000019595,TRCN0000019597 0.46, 0.42 0.73, 0.77 Stem-A Amplified 







1.47 0.0027 TRCN0000015987 0.45 0.82 Stem-A Amplified 





Appendix II. Common pathway response in OVCA433, HeyA8 and PA-1 to TUBGCP4 and NAT10 knockdown. 






1 HOFFMANN_IMMATURE_TO_MATURE_B_LYMPHOCYTE_UP TUBGCP4 + GSEA.c2 
2 V$STAT5A_04 TUBGCP4 + GSEA.c3 
3 TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_DN TUBGCP4 + GSEA.c2 
4 PROTEIN_MODIFICATION_PROCESS TUBGCP4 + GSEA.c5 
5 GAUTSCHI_SRC_SIGNALING TUBGCP4 + GSEA.c2 
6 TP63_DN TUBGCP4 + Path.Sig.SAM 
7 PHOSPHORIC_MONOESTER_HYDROLASE_ACTIVITY TUBGCP4 + GSEA.c5 
8 CHR6P TUBGCP4 + GSEA.c1 
9 STEMABR_DN TUBGCP4 + Subtype.BR 
10 YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_3 TUBGCP4 + GSEA.c2 
11 BIOPOLYMER_MODIFICATION TUBGCP4 + GSEA.c5 
12 VESICLE_MEDIATED_TRANSPORT TUBGCP4 + GSEA.c5 
13 LUND_SILENCED_BY_METHYLATION TUBGCP4 + GSEA.c2 
14 WANG_RESPONSE_TO_FORSKOLIN_DN TUBGCP4 + GSEA.c2 
15 BIOCARTA_IL17_PATHWAY TUBGCP4 + GSEA.c5 
16 WANG_HCP_PROSTATE_CANCER TUBGCP4 + GSEA.c2 
17 SINGLE_STRANDED_RNA_BINDING TUBGCP4 + GSEA.c5 
18 WANG_BARRETTS_ESOPHAGUS_AND_ESOPHAGUS_CANCER_UP TUBGCP4 + GSEA.c2 
19 AMIT_EGF_RESPONSE_20_MCF10A TUBGCP4 + GSEA.c2 
20 ST_STAT3_PATHWAY TUBGCP4 + GSEA.c2 
21 TATTATA,MIR-374 TUBGCP4 + GSEA.c3 
22 PROTEASE_INHIBITOR_ACTIVITY TUBGCP4 + GSEA.c5 
23 TRANSCRIPTION_REPRESSOR_ACTIVITY TUBGCP4 + GSEA.c5 
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24 CHR3Q22 TUBGCP4 + GSEA.c1 
25 ACTGCCT,MIR-34B TUBGCP4 + GSEA.c3 
26 LIAN_LIPA_TARGETS_3M TUBGCP4 + GSEA.c2 
27 LIAN_LIPA_TARGETS_6M TUBGCP4 + GSEA.c2 
28 BOYLAN_MULTIPLE_MYELOMA_D_DN TUBGCP4 + GSEA.c2 
29 PROTEIN_PROCESSING TUBGCP4 + GSEA.c5 
30 WILLIAMS_ESR1_TARGETS_DN TUBGCP4 + GSEA.c2 
31 HORIUCHI_WTAP_TARGETS_UP TUBGCP4 + GSEA.c2 
32 BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP TUBGCP4 + GSEA.c5 
33 BIOCARTA_FIBRINOLYSIS_PATHWAY TUBGCP4 + GSEA.c5 
34 SCIBETTA_KDM5B_TARGETS_UP TUBGCP4 + GSEA.c2 
35 SWEET_KRAS_ONCOGENIC_SIGNATURE TUBGCP4 + GSEA.c2 
36 ACTIVATION_OF_NF_KAPPAB_TRANSCRIPTION_FACTOR TUBGCP4 + GSEA.c5 
37 MAHAJAN_RESPONSE_TO_IL1A_UP TUBGCP4 + GSEA.c2 
38 SMALL_GTPASE_REGULATOR_ACTIVITY TUBGCP4 + GSEA.c5 
39 POSITIVE_REGULATION_OF_CELLULAR_PROTEIN_METABOLIC_PROCESS TUBGCP4 + GSEA.c5 
40 V$CREB_02 TUBGCP4 + GSEA.c3 
41 NUCLEAR_SPECK TUBGCP4 + GSEA.c5 
42 V$ATF4_Q2 TUBGCP4 + GSEA.c3 
43 V$HNF6_Q6 TUBGCP4 + GSEA.c3 
44 WNT_TARGETS TUBGCP4 + GSEA.c5 
45 INTRACELLULAR_SIGNALING_CASCADE TUBGCP4 + GSEA.c5 
46 MITSIADES_RESPONSE_TO_APLIDIN_UP TUBGCP4 + GSEA.c2 
 228 
 
Appendix II. Common pathway response in OVCA433, HeyA8 and PA-1 to TUBGCP4 and NAT10 knockdown. (continued) 






47 PATTERN_BINDING TUBGCP4 + GSEA.c5 
48 V$HOXA4_Q2 TUBGCP4 + GSEA.c3 
49 SH2_DOMAIN_BINDING TUBGCP4 + GSEA.c5 
50 GUTIERREZ_WALDENSTROEMS_MACROGLOBULINEMIA_1_DN TUBGCP4 + GSEA.c2 
51 KHETCHOUMIAN_TRIM24_TARGETS_UP TUBGCP4 + GSEA.c2 
52 TTGCACT,MIR-130A,MIR-301,MIR-130B TUBGCP4 + GSEA.c3 
53 KYNG_DNA_DAMAGE_UP TUBGCP4 + GSEA.c2 
54 RUNNE_GENDER_EFFECT_DN TUBGCP4 + GSEA.c2 
55 NEGATIVE_REGULATION_OF_APOPTOSIS TUBGCP4 + GSEA.c5 
56 CAIRO_HEPATOBLASTOMA_CLASSES_DN TUBGCP4 + GSEA.c2 
57 POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS TUBGCP4 + GSEA.c5 
58 GESERICK_TERT_TARGETS_DN TUBGCP4 + GSEA.c2 
59 AROMATIC_COMPOUND_METABOLIC_PROCESS TUBGCP4 - GSEA.c5 
60 CHR11Q25 TUBGCP4 - GSEA.c1 
61 ACEVEDO_LIVER_CANCER_WITH_H3K9ME3_DN TUBGCP4 - GSEA.c2 
62 LIU_SOX4_TARGETS_DN TUBGCP4 - GSEA.c2 
63 V$E2F_01 TUBGCP4 - GSEA.c3 
64 WINNEPENNINCKX_MELANOMA_METASTASIS_UP TUBGCP4 - GSEA.c2 
65 PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP TUBGCP4 - GSEA.c2 
66 REACTOME_CELL_CYCLE_MITOTIC TUBGCP4 - GSEA.c5 
67 V$USF_Q6_01 TUBGCP4 - GSEA.c3 
68 SGCGSSAAA_V$E2F1DP2_01 TUBGCP4 - GSEA.c3 
69 BIOCARTA_RB_PATHWAY TUBGCP4 - GSEA.c5 
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70 KEGG_STEROID_BIOSYNTHESIS TUBGCP4 - GSEA.c5 
71 V$E2F_02 TUBGCP4 - GSEA.c3 
72 BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_TRANS TUBGCP4 - GSEA.c2 
73 V$E2F_Q3 TUBGCP4 - GSEA.c3 
74 PUJANA_BRCA2_PCC_NETWORK TUBGCP4 - GSEA.c2 
75 UBIQUITIN_LIGASE_COMPLEX TUBGCP4 - GSEA.c5 
76 GRASEMANN_RETINOBLASTOMA_WITH_6P_AMPLIFICATION TUBGCP4 - GSEA.c2 
77 STARK_BRAIN_22Q11_DELETION TUBGCP4 - GSEA.c2 
78 SEMBA_FHIT_TARGETS_DN TUBGCP4 - GSEA.c2 
79 V$E2F1DP1_01 TUBGCP4 - GSEA.c3 
80 V$E2F1DP2_01 TUBGCP4 - GSEA.c3 
81 V$E2F4DP2_01 TUBGCP4 - GSEA.c3 
82 MORF_DEAF1 TUBGCP4 - GSEA.c4 
83 V$E2F1_Q3 TUBGCP4 - GSEA.c3 
84 ZHAN_V1_LATE_DIFFERENTIATION_GENES_DN TUBGCP4 - GSEA.c2 
85 KEGG_ALPHA_LINOLENIC_ACID_METABOLISM TUBGCP4 - GSEA.c5 
86 FINETTI_BREAST_CANCER_BASAL_VS_LUMINAL TUBGCP4 - GSEA.c2 
87 FINETTI_BREAST_CANCER_KINOME_RED TUBGCP4 - GSEA.c2 
88 CAFFAREL_RESPONSE_TO_THC_DN TUBGCP4 - GSEA.c2 
89 MORF_GNB1 TUBGCP4 - GSEA.c4 
90 GNF2_HAT1 TUBGCP4 - GSEA.c4 
91 KTGGYRSGAA_UNKNOWN TUBGCP4 - GSEA.c3 
92 S_PHASE TUBGCP4 - GSEA.c5 
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93 V$E2F1DP1RB_01 TUBGCP4 - GSEA.c3 
94 BLUM_RESPONSE_TO_SALIRASIB_DN TUBGCP4 - GSEA.c2 
95 CROONQUIST_NRAS_SIGNALING_DN TUBGCP4 - GSEA.c2 
96 KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_UP TUBGCP4 - GSEA.c2 
97 WEBER_METHYLATED_LCP_IN_FIBROBLAST_DN TUBGCP4 - GSEA.c2 
98 MORF_G22P1 TUBGCP4 - GSEA.c4 
99 PUJANA_BRCA1_PCC_NETWORK TUBGCP4 - GSEA.c2 
100 V$E2F_03 TUBGCP4 - GSEA.c3 
101 CHANG_CYCLING_GENES TUBGCP4 - GSEA.c2 
102 MODULE_147 TUBGCP4 - GSEA.c4 
103 WHITEFORD_PEDIATRIC_CANCER_MARKERS TUBGCP4 - GSEA.c2 
104 SCIAN_CELL_CYCLE_TARGETS_OF_TP53_AND_TP73_DN TUBGCP4 - GSEA.c2 




TUBGCP4 - GSEA.c5 
107 MITOTIC_CELL_CYCLE TUBGCP4 - GSEA.c5 
108 CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_4 TUBGCP4 - GSEA.c2 
109 WEST_ADRENOCORTICAL_TUMOR_UP TUBGCP4 - GSEA.c2 
110 GNF2_CKS2 TUBGCP4 - GSEA.c4 
111 MORF_PTPN11 TUBGCP4 - GSEA.c4 
112 V$E2F4DP1_01 TUBGCP4 - GSEA.c3 
113 GCM_CBFB TUBGCP4 - GSEA.c4 
114 V$E2F1_Q4_01 TUBGCP4 - GSEA.c3 
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115 TANG_SENESCENCE_TP53_TARGETS_DN TUBGCP4 - GSEA.c2 
116 CHR9P11 TUBGCP4 - GSEA.c1 
117 MORF_EI24 TUBGCP4 - GSEA.c4 
118 M_PHASE_OF_MITOTIC_CELL_CYCLE TUBGCP4 - GSEA.c5 
119 NUYTTEN_EZH2_TARGETS_DN TUBGCP4 - GSEA.c2 
120 MODULE_244 TUBGCP4 - GSEA.c4 
121 MODULE_198 TUBGCP4 - GSEA.c4 
122 REACTOME_PACKAGING_OF_TELOMERE_ENDS TUBGCP4 - GSEA.c5 
123 WEBER_METHYLATED_LCP_IN_SPERM_DN TUBGCP4 - GSEA.c2 
124 MORF_CSNK2B TUBGCP4 - GSEA.c4 
125 CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_UP TUBGCP4 - GSEA.c2 
126 MORF_BUB1B TUBGCP4 - GSEA.c4 
127 KEGG_OOCYTE_MEIOSIS TUBGCP4 - GSEA.c5 
128 T_CELL_DIFFERENTIATION TUBGCP4 - GSEA.c5 
129 LIANG_SILENCED_BY_METHYLATION_DN TUBGCP4 - GSEA.c2 
130 MODULE_203 TUBGCP4 - GSEA.c4 
131 MORF_AATF TUBGCP4 - GSEA.c4 
132 SISTER_CHROMATID_SEGREGATION TUBGCP4 - GSEA.c5 
133 MITOSIS TUBGCP4 - GSEA.c5 
134 GNF2_CCNB2 TUBGCP4 - GSEA.c4 




Appendix II. Common pathway response in OVCA433, HeyA8 and PA-1 to TUBGCP4 and NAT10 knockdown. (continued) 






136 MORF_RAD23A TUBGCP4 - GSEA.c4 
137 VECCHI_GASTRIC_CANCER_EARLY_UP TUBGCP4 - GSEA.c2 
138 MORF_ERH TUBGCP4 - GSEA.c4 
139 VANTVEER_BREAST_CANCER_METASTASIS_DN TUBGCP4 - GSEA.c2 
140 MICROTUBULE TUBGCP4 - GSEA.c5 
141 S_PHASE_OF_MITOTIC_CELL_CYCLE TUBGCP4 - GSEA.c5 
142 HAHTOLA_MYCOSIS_FUNGOIDES_CD4_DN TUBGCP4 - GSEA.c2 
143 MODULE_372 TUBGCP4 - GSEA.c4 
144 LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_LARGE_VS_TINY_UP TUBGCP4 - GSEA.c2 
145 MORF_SS18 TUBGCP4 - GSEA.c4 
146 GNF2_SMC4L1 TUBGCP4 - GSEA.c4 
147 REACTOME_G2_M_CHECKPOINTS TUBGCP4 - GSEA.c5 
148 GNF2_DEK TUBGCP4 - GSEA.c4 
149 MORF_DDB1 TUBGCP4 - GSEA.c4 
150 MORF_ACP1 TUBGCP4 - GSEA.c4 
151 GNF2_CDC2 TUBGCP4 - GSEA.c4 
152 MORF_BUB3 TUBGCP4 - GSEA.c4 
153 MORF_XRCC5 TUBGCP4 - GSEA.c4 
154 NUCLEAR_UBIQUITIN_LIGASE_COMPLEX TUBGCP4 - GSEA.c5 
155 HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_UP TUBGCP4 - GSEA.c2 
156 STARK_HYPPOCAMPUS_22Q11_DELETION_UP TUBGCP4 - GSEA.c2 
157 PUJANA_BREAST_CANCER_LIT_INT_NETWORK TUBGCP4 - GSEA.c2 
158 MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN TUBGCP4 - GSEA.c2 
 233 
 
Appendix II. Common pathway response in OVCA433, HeyA8 and PA-1 to TUBGCP4 and NAT10 knockdown. (continued) 






159 GNF2_RRM1 TUBGCP4 - GSEA.c4 
160 ZHAN_MULTIPLE_MYELOMA_PR_UP TUBGCP4 - GSEA.c2 
161 GNF2_CENPF TUBGCP4 - GSEA.c4 
162 V$E2F_Q3_01 TUBGCP4 - GSEA.c3 
163 CHR1P11 TUBGCP4 - GSEA.c1 
164 GNF2_MLH1 TUBGCP4 - GSEA.c4 
165 SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6 TUBGCP4 - GSEA.c2 
166 CHEN_HOXA5_TARGETS_9HR_DN TUBGCP4 - GSEA.c2 
167 KANG_DOXORUBICIN_RESISTANCE_UP TUBGCP4 - GSEA.c2 
168 RUIZ_TNC_TARGETS_DN TUBGCP4 - GSEA.c2 
169 SA_REG_CASCADE_OF_CYCLIN_EXPR TUBGCP4 - GSEA.c2 
170 V$MYC_Q2 TUBGCP4 - GSEA.c3 
171 MORF_SOD1 TUBGCP4 - GSEA.c4 
172 GNF2_MCM5 TUBGCP4 - GSEA.c4 
173 CONDENSED_NUCLEAR_CHROMOSOME TUBGCP4 - GSEA.c5 
174 NUCLEAR_CHROMATIN TUBGCP4 - GSEA.c5 
175 GNF2_PCNA TUBGCP4 - GSEA.c4 
176 GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN TUBGCP4 - GSEA.c2 
177 DANG_BOUND_BY_MYC TUBGCP4 - GSEA.c2 
178 KEGG_CELL_CYCLE TUBGCP4 - GSEA.c5 
179 GNF2_HMMR TUBGCP4 - GSEA.c4 
180 GNF2_RFC3 TUBGCP4 - GSEA.c4 
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182 G1_PHASE_OF_MITOTIC_CELL_CYCLE TUBGCP4 - GSEA.c5 
183 SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP TUBGCP4 - GSEA.c2 
184 GNF2_CCNA2 TUBGCP4 - GSEA.c4 
185 NUCLEAR_CHROMOSOME TUBGCP4 - GSEA.c5 
186 GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_UP TUBGCP4 - GSEA.c2 
187 GNF2_FEN1 TUBGCP4 - GSEA.c4 
188 MORF_SMC1L1 TUBGCP4 - GSEA.c4 
189 MORF_EIF3S2 TUBGCP4 - GSEA.c4 
190 MORF_MTA1 TUBGCP4 - GSEA.c4 
191 FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_DN TUBGCP4 - GSEA.c2 
192 LY_AGING_PREMATURE_DN TUBGCP4 - GSEA.c2 
193 GNF2_APEX1 TUBGCP4 - GSEA.c4 
194 SCHUHMACHER_MYC_TARGETS_UP TUBGCP4 - GSEA.c2 
195 MANALO_HYPOXIA_DN TUBGCP4 - GSEA.c2 




TUBGCP4 - GSEA.c5 
198 BIOCARTA_SRCRPTP_PATHWAY TUBGCP4 - GSEA.c5 
199 AKT_UP TUBGCP4 - Path.Sig.SAM 
200 MITOTIC_SISTER_CHROMATID_SEGREGATION TUBGCP4 - GSEA.c5 
201 MODULE_17 TUBGCP4 - GSEA.c4 
202 MOOTHA_GLUCONEOGENESIS TUBGCP4 - GSEA.c2 
203 REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX TUBGCP4 - GSEA.c5 
204 MORF_GMPS TUBGCP4 - GSEA.c4 
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205 V$AHR_Q5 TUBGCP4 - GSEA.c3 
206 RICKMAN_TUMOR_DIFFERENTIATED_MODERATELY_VS_POORLY_DN TUBGCP4 - GSEA.c2 
207 RICKMAN_TUMOR_DIFFERENTIATED_MODERATELY_VS_POORLY_UP TUBGCP4 - GSEA.c2 
208 MORF_HDAC1 TUBGCP4 - GSEA.c4 
209 MITSIADES_RESPONSE_TO_APLIDIN_DN TUBGCP4 - GSEA.c2 
210 GNF2_BUB1 TUBGCP4 - GSEA.c4 
211 MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_15 TUBGCP4 - GSEA.c2 
212 ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER TUBGCP4 - GSEA.c2 
213 MODULE_439 TUBGCP4 - GSEA.c4 
214 KEGG_PYRUVATE_METABOLISM TUBGCP4 - GSEA.c5 
215 LINDGREN_BLADDER_CANCER_CLUSTER_3_UP TUBGCP4 - GSEA.c2 
216 MATTIOLI_MGUS_VS_PCL TUBGCP4 - GSEA.c2 
217 YU_MYC_TARGETS_UP TUBGCP4 - GSEA.c2 
218 REACTOME_TELOMERE_MAINTENANCE TUBGCP4 - GSEA.c5 
219 CHROMATIN_BINDING TUBGCP4 - GSEA.c5 
220 ENDODEOXYRIBONUCLEASE_ACTIVITY TUBGCP4 - GSEA.c5 
221 MODULE_54 TUBGCP4 - GSEA.c4 
222 LEE_EARLY_T_LYMPHOCYTE_UP TUBGCP4 - GSEA.c2 
223 ISOPRENOID_METABOLIC_PROCESS TUBGCP4 - GSEA.c5 
224 GCM_ANP32B TUBGCP4 - GSEA.c4 
225 GCM_PPP1CC TUBGCP4 - GSEA.c4 
226 MORF_FBL TUBGCP4 - GSEA.c4 
227 REACTOME_CHOLESTEROL_BIOSYNTHESIS TUBGCP4 - GSEA.c5 
228 MISSIAGLIA_REGULATED_BY_METHYLATION_DN TUBGCP4 - GSEA.c2 
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229 BIOCARTA_SKP2E2F_PATHWAY TUBGCP4 - GSEA.c5 
230 NUNODA_RESPONSE_TO_DASATINIB_IMATINIB_UP TUBGCP4 - GSEA.c2 
231 SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_UP TUBGCP4 - GSEA.c2 
232 BENPORATH_MYC_TARGETS_WITH_EBOX TUBGCP4 - GSEA.c2 
233 SHEPARD_BMYB_MORPHOLINO_DN TUBGCP4 - GSEA.c2 
234 MODULE_538 TUBGCP4 - GSEA.c4 
235 KERLEY_RESPONSE_TO_CISPLATIN_DN TUBGCP4 - GSEA.c2 
236 BIOCARTA_P27_PATHWAY TUBGCP4 - GSEA.c5 
237 PRAMOONJAGO_SOX4_TARGETS_DN TUBGCP4 - GSEA.c2 
238 DAIRKEE_CANCER_PRONE_RESPONSE_BPA_E2 TUBGCP4 - GSEA.c2 
239 KYNG_DNA_DAMAGE_BY_4NQO_OR_GAMMA_RADIATION NAT10 + GSEA.c2 
240 RUGO_STRESS_RESPONSE_SUBSET_F NAT10 + GSEA.c2 
241 REACTOME_CHAPERONIN_MEDIATED_PROTEIN_FOLDING NAT10 + GSEA.c5 
242 BIOCARTA_EPHA4_PATHWAY NAT10 + GSEA.c5 
243 WU_SILENCED_BY_METHYLATION_IN_BLADDER_CANCER NAT10 + GSEA.c2 
244 EXTRACELLULAR_STRUCTURE_ORGANIZATION_AND_BIOGENESIS NAT10 + GSEA.c5 
245 MODULE_491 NAT10 + GSEA.c4 
246 GOLGI_VESICLE_TRANSPORT NAT10 + GSEA.c5 
247 TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_DN NAT10 + GSEA.c2 
248 V$FOXO4_02 NAT10 + GSEA.c3 
249 NOJIMA_SFRP2_TARGETS_UP NAT10 + GSEA.c2 
250 LANDIS_ERBB2_BREAST_TUMORS_65_UP NAT10 + GSEA.c2 
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NAT10 + GSEA.c5 
253 TATTATA,MIR-374 NAT10 + GSEA.c3 
254 SYNAPSE_ORGANIZATION_AND_BIOGENESIS NAT10 + GSEA.c5 
255 SILIGAN_TARGETS_OF_EWS_FLI1_FUSION_UP NAT10 + GSEA.c2 
256 V$CEBPA_01 NAT10 + GSEA.c3 
257 PHOSPHOLIPID_BINDING NAT10 + GSEA.c5 
258 TRANSPORT_VESICLE NAT10 + GSEA.c5 
259 SHEPARD_CRUSH_AND_BURN_MUTANT_UP NAT10 + GSEA.c2 
260 REACTOME_SIGNALING_BY_WNT NAT10 + GSEA.c5 
261 SASAKI_TARGETS_OF_TP73_AND_TP63 NAT10 + GSEA.c2 
262 CHR6Q12 NAT10 + GSEA.c1 
263 HEIDENBLAD_AMPLIFIED_IN_PANCREATIC_CANCER NAT10 + GSEA.c2 
264 DAZARD_UV_RESPONSE_CLUSTER_G1 NAT10 + GSEA.c2 
265 BLUM_RESPONSE_TO_SALIRASIB_UP NAT10 + GSEA.c2 
266 SA_CASPASE_CASCADE NAT10 + GSEA.c2 
267 CELLULAR_MACROMOLECULE_METABOLIC_PROCESS NAT10 + GSEA.c5 
268 GCTCTTG,MIR-335 NAT10 + GSEA.c3 
269 DOANE_RESPONSE_TO_ANDROGEN_UP NAT10 + GSEA.c2 
270 KAAB_HEART_ATRIUM_VS_VENTRICLE_DN NAT10 + GSEA.c2 
271 HORIUCHI_WTAP_TARGETS_UP NAT10 + GSEA.c2 
272 V$POU3F2_01 NAT10 + GSEA.c3 
273 FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_UP NAT10 + GSEA.c2 
274 INTRACELLULAR_TRANSPORT NAT10 + GSEA.c5 
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Appendix II. Common pathway response in OVCA433, HeyA8 and PA-1 to TUBGCP4 and NAT10 knockdown. (continued) 






275 PROTEASE_INHIBITOR_ACTIVITY NAT10 + GSEA.c5 
276 DANG_REGULATED_BY_MYC_DN NAT10 + GSEA.c2 
277 BRUNEAU_HEART_GREAT_VESSELS_AND_VALVULOGENESIS NAT10 + GSEA.c2 
278 GTGCAAT,MIR-25,MIR-32,MIR-92,MIR-363,MIR-367 NAT10 + GSEA.c3 
279 EXOCYTOSIS NAT10 + GSEA.c5 
280 JIANG_HYPOXIA_NORMAL NAT10 + GSEA.c2 
281 CELLULAR_PROTEIN_METABOLIC_PROCESS NAT10 + GSEA.c5 
282 BIOCARTA_D4GDI_PATHWAY NAT10 + GSEA.c5 
283 ACID_AMINO_ACID_LIGASE_ACTIVITY NAT10 + GSEA.c5 
284 CHR7P11 NAT10 + GSEA.c1 
285 V$HNF3B_01 NAT10 + GSEA.c3 
286 OXIDOREDUCTASE_ACTIVITY_GO_0016706 NAT10 + GSEA.c5 




NAT10 + GSEA.c5 
289 V$FOXD3_01 NAT10 + GSEA.c3 
290 CHR5Q32 NAT10 + GSEA.c1 
291 ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP NAT10 + GSEA.c2 
292 GCAAGAC,MIR-431 NAT10 + GSEA.c3 
293 BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_DN NAT10 + GSEA.c2 
294 KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_UP NAT10 + GSEA.c2 
295 EMBRYONIC_DEVELOPMENT NAT10 + GSEA.c5 
296 NOUZOVA_METHYLATED_IN_APL NAT10 + GSEA.c2 
297 REGULATION_OF_T_CELL_PROLIFERATION NAT10 + GSEA.c5 
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Appendix II. Common pathway response in OVCA433, HeyA8 and PA-1 to TUBGCP4 and NAT10 knockdown. (continued) 






298 GENTILE_UV_RESPONSE_CLUSTER_D8 NAT10 + GSEA.c2 
299 FUJII_YBX1_TARGETS_UP NAT10 + GSEA.c2 
300 BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_AND_PAX3 NAT10 + GSEA.c2 
301 UDAYAKUMAR_MED1_TARGETS_DN NAT10 + GSEA.c2 
302 ABDULRAHMAN_KIDNEY_CANCER_VHL_DN NAT10 + GSEA.c2 
303 MODULE_447 NAT10 + GSEA.c4 
304 KEGG_SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT NAT10 + GSEA.c5 
305 EMBRYO_IMPLANTATION NAT10 + GSEA.c5 
306 V$ELK1_01 NAT10 + GSEA.c3 
307 V$POU6F1_01 NAT10 + GSEA.c3 
308 POSITIVE_REGULATION_OF_MAPKKK_CASCADE NAT10 + GSEA.c5 
309 SCIBETTA_KDM5B_TARGETS_UP NAT10 + GSEA.c2 
310 CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_UP NAT10 + GSEA.c2 
311 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN NAT10 + GSEA.c2 
312 REACTOME_REGULATED_PROTEOLYSIS_OF_P75NTR NAT10 + GSEA.c5 
313 MODULE_543 NAT10 + GSEA.c4 
314 BIOCARTA_VITCB_PATHWAY NAT10 + GSEA.c5 
315 CAIRO_HEPATOBLASTOMA_DN NAT10 + GSEA.c2 
316 SHARMA_ASTROCYTOMA_WITH_NF1_SYNDROM NAT10 + GSEA.c2 
317 GTCTACC,MIR-379 NAT10 + GSEA.c3 
318 POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS NAT10 + GSEA.c5 
319 MODULE_259 NAT10 + GSEA.c4 
320 CHR3P23 NAT10 + GSEA.c1 
321 BLALOCK_ALZHEIMERS_DISEASE_INCIPIENT_UP NAT10 + GSEA.c2 
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Appendix II. Common pathway response in OVCA433, HeyA8 and PA-1 to TUBGCP4 and NAT10 knockdown. (continued) 






322 BOYAULT_LIVER_CANCER_SUBCLASS_G2 NAT10 + GSEA.c2 




NAT10 + GSEA.c5 
325 REACTOME_SIGNALING_BY_NOTCH NAT10 + GSEA.c5 
326 HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS NAT10 + GSEA.c5 
327 TTCCGTT,MIR-191 NAT10 + GSEA.c3 
328 CAIRO_HEPATOBLASTOMA_CLASSES_DN NAT10 + GSEA.c2 
329 SECRETION NAT10 + GSEA.c5 
330 V$GATA1_02 NAT10 + GSEA.c3 
331 BROWNE_HCMV_INFECTION_20HR_DN NAT10 + GSEA.c2 
332 TGGTGCT,MIR-29A,MIR-29B,MIR-29C NAT10 + GSEA.c3 
333 RODRIGUES_DCC_TARGETS_DN NAT10 + GSEA.c2 
334 CHR4P12 NAT10 + GSEA.c1 
335 GCAAGGA,MIR-502 NAT10 + GSEA.c3 
336 POSITIVE_REGULATION_OF_CELLULAR_PROTEIN_METABOLIC_PROCESS NAT10 + GSEA.c5 
337 CHRXQ26 NAT10 - GSEA.c1 
338 THUM_MIR21_TARGETS_HEART_DISEASE_DN NAT10 - GSEA.c2 
339 APPIERTO_RESPONSE_TO_FENRETINIDE_DN NAT10 - GSEA.c2 
340 XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_DN NAT10 - GSEA.c2 
341 MODULE_471 NAT10 - GSEA.c4 
342 MORF_RAN NAT10 - GSEA.c4 
343 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_RED_UP NAT10 - GSEA.c2 
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Appendix II. Common pathway response in OVCA433, HeyA8 and PA-1 to TUBGCP4 and NAT10 knockdown. (continued) 






344 MORF_UBE2I NAT10 - GSEA.c4 
345 MICROTUBULE_POLYMERIZATION_OR_DEPOLYMERIZATION NAT10 - GSEA.c5 
346 MODULE_18 NAT10 - GSEA.c4 
347 BIOCARTA_NEUROTRANSMITTERS_PATHWAY NAT10 - GSEA.c5 
348 BETA_TUBULIN_BINDING NAT10 - GSEA.c5 
349 BASE_EXCISION_REPAIR NAT10 - GSEA.c5 




NAT10 - GSEA.c5 
352 KENNY_CTNNB1_TARGETS_UP NAT10 - GSEA.c2 
353 BIOCARTA_SHH_PATHWAY NAT10 - GSEA.c5 
354 CHR11Q24 NAT10 - GSEA.c1 
355 GAMETE_GENERATION NAT10 - GSEA.c5 
356 MODULE_428 NAT10 - GSEA.c4 
357 REACTOME_TRANSMEMBRANE_TRANSPORT_OF_SMALL_MOLECULES NAT10 - GSEA.c5 
358 REACTOME_BASE_EXCISION_REPAIR NAT10 - GSEA.c5 
359 WELCSH_BRCA1_TARGETS_1_DN NAT10 - GSEA.c2 
360 MORF_G22P1 NAT10 - GSEA.c4 
361 V$NFY_01 NAT10 - GSEA.c3 
362 KEGG_ACUTE_MYELOID_LEUKEMIA NAT10 - GSEA.c5 
363 SA_G1_AND_S_PHASES NAT10 - GSEA.c2 
364 CHR7P13 NAT10 - GSEA.c1 
365 FERRANDO_HOX11_NEIGHBORS NAT10 - GSEA.c2 
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Appendix II. Common pathway response in OVCA433, HeyA8 and PA-1 to TUBGCP4 and NAT10 knockdown. (continued) 






366 CONCANNON_APOPTOSIS_BY_EPOXOMICIN_DN NAT10 - GSEA.c2 
367 REACTOME_APOPTOSIS_INDUCED_DNA_FRAGMENTATION NAT10 - GSEA.c5 
368 GAL_LEUKEMIC_STEM_CELL_DN NAT10 - GSEA.c2 
369 V$E2F1_Q3_01 NAT10 - GSEA.c3 
370 DAIRKEE_TERT_TARGETS_UP NAT10 - GSEA.c2 
371 MORF_ERH NAT10 - GSEA.c4 
372 V$MYC_Q2 NAT10 - GSEA.c3 
373 REGULATION_OF_NEUROTRANSMITTER_LEVELS NAT10 - GSEA.c5 
374 ATPASE_ACTIVITY_COUPLED NAT10 - GSEA.c5 
375 HASLINGER_B_CLL_WITH_CHROMOSOME_12_TRISOMY NAT10 - GSEA.c2 
376 PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_DN NAT10 - GSEA.c2 
377 MODULE_303 NAT10 - GSEA.c4 
378 MODULE_16 NAT10 - GSEA.c4 
379 PODAR_RESPONSE_TO_ADAPHOSTIN_DN NAT10 - GSEA.c2 
380 TTTNNANAGCYR_UNKNOWN NAT10 - GSEA.c3 
381 MODULE_149 NAT10 - GSEA.c4 




NAT10 - GSEA.c5 
384 ACTIVATION_OF_JNK_ACTIVITY NAT10 - GSEA.c5 
385 MODULE_253 NAT10 - GSEA.c4 




Appendix II. Common pathway response in OVCA433, HeyA8 and PA-1 to TUBGCP4 and NAT10 knockdown. (continued) 









NAT10 - GSEA.c5 
388 BIOCARTA_SET_PATHWAY NAT10 - GSEA.c5 
389 SHEPARD_CRUSH_AND_BURN_MUTANT_DN NAT10 - GSEA.c2 
390 SESTO_RESPONSE_TO_UV_C7 NAT10 - GSEA.c2 
391 MARKEY_RB1_CHRONIC_LOF_UP NAT10 - GSEA.c2 
392 REACTOME_REMOVAL_OF_DNA_PATCH_CONTAINING_ABASIC_RESIDUE NAT10 - GSEA.c5 
393 REACTOME_AMINO_ACID_TRANSPORT_ACROSS_THE_PLASMA_MEMBRANE NAT10 - GSEA.c5 
394 CELL_DIVISION NAT10 - GSEA.c5 
395 MODULE_115 NAT10 - GSEA.c4 
396 NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP NAT10 - GSEA.c2 
397 REACTOME_EARLY_PHASE_OF_HIV_LIFE_CYCLE NAT10 - GSEA.c5 
398 BENPORATH_ES_CORE_NINE_CORRELATED NAT10 - GSEA.c2 
399 MORF_ORC1L NAT10 - GSEA.c4 
400 GLINSKY_CANCER_DEATH_UP NAT10 - GSEA.c2 
401 CUI_GLUCOSE_DEPRIVATION NAT10 - GSEA.c2 
402 SEXUAL_REPRODUCTION NAT10 - GSEA.c5 
403 CHIARETTI_T_ALL_RELAPSE_PROGNOSIS NAT10 - GSEA.c2 
404 V$CMYB_01 NAT10 - GSEA.c3 
405 LAMELLIPODIUM NAT10 - GSEA.c5 
406 AROMATIC_COMPOUND_METABOLIC_PROCESS NAT10 - GSEA.c5 
407 BIOCARTA_CARM1_PATHWAY NAT10 - GSEA.c5 
408 GCM_HDAC1 NAT10 - GSEA.c4 
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Appendix II. Common pathway response in OVCA433, HeyA8 and PA-1 to TUBGCP4 and NAT10 knockdown. (continued) 






409 BOGNI_TREATMENT_RELATED_MYELOID_LEUKEMIA_UP NAT10 - GSEA.c2 
410 TP63_UP NAT10 - Path.Sig.SAM 
411 MORF_MYST2 NAT10 - GSEA.c4 
412 SHEPARD_BMYB_TARGETS NAT10 - GSEA.c2 
413 KTGGYRSGAA_UNKNOWN NAT10 - GSEA.c3 
414 LEE_LIVER_CANCER_MYC_UP NAT10 - GSEA.c2 
415 SA_REG_CASCADE_OF_CYCLIN_EXPR NAT10 - GSEA.c2 
416 CYTOKINESIS NAT10 - GSEA.c5 
417 MODULE_56 NAT10 - GSEA.c4 
418 PRODUCTION_OF_MOLECULAR_MEDIATOR_OF_IMMUNE_RESPONSE NAT10 - GSEA.c5 
419 MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_15 NAT10 - GSEA.c2 
420 MODULE_21 NAT10 - GSEA.c4 




NAT10 - GSEA.c5 
423 PUIFFE_INVASION_INHIBITED_BY_ASCITES_UP NAT10 - GSEA.c2 
424 MODULE_53 NAT10 - GSEA.c4 
425 OHASHI_AURKB_TARGETS NAT10 - GSEA.c2 
 
GSEA: Curated gene sets from GSEA database. 
Path.Sig.SAM: Gene sets generated using significance analysis of microarrays (SAM) from Gatza et al (2010). 
Subtype.BR: Gene sets generated for each subtype by binary regression (BinReg) analysis from Tan et al (2013). 




Appendix III. List of PA-1 specific down-regulated pathways that overlapped with Stem-A cell lines enriched gene sets. 
Index Gene set Gene knocked down Source Recurrence 
1 CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT NAT10 GSEA.c5 No 
2 TGCGCANK_UNKNOWN NAT10 GSEA.c3 No 
3 GCM_NF2 NAT10 GSEA.c4 No 
4 GNF2_MLF1 NAT10 GSEA.c4 No 
5 MOOTHA_VOXPHOS NAT10 GSEA.c2 No 
6 MITOCHONDRIAL_MEMBRANE_PART NAT10 GSEA.c5 Yes 
7 MODULE_519 NAT10 GSEA.c4 No 
8 MORF_BECN1 NAT10 GSEA.c4 No 
9 YATGNWAAT_V$OCT_C NAT10 GSEA.c3 No 
10 GNF2_CCNA1 NAT10 GSEA.c4 Yes 
11 HEME_BIOSYNTHETIC_PROCESS NAT10 GSEA.c5 Yes 
12 GLUTATHIONE_TRANSFERASE_ACTIVITY NAT10 GSEA.c5 Yes 
13 UBIQUITIN_PROTEIN_LIGASE_ACTIVITY NAT10 GSEA.c5 Yes 
14 KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_BIOSYNTHESIS NAT10 GSEA.c5 No 
15 MICROBODY_MEMBRANE NAT10 GSEA.c5 Yes 
16 PEROXISOMAL_MEMBRANE NAT10 GSEA.c5 Yes 
17 KEGG_PYRUVATE_METABOLISM NAT10 GSEA.c5 No 
18 SMITH_LIVER_CANCER NAT10 GSEA.c2 No 
19 TRANSITION_METAL_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY NAT10 GSEA.c5 No 
20 HOEGERKORP_CD44_TARGETS_TEMPORAL_DN NAT10 GSEA.c2 Yes 
21 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_DN NAT10 GSEA.c2 Yes 
22 HASLINGER_B_CLL_WITH_17P13_DELETION NAT10 GSEA.c2 No 
23 BROWNE_HCMV_INFECTION_10HR_UP NAT10 GSEA.c2 Yes 
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Appendix III. List of PA-1 specific down-regulated pathways that overlapped with Stem-A cell lines enriched gene sets. (continued) 
Index Gene set Gene knocked down Source Recurrence 
24 MODULE_152 NAT10 GSEA.c4 No 
25 PENG_RAPAMYCIN_RESPONSE_DN NAT10 GSEA.c2 Yes 
26 PIGMENT_METABOLIC_PROCESS NAT10 GSEA.c5 No 
27 PIGMENT_BIOSYNTHETIC_PROCESS NAT10 GSEA.c5 Yes 
28 HETEROCYCLE_METABOLIC_PROCESS NAT10 GSEA.c5 Yes 
29 SPERM_MOTILITY NAT10 GSEA.c5 Yes 
30 V$PAX3_01 NAT10 GSEA.c3 Yes 
31 VALK_AML_CLUSTER_16 NAT10 GSEA.c2 No 
32 GTTGNYNNRGNAAC_UNKNOWN NAT10 GSEA.c3 Yes 
33 GGTGAAG,MIR-412 NAT10 GSEA.c3 Yes 
34 KEGG_OXIDATIVE_PHOSPHORYLATION NAT10 GSEA.c5 No 
35 ISOMERASE_ACTIVITY NAT10 GSEA.c5 Yes 
36 DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_UP NAT10 GSEA.c2 Yes 
37 AGGAGTG,MIR-483 NAT10 GSEA.c3 No 
38 MODULE_221 NAT10 GSEA.c4 Yes 
39 MODULE_22 NAT10 GSEA.c4 No 
40 MODULE_184 NAT10 GSEA.c4 Yes 
41 PURINE_NUCLEOTIDE_METABOLIC_PROCESS NAT10 GSEA.c5 No 
42 SMALL_PROTEIN_CONJUGATING_ENZYME_ACTIVITY NAT10 GSEA.c5 No 
43 MITOCHONDRIAL_MEMBRANE NAT10 GSEA.c5 No 
44 ZHAN_MULTIPLE_MYELOMA_CD1_AND_CD2_UP NAT10 GSEA.c2 No 
45 FAELT_B_CLL_WITH_VH3_21_DN NAT10 GSEA.c2 No 
46 MODULE_42 NAT10 GSEA.c4 No 
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Appendix III. List of PA-1 specific down-regulated pathways that overlapped with Stem-A cell lines enriched gene sets. (continued) 
Index Gene set Gene knocked down Source Recurrence 
47 MODULE_62 NAT10 GSEA.c4 No 
48 MODULE_77 NAT10 GSEA.c4 No 
49 GAUSSMANN_MLL_AF4_FUSION_TARGETS_B_UP NAT10 GSEA.c2 Yes 
50 BARRIER_COLON_CANCER_RECURRENCE_UP NAT10 GSEA.c2 No 
51 BIOCARTA_ACTINY_PATHWAY NAT10 GSEA.c5 No 
52 MITOCHONDRIAL_ENVELOPE NAT10 GSEA.c5 No 
53 CHOI_ATL_STAGE_PREDICTOR NAT10 GSEA.c2 No 
54 V$CREB_Q3 NAT10 GSEA.c3 Yes 
55 MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_25 NAT10 GSEA.c2 No 
56 V$VDR_Q3 NAT10 GSEA.c3 No 
57 MITOCHONDRIAL_RESPIRATORY_CHAIN_COMPLEX_I NAT10 GSEA.c5 No 
58 NADH_DEHYDROGENASE_COMPLEX NAT10 GSEA.c5 No 
59 RESPIRATORY_CHAIN_COMPLEX_I NAT10 GSEA.c5 No 
60 HISTONE_DEACETYLASE_COMPLEX NAT10 GSEA.c5 No 
61 ACAACCT,MIR-453 NAT10 GSEA.c3 No 
62 DING_LUNG_CANCER_MUTATED_FREQUENTLY NAT10 GSEA.c2 No 
63 LIN_MELANOMA_COPY_NUMBER_UP NAT10 GSEA.c2 No 
64 GGGGCCC,MIR-296 NAT10 GSEA.c3 No 
65 GCM_CSNK1D NAT10 GSEA.c4 No 
66 HOEGERKORP_CD44_TARGETS_TEMPORAL_DN TUBGCP4 GSEA.c2 Yes 
67 GTTGNYNNRGNAAC_UNKNOWN TUBGCP4 GSEA.c3 Yes 
68 ISOMERASE_ACTIVITY TUBGCP4 GSEA.c5 Yes 
69 BROWNE_HCMV_INFECTION_10HR_UP TUBGCP4 GSEA.c2 Yes 
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Appendix III. List of PA-1 specific down-regulated pathways that overlapped with Stem-A cell lines enriched gene sets. (continued) 
Index Gene set Gene knocked down Source Recurrence 
70 PENG_RAPAMYCIN_RESPONSE_DN TUBGCP4 GSEA.c2 Yes 
71 HETEROCYCLE_METABOLIC_PROCESS TUBGCP4 GSEA.c5 Yes 
72 SPERM_MOTILITY TUBGCP4 GSEA.c5 Yes 
73 V$PAX3_01 TUBGCP4 GSEA.c3 Yes 
74 MICROBODY_MEMBRANE TUBGCP4 GSEA.c5 Yes 
75 PEROXISOMAL_MEMBRANE TUBGCP4 GSEA.c5 Yes 
76 GGTGAAG,MIR-412 TUBGCP4 GSEA.c3 Yes 
77 HEME_BIOSYNTHETIC_PROCESS TUBGCP4 GSEA.c5 Yes 
78 PIGMENT_BIOSYNTHETIC_PROCESS TUBGCP4 GSEA.c5 Yes 
79 UBIQUITIN_PROTEIN_LIGASE_ACTIVITY TUBGCP4 GSEA.c5 Yes 
80 CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2 TUBGCP4 GSEA.c2 No 
81 GLUTATHIONE_TRANSFERASE_ACTIVITY TUBGCP4 GSEA.c5 Yes 
82 GAUSSMANN_MLL_AF4_FUSION_TARGETS_B_UP TUBGCP4 GSEA.c2 Yes 
83 MITOCHONDRIAL_MEMBRANE_PART TUBGCP4 GSEA.c5 Yes 
84 V$CREB_Q3 TUBGCP4 GSEA.c3 Yes 
85 MODULE_356 TUBGCP4 GSEA.c4 No 
86 GNF2_CCNA1 TUBGCP4 GSEA.c4 Yes 
87 GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_DN TUBGCP4 GSEA.c2 Yes 
88 MODULE_49 TUBGCP4 GSEA.c4 No 
89 MODULE_184 TUBGCP4 GSEA.c4 Yes 
90 MODULE_221 TUBGCP4 GSEA.c4 Yes 
91 DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_UP TUBGCP4 GSEA.c2 Yes 
 
GSEA: Curated gene sets from GSEA database. 
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Appendix IV. Cisplatin resistance candidate genes and cisplatin sensitizing genes identified from RNAi screen (q < 0.005). 




Hairpin ID Hairpin score Category 




2 RB1 0.96 0 TRCN0000040164,TRCN0000040167,TRCN0000040163,TRCN0000040165 1.01,0.91,0.66,0.52 Resistance 




4 SLC6A13 0.94 0 TRCN0000042915,TRCN0000042917,TRCN0000042916 0.49,0.49,0.47 Resistance 
5 ANAPC11 0.99 0 TRCN0000038800,TRCN0000038799 0.84,0.69 Resistance 




































15 TBL3 0.88 0.0003 TRCN0000078058,TRCN0000078059,TRCN0000078061,TRCN0000078062 0.43,0.54,0.48,0.34 Resistance 
16 CLDN14 0.91 0.0003 TRCN0000082913,TRCN0000082914,TRCN0000082917 0.51,0.52,0.40 Resistance 
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Appendix IV. Cisplatin resistance candidate genes and cisplatin sensitizing genes identified from RNAi screen (q < 0.005). (continued) 




Hairpin ID Hairpin score Category 
















20 EXOC3 0.91 0.0004 TRCN0000074303,TRCN0000074306,TRCN0000074307 0.40,0.46,0.55 Resistance 
21 HIST1H4F 0.97 0.0004 TRCN0000106726,TRCN0000106729 0.69,0.59 Resistance 












25 AP1M1 0.85 0.0006 TRCN0000065089,TRCN0000065090,TRCN0000065091,TRCN0000065092 0.80,0.30,0.32,0.32 Resistance 
26 RPL7L1 0.86 0.0006 TRCN0000117687,TRCN0000117689,TRCN0000117690,TRCN0000117691 0.32,0.36,0.34,0.31 Resistance 












30 SLC6A17 0.84 0.0008 TRCN0000038514,TRCN0000038515,TRCN0000038517,TRCN0000038518 1.47,0.29,0.29,0.32 Resistance 
31 CTAG2 0.89 0.0008 TRCN0000115762,TRCN0000115764,TRCN0000115765 0.36,0.49,0.53 Resistance 
32 CYB5R3 0.84 0.0009 TRCN0000038974,TRCN0000038975,TRCN0000038976,TRCN0000038978 0.75,0.28,0.45,0.72 Resistance 




Appendix IV. Cisplatin resistance candidate genes and cisplatin sensitizing genes identified from RNAi screen (q < 0.005). (continued) 




Hairpin ID Hairpin score Category 




35 FKSG30 0.96 0.001 TRCN0000117202,TRCN0000117204 0.53,0.54 Resistance 
36 LOC393062 0.96 0.0011 TRCN0000038484,TRCN0000038487 0.52,0.63 Resistance 




38 SLC5A12 0.82 0.0012 TRCN0000043653,TRCN0000043654,TRCN0000043656,TRCN0000043657 0.33,0.26,0.37,0.64 Resistance 
39 DUOX2 0.82 0.0012 TRCN0000045963,TRCN0000045964,TRCN0000045966,TRCN0000045967 0.35,0.33,0.54,0.26 Resistance 
40 SPTBN4 0.82 0.0012 TRCN0000113936,TRCN0000113937,TRCN0000113938,TRCN0000113940 0.38,0.28,0.28,0.26 Resistance 




42 ABCC3 0.88 0.0013 TRCN0000059404,TRCN0000059406,TRCN0000059407 0.70,0.74,0.34 Resistance 
43 MR1 0.81 0.0014 TRCN0000057288,TRCN0000057289,TRCN0000057290,TRCN0000057291 0.58,0.25,0.36,0.27 Resistance 
44 VKORC1 0.95 0.0015 TRCN0000038970,TRCN0000038973 0.50,0.66 Resistance 
45 RAB3GAP2 0.87 0.0016 TRCN0000047218,TRCN0000047219,TRCN0000047222 0.33,0.48,0.51 Resistance 
46 PPL 0.81 0.0016 TRCN0000116937,TRCN0000116938,TRCN0000116939,TRCN0000116941 0.24,0.51,0.53,0.25 Resistance 
47 SLCO4C1 0.8 0.0018 TRCN0000038310,TRCN0000038311,TRCN0000038312,TRCN0000038313 0.88,0.24,0.29,0.38 Resistance 




49 PEX5 0.95 0.0018 TRCN0000082820,TRCN0000082822 0.82,0.49 Resistance 
50 SLCO2A1 0.95 0.0019 TRCN0000043063,TRCN0000043064 0.49,0.58 Resistance 
51 ATP6V0D2 0.8 0.002 TRCN0000043518,TRCN0000043519,TRCN0000043520,TRCN0000043521 0.23,0.54,0.26,0.55 Resistance 







Appendix IV. Cisplatin resistance candidate genes and cisplatin sensitizing genes identified from RNAi screen (q < 0.005). (continued) 




Hairpin ID Hairpin score Category 




54 AKAP8 0.79 0.0021 TRCN0000037944,TRCN0000037945,TRCN0000037946,TRCN0000037947 0.37,0.46,0.22,0.43 Resistance 
55 ATP6V0A2 0.79 0.0021 TRCN0000043493,TRCN0000043494,TRCN0000043495,TRCN0000043496 0.99,0.23,0.27,0.38 Resistance 
56 CLCN1 0.79 0.0021 TRCN0000043883,TRCN0000043884,TRCN0000043885,TRCN0000043887 0.31,0.23,0.25,0.34 Resistance 




58 KCNJ3 0.78 0.0022 TRCN0000044328,TRCN0000044329,TRCN0000044330,TRCN0000044332 0.22,0.25,0.32,0.25 Resistance 




60 CKAP1 0.78 0.0025 TRCN0000117032,TRCN0000117033,TRCN0000117034,TRCN0000117035 0.68,0.32,0.21,0.47 Resistance 
61 ZNF694 0.78 0.0025 TRCN0000107350,TRCN0000107351,TRCN0000107353,TRCN0000107354 0.34,0.21,0.44,0.33 Resistance 




63 ATP1B3 0.78 0.0026 TRCN0000043368,TRCN0000043369,TRCN0000043370,TRCN0000043371 0.30,0.47,0.27,0.21 Resistance 
64 SLC25A17 0.78 0.0026 TRCN0000043908,TRCN0000043909,TRCN0000043910,TRCN0000043912 0.43,0.31,0.55,0.21 Resistance 
65 ZNF546 0.78 0.0026 TRCN0000108170,TRCN0000108171,TRCN0000108172,TRCN0000108174 0.21,0.21,0.30,0.55 Resistance 






















Appendix IV. Cisplatin resistance candidate genes and cisplatin sensitizing genes identified from RNAi screen (q < 0.005). (continued) 




Hairpin ID Hairpin score Category 




72 CACNA2D1 0.85 0.003 TRCN0000043768,TRCN0000043769,TRCN0000043770 0.34,0.55,0.30 Resistance 
73 KCNH3 0.77 0.003 TRCN0000044593,TRCN0000044594,TRCN0000044595,TRCN0000044596 0.33,0.20,0.34,0.21 Resistance 
74 HIST1H4B 0.85 0.003 TRCN0000106686,TRCN0000106687,TRCN0000106689 0.30,0.66,0.34 Resistance 
75 NMRAL1 0.77 0.0033 TRCN0000036909,TRCN0000036911,TRCN0000036912,TRCN0000036913 0.20,0.61,0.46,0.28 Resistance 
76 INCENP 0.77 0.0033 TRCN0000074143,TRCN0000074144,TRCN0000074145,TRCN0000074146 0.26,0.20,0.35,0.26 Resistance 
77 TMEM16A 0.85 0.0034 TRCN0000040265,TRCN0000040266,TRCN0000040267 0.29,0.34,0.79 Resistance 
78 AKAP13 0.77 0.0034 TRCN0000037970,TRCN0000037971,TRCN0000037972,TRCN0000037973 0.40,0.20,0.35,0.62 Resistance 




80 TNPO2 0.76 0.0036 TRCN0000043468,TRCN0000043469,TRCN0000043470,TRCN0000043471 0.20,0.68,0.27,0.19 Resistance 




82 GPC3 0.76 0.0036 TRCN0000078558,TRCN0000078559,TRCN0000078561,TRCN0000078562 0.22,0.77,0.77,0.19 Resistance 
83 MYO15A 0.76 0.0036 TRCN0000083324,TRCN0000083325,TRCN0000083326,TRCN0000083327 0.35,0.31,0.19,0.31 Resistance 






















Appendix IV. Cisplatin resistance candidate genes and cisplatin sensitizing genes identified from RNAi screen (q < 0.005). (continued) 




Hairpin ID Hairpin score Category 








91 AOF1 0.84 0.0042 TRCN0000046073,TRCN0000046076,TRCN0000046077 0.48,0.52,0.28 Resistance 
















96 PKIG 0.93 0.0047 TRCN0000037965,TRCN0000037966 0.43,0.45 Resistance 
















101 CLEC4C 0.9 0 TRCN0000055458,TRCN0000055460,TRCN0000055461,TRCN0000055462 0.63,0.60,0.59,0.71 Sensitizing 
102 DNTTIP2 0.94 0 TRCN0000061513,TRCN0000061514,TRCN0000061515 1.07,0.71,0.68 Sensitizing 
103 CTGF 0.92 0 TRCN0000061949,TRCN0000061950,TRCN0000061951,TRCN0000061952 0.66,0.70,0.65,0.63 Sensitizing 
104 LEPREL1 0.95 0 TRCN0000064793,TRCN0000064795,TRCN0000064797 0.77,0.70,1.03 Sensitizing 






Appendix IV. Cisplatin resistance candidate genes and cisplatin sensitizing genes identified from RNAi screen (q < 0.005). (continued) 




Hairpin ID Hairpin score Category 
106 AP1GBP1 0.93 0.0001 TRCN0000054121,TRCN0000054118,TRCN0000054120 0.77,0.69,0.64 Sensitizing 








109 SCG2 0.92 0.0001 TRCN0000055603,TRCN0000055605,TRCN0000055606 0.67,0.66,0.64 Sensitizing 












113 CXorf9 0.91 0.0003 TRCN0000062584,TRCN0000062585,TRCN0000062586 0.72,0.64,0.62 Sensitizing 








116 CDH9 0.86 0.0004 TRCN0000054253,TRCN0000054254,TRCN0000054255,TRCN0000054257 0.76,0.58,0.54,0.64 Sensitizing 




118 MRPS26 0.97 0.0004 TRCN0000146373,TRCN0000179426 0.82,0.77 Sensitizing 
119 CPXCR1 0.97 0.0005 TRCN0000134254,TRCN0000135021 0.87,0.76 Sensitizing 
120 TNKS2 0.85 0.0006 TRCN0000053238,TRCN0000053239,TRCN0000053240,TRCN0000053241 0.56,0.52,1.03,0.53 Sensitizing 
121 ANXA7 0.86 0.0006 TRCN0000056303,TRCN0000056305,TRCN0000056306,TRCN0000056307 0.74,0.54,0.62,0.73 Sensitizing 
122 GUCA1A 0.9 0.0008 TRCN0000056259,TRCN0000056260,TRCN0000056262 1.00,0.57,0.77 Sensitizing 






Appendix IV. Cisplatin resistance candidate genes and cisplatin sensitizing genes identified from RNAi screen (q < 0.005). (continued) 




Hairpin ID Hairpin score Category 




125 RAB20 0.83 0.001 TRCN0000048093,TRCN0000048094,TRCN0000048096,TRCN0000048097 0.60,0.58,0.67,0.50 Sensitizing 
126 NCOA6 0.89 0.001 TRCN0000063263,TRCN0000063264,TRCN0000063265 2.98,0.14,1.12 Sensitizing 
127 TATDN2 0.89 0.0011 TRCN0000049828,TRCN0000049830,TRCN0000049831 0.96,0.56,0.81 Sensitizing 
128 PCDHA8 0.83 0.0011 TRCN0000056018,TRCN0000056019,TRCN0000056020,TRCN0000056022 0.70,0.50,0.65,0.55 Sensitizing 
129 PRRG1 0.83 0.0011 TRCN0000056433,TRCN0000056434,TRCN0000056436,TRCN0000056437 0.50,0.53,0.71,0.56 Sensitizing 
130 PCDHB5 0.82 0.0012 TRCN0000056218,TRCN0000056220,TRCN0000056221,TRCN0000056222 0.51,0.72,0.48,0.60 Sensitizing 








133 PATE 0.81 0.0015 TRCN0000055671,TRCN0000055672,TRCN0000055669,TRCN0000055670 0.54,0.83,0.47,0.72 Sensitizing 
134 DNM3 0.81 0.0015 TRCN0000051404,TRCN0000051405,TRCN0000051406,TRCN0000051407 0.47,0.60,0.59,0.53 Sensitizing 
135 ZZEF1 0.81 0.0015 TRCN0000055663,TRCN0000055664,TRCN0000055665,TRCN0000055667 0.47,0.54,0.62,0.51 Sensitizing 
136 ACTN3 0.8 0.0016 TRCN0000055908,TRCN0000055909,TRCN0000055910,TRCN0000055911 0.70,0.63,0.96,0.46 Sensitizing 
137 RPL23 0.87 0.0016 TRCN0000117542,TRCN0000117543,TRCN0000117544 0.55,0.80,1.28 Sensitizing 




139 CSF2RB 0.86 0.0018 TRCN0000059219,TRCN0000059221,TRCN0000059222 0.81,0.54,0.54 Sensitizing 
140 CEP164 0.95 0.0018 TRCN0000147245,TRCN0000148591 0.70,0.70 Sensitizing 
141 RHBDF2 0.79 0.0019 TRCN0000048683,TRCN0000048684,TRCN0000048685,TRCN0000048687 0.44,0.72,0.79,0.65 Sensitizing 
142 PCDH8 0.79 0.0019 TRCN0000055863,TRCN0000055864,TRCN0000055865,TRCN0000055866 -0.39,1.20,0.71,0.70 Sensitizing 
143 PLSCR1 0.79 0.0019 TRCN0000056269,TRCN0000056270,TRCN0000056271,TRCN0000056272 1.45,0.74,0.44,0.52 Sensitizing 
 257 
 
Appendix IV. Cisplatin resistance candidate genes and cisplatin sensitizing genes identified from RNAi screen (q < 0.005). (continued) 




Hairpin ID Hairpin score Category 
144 CDH7 0.79 0.002 TRCN0000054158,TRCN0000054159,TRCN0000054160,TRCN0000054161 0.52,0.44,0.52,0.47 Sensitizing 
145 PCDHA12 0.78 0.002 TRCN0000055749,TRCN0000055750,TRCN0000055751,TRCN0000055752 0.64,0.48,0.43,0.45 Sensitizing 
146 SNAI3 0.95 0.0022 TRCN0000033299,TRCN0000033303 0.70,0.70 Sensitizing 
























153 GOLGA4 0.86 0.0023 TRCN0000061990,TRCN0000061991,TRCN0000061992 0.65,0.53,0.93 Sensitizing 
154 KNDC1 0.51 0.0024 
TRCN0000048293,TRCN0000048294,TRCN0000048295,TRCN0000048296
,TRCN0000048297,TRCN0000048298,TRCN0000048299,TRCN000004830





155 EFHA2 0.77 0.0025 TRCN0000056083,TRCN0000056084,TRCN0000056085,TRCN0000056086 0.56,-0.19,0.63,2.57 Sensitizing 








158 GCLC 0.76 0.0029 TRCN0000048483,TRCN0000048484,TRCN0000048485,TRCN0000048486 -0.17,0.72,0.65,1.11 Sensitizing 






Appendix IV. Cisplatin resistance candidate genes and cisplatin sensitizing genes identified from RNAi screen (q < 0.005). (continued) 




Hairpin ID Hairpin score Category 




161 LTBP4 0.85 0.003 TRCN0000055828,TRCN0000055830,TRCN0000055831 0.52,0.59,0.65 Sensitizing 
162 PSMD13 0.85 0.003 TRCN0000058109,TRCN0000058110,TRCN0000058111 0.95,0.52,0.55 Sensitizing 




164 CD40LG 0.76 0.0031 TRCN0000059113,TRCN0000059115,TRCN0000059116,TRCN0000059117 0.54,0.59,0.43,0.44 Sensitizing 
165 CANT1 0.85 0.0032 TRCN0000051898,TRCN0000051900,TRCN0000051901 0.52,0.54,0.66 Sensitizing 








168 IFNA4 0.94 0.0034 TRCN0000005814,TRCN0000005817 0.67,0.70 Sensitizing 






170 OR51B6 0.75 0.0043 TRCN0000060783,TRCN0000060784,TRCN0000060785,TRCN0000060786 0.65,0.57,0.51,0.43 Sensitizing 
171 PCDHGA9 0.84 0.0045 TRCN0000053404,TRCN0000053405,TRCN0000053407 1.58,0.51,0.61 Sensitizing 




173 GNB3 0.74 0.0047 TRCN0000036784,TRCN0000036786,TRCN0000036787,TRCN0000036788 1.17,0.38,0.61,0.62 Sensitizing 
174 MMAB 0.74 0.0047 TRCN0000083903,TRCN0000083905,TRCN0000083906,TRCN0000083907 0.88,0.57,0.43,0.73 Sensitizing 
 
 
